Combining SPECT and CT imaging in coronary artery disease by Engbers, E.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/194324
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.


Combining SPECT and CT imaging
in coronary artery disease
Elsemiek Engbers
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   1 17-08-18   07:37
Combining SPECT and CT imaging in coronary artery disease
© Elsemiek Engbers (2018)
ISBN: 978-94-93019-13-3
Layout and design by  Wendy Schoneveld  ||  wenz iD.nl
printed by ProefschriftMaken  ||  Proefschriftmaken.nl
Financial support by the Dutch Heart Foundation and the Zwolle Research Foundation 
Isala for the publication of this thesis is gratefully acknowledged.
The printing of this thesis was financially supported by Bayer HealthCare and Sanofi.
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   2 17-08-18   07:37
Combining SPECT and CT imaging
in coronary artery disease
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen op vrijdag 28 september 2018
om 12.30 uur precies
door
Elsemiek Maria Engbers
geboren op 6 juni 1986
te Emmen
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   3 17-08-18   07:37
Promotoren:
Prof. dr. M.J. de Boer
Prof. dr. P.L. Jager (Mc Master University, Canada)
Copromotoren:
Dr. J.R. Timmer (Isala, Zwolle)
Dr. J.P. Ottervanger (Isala, Zwolle)
Manuscriptcommissie:
Prof dr. W.M. Prokop
Prof dr. J.F. Verzijlbergen (Erasmus MC)
Prof dr. F. Zijlstra (Erasmus MC)
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   4 17-08-18   07:37
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   5 17-08-18   07:37
Chapter 1 General introduction 9
Part I  The added value of CAC score to SPECT
Chapter 2 Prognostic value of coronary artery calcium score in addition 
to single photon emission computed tomography myocardial 
perfusion imaging in symptomatic patients
Engbers EM, Timmer JR, Ottervanger JP, Mouden M, Knollema S, Jager PL.  
Circ Cardiovasc Imaging. 2016;9(5)
23
Chapter 3 Impact of gender on the prognostic value of coronary artery 
calcium in symptomatic patients with normal single-photon 
emission computed tomography myocardial perfusion
Engbers EM, Timmer JR, Ottervanger JP, Mouden M, Knollema S, Jager PL.  
Am J Cardiol. 2016;118(11):1611-1615
43
Chapter 4 Changes in cardiovascular medication after coronary artery 
calcium scanning and normal single photon emission computed 
tomography myocardial perfusion imaging in symptomatic 
patients
Engbers EM, Timmer JR, Mouden M, Knollema S, Jager PL, Ottervanger JP. 
Am Heart J. 2017;186:56-62
 
57
Part II The benefits of sequential cardiac imaging in clinical practice
Chapter 5 Sequential SPECT/CT imaging for detection of coronary artery 
disease in a large cohort: evaluation of the need for additional 
imaging and radiation exposure
Engbers EM, Timmer JR, Ottervanger JP, Mouden M, Oostdijk AHJ, Knollema S, Jager PL. J 
Nucl Cardiol. 2017;24(1):212-223
75
Table of contents
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   6 17-08-18   07:37
Chapter 6 Sequential SPECT/CT imaging starting with stress SPECT in 
patients with left bundle branch block suspected for coronary 
artery disease
Engbers EM, Timmer JR, Mouden M, Knollema S, Jager PL, Ottervanger JP. 
Eur Radiol. 2017;27(1):178-187
97
Chapter 7 Coronary artery calcium score as a gatekeeper in the non-invasive 
evaluation of suspected coronary artery disease in symptomatic 
patients
Engbers EM, Timmer JR, Ottervanger JP. 
J Nucl Cardiol. 2017; Jun;24(3):826-831
115
Part III Evaluation of novel features in non-invasive imaging
Chapter 8 Prognostic value of myocardial perfusion imaging with a 
cadmium zinc telluride SPECT camera in patients suspected of 
having coronary artery disease
Engbers EM, Timmer JR, Mouden M, Knollema S, Jager PL, Ottervanger JP. 
J Nucl Med. 2017; J Nucl Med. 2017; Sep;58(9):1459-1463.
129
Chapter 9 Visual estimation of coronary artery calcium on computed 
tomography for attenuation correction 
Engbers EM, Timmer JR, Mouden M, Jager PL, Knollema S, Oostdijk AHJ, Ottervanger JP. 
J Cardiovasc Comput Tomogr. 2016;10(4):327-329
145
Chapter 10 General discussion 155
Chapter 11 Nederlandse samenvatting | Dutch summary 165
Appendices
Acknowledgements 174
List of publications 177
Curriculum Vitae 179
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   7 17-08-18   07:37

Chapter 1
General introduction
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   9 17-08-18   07:37
Chapter 1
10
Clinical perspective
Cardiovascular disease is the number one cause of death globally, accounting for 30% 
of all deaths1. Coronary artery disease (CAD) is responsible for around 40% of these 
deaths1. Patients with CAD may present with stable chest pain complaints (stable 
angina pectoris), or with acute coronary syndromes (myocardial infarction, unstable 
angina or sudden cardiac death). The typical clinical presentation of stable angina 
pectoris comprises the presence of substernal chest pain or discomfort provoked by 
exertion or emotional stress and relieved by rest and/or nitroglycerin. However, stable 
angina can present itself  in varying ways and the diagnostic challenge is to discriminate 
CAD from more benign causes of chest pain, such as musculoskeletal complaints or 
gastroesophageal reflux disease. A correct diagnosis enables appropriate therapy for 
stable CAD consisting of anti-thrombotic, lipid-lowering and anti-anginal agents and 
potentially revascularization strategies. Besides sound clinical judgement, additional 
diagnostic tests are available to make CAD more or less likely. The appropriate initial 
diagnostic test which should be performed depends on the pre-test likelihood of CAD2,3, 
which can be assessed by implementing the (modified) Diamond and Forrester risk 
classification4,5. 
Immediate invasive coronary angiography (ICA) is indicated only in patients with a 
high pre-test likelihood2,6, as it is costly, labor-intensive, but foremost it carries a small 
but definite risk for serious complications such as ischemic stroke and coronary artery 
dissection. The absence of coronary stenoses on ICA excludes obstructive CAD. However, 
ICA falls short in discriminating whether visualized stenoses are of hemodynamic 
significance. Therefore, nowadays the addition of fractional flow reserve measurements 
when intermediate stenoses are visualized is common practice7,8.
Fortunately, the largest subset of patients with stable angina are not at high risk, but 
have a low to intermediate pre-test likelihood. Current guidelines recommend to 
perform non-invasive imaging in this patient group2,6, as the pre-test likelihood does 
not outweigh the risk of invasive testing. The primary goal of these non-invasive tests is 
to establish the presence or absence of obstructive CAD (diagnostic testing). These test 
can also be used to evaluate the risk for future events, wherein patients with a normal 
imaging test can be identified as having an excellent prognosis, whereas patients with an 
abnormal test are at higher future risk of events (prognostic testing).
Three non-invasive imaging techniques will be introduced below:
1. Single photon emission computed tomography (SPECT) myocardial perfusion 
imaging (MPI)  
2. Coronary artery calcium (CAC) score
3. Coronary computed tomography angiography (CCTA) 
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SPECT-MPI  
SPECT is a widely available method to assess myocardial perfusion. During several 
decades of experience, the safety, diagnostic and prognostic value is well established 
and therefore it holds a prominent place in several professional guidelines2,6,9. It 
is performed with an intravenous injection of small amounts of a radioactive tracer 
(99mTc-tetrofosmin), usually during rest as well as during some form of cardiovascular 
stress (treadmill/bicycle testing or pharmacological stress). The radioactive tracer is 
extracted by cardiac myocytes and thereby their distribution reflects the distribution of 
myocytes and myocardial perfusion. Homogenous myocardial uptake indicates normal 
myocardium and perfusion and thereby the absence of significant myocardial infarction 
and of hemodynamically significant coronary stenosis. A perfusion defect which is 
present during stress, but resolves during rest is called a reversible defect and is associated 
with a hemodynamically significant coronary obstruction (Figure 1). A fixed perfusion 
defect is present in both rest and stress and is associated with the presence of myocardial 
infarction. In order to decrease radiation dose, stress imaging can be performed first 
and in case of normal perfusion, no additional rest imaging is acquired. This stress-first 
SPECT imaging strategy has demonstrated to have comparable diagnostic accuracy and 
prognostic value as routinely collecting both stress and rest images10,11.  
A major advantage of SPECT is that it can be performed in almost all patients (regardless 
of renal function, contrast allergy or rhythm disorders). With regard to the diagnostic 
accuracy, the sensitivity and specificity of SPECT MPI are generally 67-94% and 
61-87% compared with ICA, respectively, depending on the choice of radionuclide 
and stress modality9. Regarding the prognostic value, patient with a normal SPECT 
perfusion generally have a low annual risk (<1%) for future cardiac events9. The extent of 
myocardial perfusion defect can be used to guide revascularization procedures. In small 
perfusion defects, medical therapy is equivalent or better, whereas in large perfusion 
defects a revascularization procedure improves patient’s outcome12.
CAC score 
In advanced stages of CAD coronary calcification will occur. This presence of calcium 
in the coronary arteries is pathognomonic of atherosclerosis13. The calcium deposits can 
be non-invasively visualized and quantified by an anatomical imaging method: the CAC 
score. An ECG-gated CT scan without contrast agents and with 3 mm consecutive slices 
is acquired for the CAC score. With appropriately selected imaging parameters, CAC 
scanning can be performed with a radiation dose around 1 mSv. The Agatston score 
is calculated with the product of the lesion area (mm2) and density factor14. The CAC 
score has been extensively validated as a marker for cardiovascular risk in asymptomatic 
patients, and provides incremental prognostic value in prediction of mortality on top 
of well-established risk factors15-17. The CAC score is not able to detect non-calcified 
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plaques, therefore it is not able to detect early stages of CAD or (unstable) coronary 
lesions without the presence of CAC. Since the CAC score is not able to assess the 
luminal obstruction directly, it is not used as a sole imaging technique in symptomatic 
patients. 
CCTA
CCTA is a contrast enhanced CT acquisition enabling visualization of the lumen and 
wall of the coronary arteries (Figure 2). Owing to lower tube voltage settings, prospective 
triggering and iterative reconstruction techniques, current radiation doses are in the 
range of 1-5 mSv. In carefully selected patients, CCTA has demonstrated high sensitivity 
and negative predictive value for excluding obstructive CAD18. However, CCTA does 
Figure 1. Stress and rest SPECT findings demonstrating a large inferolateral ischemic perfusion defect
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not perform well in patients with high/irregular heart rates and with severe CAC19. 
CCTA is not able to detect whether the coronary lesions are of hemodynamically 
importance (limited positive predictive value), especially in the presence of severe 
calcifications20,21. Therefore, it is recommended to perform CCTA especially in patients 
with a low-intermediate risk to exclude obstructive CAD2,19. Another limitation of the 
CCTA is the use of contrast agents, therefore precluding its application in patients with 
contrast allergy and (severe) kidney dysfunction. 
Hybrid imaging
Functional imaging aims to evaluate the myocardial perfusion while anatomical imaging 
directly visualizes the coronary arteries. Formerly, often one imaging technique was 
performed in the evaluation of suspected CAD. However, all imaging techniques have 
their own pro’s and con’s, as described above. The combination of both functional 
and anatomical imaging (hybrid imaging), is likely to provide additional value in the 
evaluation of patients suspected of CAD, as they offer complementary information. 
Figure 2.
CCTA demonstrating no atherosclerosis
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With the introduction of integrated SPECT/CT cameras, the different imaging 
modalities can be more easily combined and obtained in a single session. There is room 
for improvement in the field of non-invasive detection of CAD and selecting patients 
to undergo ICA, as around two thirds of patients do not have obstructive CAD at 
diagnostic angiography22. 
 
Combination of functional and anatomical imaging: added diagnostic value
When a coronary lesion is depicted on CCTA, its functional significance is difficult 
to assess. Functional interrogation of the coronary lesion is possible with SPECT. 
The additional value of SPECT/CCTA compared to CCTA alone was demonstrated 
by Rispler et al, who found an increase in specificity (from 63 to 95%) and positive 
predictive value (from 31 to 77%) for the detection of hemodynamically significant 
coronary lesions23. In case of a perfusion defect on SPECT, without any corresponding 
anatomical substrate on CCTA, it is more likely that the perfusion defect is caused by an 
attenuation artefact. The combined evaluation of SPECT and CAC scoring also provides 
added diagnostic information. With the knowledge of the CAC score, interpretative 
certainty for SPECT improved24,25. The sensitivity of SPECT improved from 76 to 86% 
when the CAC score was added (with a cutoff of CAC ≥709)26. 
Combination of functional and anatomical imaging: added prognostic value
In patients with normal SPECT imaging a low but existent risk of events remains27. 
This can be explained by the fact that non-obstructive CAD is not visualized by SPECT. 
This subclinical CAD could influence prognosis and can be easily demonstrated with 
the CAC score. For example, in patients with three-vessel disease false negative SPECT 
can occur (“balanced ischemia”)28. Therefore, in case of normal SPECT but high CAC 
scores or several coronary lesions on CCTA, the risk of a false negative SPECT is higher 
and the prognosis could be worse than expected based on SPECT findings alone. CCTA 
demonstrated to be an independent predictor of events and provided incremental 
prognostic value to SPECT29. In part I of this thesis we aimed to evaluate the added 
value of the CAC score on top of SPECT imaging in patients suspected for CAD. 
Although the additional prognostic value of CAC score on top of SPECT imaging is 
demonstrated in asymptomatic (screening) populations30, this is less well established in 
symptomatic patients. Therefore, in chapter 2 we evaluated the prognostic value of the 
CAC score on top of SPECT in a large symptomatic patient population. 
The prognostic value of the CAC score could be gender-specific, as comparable CAC 
burden could have more impact in females because of smaller coronary arteries31,32. In 
chapter 3 we investigated whether gender impacted the prognostic value of the CAC 
score on top of SPECT. After evaluation of the additional prognostic value of the CAC 
score, we aimed to evaluate clinical implication of additional CAC score to SPECT 
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as reflected by post-imaging patient management. In patients with abnormal SPECT, 
it is likely that medication treatment is intensified according to guidelines2,6. It is not 
known whether the concomitant CAC scoring acquired in patient with normal SPECT 
influences patient medication management. In chapter 4 therefore, we evaluated 
whether the knowledge of the CAC score impacted the prescription of cardiovascular 
preventive medication by the referring cardiologist.
Sequential imaging 
If all symptomatic patients suspected of CAD would undergo both anatomical and 
functional imaging, this would result in higher costs, radiation dose and decreased 
imaging laboratory efficacy. Therefore, in part II of this manuscript, we evaluated the use 
of sequential individualized imaging protocols. In chapter 5 we described a step-wise, 
individualized imaging protocol which is incorporated in our clinical practice in stable 
patients without known CAD. It consists of initial stress SPECT and CAC scoring in 
all patients. In case of abnormal perfusion, patients will undergo rest SPECT to assess 
whether or not the perfusion defect is reversible (ischemic). On the basis of the CAC 
score, the heart rate (regular and not too high) and renal function it is decided whether 
or not the rest SPECT is combined with CCTA (Figure 3). 
Left bundle branch block is well described to influence SPECT imaging results, 
therefore we evaluated the impact of left bundle branch block on this sequential imaging 
in chapter 6. 
Many characteristics can be considered in creating the most optimal sequential imaging 
protocol, however, it should remain manageable for the imaging laboratory and not 
Figure 3. Flowchart of the individualized sequential SPECT/CT algorithm
CAC, coronary artery calcium; CCTA, coronary computed tomography angiography
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constipate patient flow. It would be efficient to have an initial test which: 1) can be 
applied in all patients; 2) is easy to perform and; 3) can serve as a gatekeeper for further 
imaging. Therefore, in chapter 7, we reviewed the literature to evaluate the CAC score 
as an initial non-invasive test for all patients suspected of CAD.
Evaluation of novel features in non-invasive imaging 
In part III we evaluated novel features in non-invasive cardiac imaging.
CZT SPECT
The conventional Anger gamma camera with standard parallel-hole collimator with 
NaCl crystal is more than 50 years old. The camera rotates around the patient in 10-20 
minutes and the set of planar projection images are reconstructed into slices through the 
myocardium. With this conventional camera only a small portion of the crystal detector 
area is used to image the heart33. In recent years, heart-dedicated gamma camera systems 
based on a novel detector technology utilizing solid-state semiconductor detectors of 
cadmium zinc telluride (CZT) and multipinhole collimators was developed, which have 
a 5- to 10- fold increase in count sensitivity at no loss, or even at gain in, resolution34. 
The diagnostic accuracy of CZT-SPECT proved to be excellent35,36. Data on the 
prognostic value of SPECT imaging acquired on CZT imaging are scarce37,38. Therefore, 
we evaluated the prognostic value of CZT SPECT in chapter 8. 
Estimating CAC scores on attenuation CT
The CT for attenuation correction has demonstrated to improve diagnostic accuracy of 
SPECT and is therefore now routinely performed in combination with SPECT imaging. 
For the Agatston CAC score, a separate CT is made. Evidence about estimating the 
CAC score on the attenuation CT is limited39. We evaluated whether it was possible 
to use this attenuation CT scan to determine the CAC score in chapter 9, and if the 
additional CT only acquired for the CAC score could be omitted. 
Summary of the aims of this thesis
In summary, in this thesis we aimed to: 1) investigate the added value of the CAC 
score in addition to SPECT MPI in symptomatic patients suspected of CAD; 2) 
investigate sequential SPECT/CT protocols; 3) investigate whether it is possible to use 
the attenuation CT scan to estimate the CAC score and; 4) evaluate the prognostic value 
of a new SPECT imaging technique. The implications and future perspectives of our 
findings are discussed in chapter 10. 
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ABSTRACT
Background
The prognostic value of coronary artery calcium (CAC) scoring on top of myocardial 
perfusion imaging with single-photon emission computed tomography (SPECT) in 
patients suspected for coronary artery disease is not well established. 
Methods and Results
4897 symptomatic patients without a history of coronary artery disease referred for 
SPECT and CAC scoring were included. Major adverse cardiac events (MACE) 
were defined as late revascularization (>90 days after scanning), non-fatal myocardial 
infarction and all-cause mortality. The frequency of abnormal SPECT increased with 
higher CAC scores, from 12% in patients with CAC scores of 0, to 19%, 32%, 37% and 
50% among those with CAC scores 1-99, 100-399, 400-999 and ≥1000, respectively 
(p<0.001). During a median follow-up of 940 days [25th-75th percentile, 581-1377], 
a total of 278 MACE were observed. Overall incidence of MACE was 2.3%/year. 
A stepwise increase of MACE was present with increasing CAC scores, both in patients 
with normal SPECT (annual event rate CAC score 0: 0.6%, CAC score ≥1000: 5.5%) 
and abnormal SPECT (annual event rate CAC score 0: 0.4%, CAC score ≥1000: 7.6%). 
After multivariate analysis, both SPECT and CAC score were independent predictors 
for MACE (CAC score ≥1000: hazard ratio 7.7, p<0.001; large perfusion defect on 
SPECT: hazard ratio 3.7, p<0.001). 
Conclusions
CAC score and SPECT are independent predictors for MACE in patients suspected 
for coronary artery disease. Our findings strongly support performing a CAC score in 
addition to SPECT in symptomatic patients to better define the risk of events during 
follow-up.
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INTRODUCTION
Myocardial perfusion imaging with single-photon emission computed tomography 
(SPECT) is well established for the prognostic evaluation of patients suspected for 
coronary artery disease (CAD)1. However, this functional imaging modality is not able 
to detect non-flow-limiting CAD. There has been increasing interest to reveal subclinical 
atherosclerosis by coronary artery calcium (CAC) scoring, which has demonstrated a 
close correlation with atherosclerotic plaque burden2. With the advent of combined 
SPECT/computed tomography (CT) cameras, it is possible to acquire both SPECT and 
CAC score in a single session. 
In asymptomatic populations, CAC scoring provides incremental prognostic information 
on top of SPECT myocardial perfusion imaging3,4. However, in symptomatic patients, 
the prognostic value of CAC scoring on top of SPECT imaging is less well established. 
The aim of the current study was to investigate the prognostic value of CAC score as 
an adjunct to SPECT in a low- to intermediate-risk population suspected for stable 
coronary artery disease.
METHODS
Study population
We studied stable patients with suspected CAD prospectively enrolled in a SPECT/
CT registry. It was approved by the Isala Medical Ethics committee and included a 
waiver of consent. Consecutive patients referred for clinically indicated non-invasive 
CAD detection with SPECT/CT in the Isala Hospital between January 2009 until June 
2013 were included. Patients were referred from the cardiology outpatient clinics of our 
hospital, which is a large cardiovascular center with a local, regional and supraregional 
catchment area. Patients with unstable chest pain syndromes, a known history of CAD 
and patients in whom no CAC score could be acquired (mainly because of high or 
irregular heart rate, n=121) were excluded. No other exclusion criteria were applied. 
Information regarding medication use and the presence of risk factors was prospectively 
collected by written questionnaires. Height and weight were measured, and body mass 
index (BMI) was calculated. The pre-test likelihood of CAD was assigned according to 
the criteria of Diamond and Forrester, with a risk threshold of <13.4% for low-risk, 
between 13.4 and 87.2 % for intermediate-risk, and >87.2 % for high-risk5. All patients 
underwent initial 99mTc-tetrofosmin stress-first SPECT combined with CAC scoring. 
Immediately after acquisition of stress SPECT and CAC scan, a cardiologist and nuclear 
physician together assessed the need for additional rest SPECT imaging. In case of an 
abnormal stress perfusion, additional rest SPECT was performed. 
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Myocardial perfusion imaging
Stress testing was routinely performed with pharmacological stress using adenosine 
(140 μg /min/kg for 6 min) in all patients, unless there was a contra-indication for 
pharmacological stress. Due to logistical reasons this is common practice in our high 
volume center. Patients were instructed to refrain from caffeine containing beverages 
for at least 24h before the test. In case of a contraindication for adenosine, patients 
underwent dobutamine (starting dose of 10 μg/kg per min, increased at 3-min intervals 
to a maximum of 50 μg/kg per min), regadenoson (fixed-dose of 400 ug bolus injection 
over 15 sec) or bicycle testing. A weight-adjusted dose of 99mTc-tetrofosmin (standard 
370 MBq, 500 MBq for patients >100 kg) was administered after 3 minutes (adenosine), 
after 35 seconds (regadenoson) or when the target heart rate of >85% of predicted 
maximal was reached (dobutamine, bicycle test). Patients scheduled for rest imaging 
received a dose of 99mTc-Tetrofosmin (standard 740 MBq, but 1000 MBq for patients 
> 100 kg). Both stress and rest SPECT images were acquired 45–60 min after tracer 
injection. Time delay between the stress and rest studies was >3 hours6.
From January 2009 until April 2010, patients (n=977) were scanned on a conventional 
dual-detector gamma camera (Ventri-LightSpeed VCT XT, GE Healthcare), using a 
low-energy, high-resolution collimator, a 20% symmetrical window at 140 keV, a 64x64 
matrix, and an elliptical orbit with step-and-shoot acquisition at 6 º intervals over a 180 
º arc (45 º right anterior oblique to 45 º left posterior oblique) with 15 steps (15 views). 
Acquisition time was 12 min for the stress images and 15 min for the rest images as 
previously described7.
From May 2010 until June 2013, patients (n=4049) were scanned with a cadmium zinc 
telluride (CZT)-based SPECT/CT camera (Discovery NM/CT 570c, GE Healthcare) 
with 19 stationary CZT detectors simultaneously imaging 19 cardiac views. Each 
detector comprised 32×32 pixelated (2.46×2.46 mm) CZT elements. Acquisition time 
was 5 min for the stress images and 4 min for the rest images. This was derived from the 
recommendations of the manufacturer, published experience and our own qualitative 
assessment in heart phantom studies and our initial experience in patients8. All SPECT 
studies were followed by an unenhanced low-dose CT scan during a breath-hold at 
end expiration to provide the attenuation map for attenuation correction as previously 
described9. 
Perfusion images were interpreted unblinded and semiquantitatively interpreted 
using a 17-segment model10. Segments were scored by consensus of two experienced 
nuclear cardiology observers using a 5-points scoring system (0=normal, 1= equivocal, 
2=moderate, 3= severe reduction of radioisotope uptake, 4= absence of detectable tracer 
uptake)11. The combination of  attenuation corrected and non-attenuation corrected 
images were reviewed. A stress study was interpreted as normal if the summed stress 
scores was ≤311. Additional rest SPECT was acquired if the stress images did not fulfill 
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these criteria. An ischemic defect was defined as a summed difference score ≥211. 
Reversible defects not fulfilling these criteria were assessed as equivocal for ischemia. 
Perfusion defects which demonstrated no reversibility were defined as fixed defects. 
Perfusion defects were rated as small, moderate or large. Small defects represents less 
than 10%, moderate 10-20% and large represents greater than or equal to 20% of 
the left ventricular myocardium. The SPECT was defined as abnormal if the perfusion 
images demonstrated either reversible (both ischemia and equivocal for ischemia) or 
fixed defects.
CAC scoring
All patients with heart rates greater than 70 beats per minute received oral b-blocker 
therapy, with 50 or 100 mg of metoprolol tartrate (AstraZeneca, Zoetermeer, the 
Netherlands) after stress testing to achieve a heart rate lower than 70 beats per minute 
for the CAC scan.
A nonenhanced CT scan (LightSpeed VCT XT; GE Healthcare) during breath-hold 
at end expiration to calculate the total CAC score was acquired with ECG triggering 
at 75% of the R-R interval and the following scanning parameters: 40 or 48 sections 
and 2.5-mm section thickness; gantry rotation time, 330 msec; tube voltage, 120 kV; 
and a tube current of 125 mA. If patients were not able to hold their breath a free 
breathing CT was acquired. Post-processing was conducted at a dedicated workstation 
using Smartscore software (GE Healthcare). The CAC score was calculated using the 
standard Agatston criteria12.
Follow-up
Follow-up data was based on clinical visits or standardized telephone interviews. Major 
adverse cardiac events (MACE) were defined as late revascularization (angioplasty or 
coronary artery bypass surgery, >90 days after scanning), nonfatal myocardial infarction 
(MI) or all-cause mortality. Early elective revascularizations within 90 days after imaging 
were excluded from the survival analysis to eliminate events driven by imaging findings. 
Patients undergoing early revascularization were censored. Non-fatal myocardial 
infarction was defined based on the criteria of typical chest pain, elevated cardiac enzyme 
levels, and typical changes on the ECG as defined by Thygesen et al13.
Statistical analysis
Continuous variables are expressed as mean ± SD or median [25th-75th percentile] and 
categorical variables are expressed as frequency (percentage). Differences between groups 
were assessed by unpaired Student’s t-test, Mann-Whitney U test and by Chi-square test, 
where appropriate. The patient’s pre-test likelihood for CAD was determined with the 
standard Diamond criteria with the assumption that chest pain was atypical5. SPECT 
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findings and patient clinical characteristics were compared across different CAC score 
categories using the Chi-square test for trend. We calculated annualized event rates on the 
basis of events per patients-year and compared differences in annualized events between 
patients with normal and abnormal SPECT in the different CAC score categories 
by Poisson regression for rate data. Multivariate logistic regression was performed to 
investigate whether CAC score was an independent predictor for an abnormal SPECT 
result after adjusting for the effects of age, gender, BMI and traditional risk factors which 
were significant variables in univariate analysis (diabetes mellitus and hypertension). 
The CAC score was entered in the model as a categorical variable. Continuous predictors 
Table 1. General patient characteristics, and comparison of patients with normal and abnormal SPECT 
perfusion
Overall 
(n=4897)
Normal 
SPECT
(n=3702)
Abnormal 
SPECT
(n=1195)
p-value
Age 61±11 60±12 63±11 <0.001
Male gender 2098 (43) 1438 (39) 660 (55) <0.001
Risk factors
   Diabetes mellitus 649 (13) 427 (12) 222 (19) <0.001
   Current smoking 775 (16) 567 (15) 208 (18) 0.08
   Hypertension 2991 (61) 2231 (60) 760 (64) 0.047
   Hypercholesterolemia 2108 (43) 1577 (43) 531 (44) 0.28
   Family history of CAD 2665 (55) 2027 (55) 638 (53) 0.40
BMI 27.6±4.8 27.2±4.5 28.7±5.3 <0.001
CAC score 39 [0-282] 21 [0-184] 183 [16-730] <0.001
   CAC score >0 3582 (73) 2546 (69) 1036 (87) <0.001
Medication use
   Aspirin 1948 (40) 1385 (37) 563 (47) <0.001
   Beta blocker 2579 (53) 1906 (52) 673 (56) 0.004
   Statin 3106 (63) 1286 (35) 505 (42) <0.001
   ACE inhibitor 3202 (65) 1209 (33) 486 (41) <0.001
Abnormal SPECT findings
   Small perfusion defect 691 (58)
   Moderate perfusion defect 359 (30)
   Large perfusion defect 145 (12)
values are shown as number (percentage), mean ± SD, median [25th-75th percentile]. BMI, body mass index; 
CAC, coronary artery calcium; CAD, coronary artery disease; SPECT, single-photon emission computed 
tomography 
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with a linear relationship were included in the model as a continuous variable. We 
used Cox proportional hazard regression to analyse the association between imaging 
results, patient characteristics and clinical outcomes. The Cox model was adjusted for 
age, gender and all traditional risk factors. We evaluated interaction terms for CAC 
score, SPECT findings and MACE outcome. Effect modification by gender, BMI, age, 
and traditional risk factors  was evaluated. Cox survival curves were constructed with 
separate lines for the different CAC score categories and were adjusted for age, gender 
and traditional risk factors. We examined the discriminatory power for both the logistic 
regression and the Cox regression model by means of the c-index. C-indexes for the 
models with and without including the CAC score as a predictive variable were reported. 
Two sided p-values of less than 0.05 were considered statistically significant in all tests. 
Statistical analysis was performed with a commercially available software package (SPSS, 
version 20.0 for Windows), the Poisson regression for rate data was performed with 
Medcalc (version 16.2 for Windows). 
RESULTS
Study population 
During a period of 4.5 years a total of 4905 patients were included. Follow-up information 
was not available for 8 (0.2%) of the patients. The remainder of 4897 patients are 
the subject of this report. Relevant general characteristic of the study population are 
demonstrated in Table 1. Pre-test likelihood was considered to be low in 9% of the 
patients and intermediate in 91% of the patients. The mean age was 61 ± 11 years, 43% 
of the patients were male and 13% were diabetic. Stress testing was performed with 
adenosine in 4746 (96.9%), with dobutamine in 97 (2.0%), with regadenoson in 14 
(0.3%) and with exercise testing in 40 (0.8%) of the patients. 
CAC score and SPECT findings
The median CAC score was 39 [25th-75th percentile, 0-282] with a range from 0 to 
18041. The distribution of CAC score and patient characteristics in the different CAC 
score categories are demonstrated in Table 2. Patients with a higher CAC score were 
more frequently male, older and demonstrated more cardiac risk factors. SPECT was 
normal in 3702 patients (76%), the remaining 1195 patients (24%) showed abnormal 
SPECT. Increasing CAC scores were significantly associated with a higher frequency of 
abnormal SPECT (Figure 1) and a higher frequency of large perfusion defects (Table 
2). Of the 3702 patients with normal SPECT, 2546 (69%) had a CAC score > 0,  with 
a CAC score ≥400 in 569 (15%) and a CAC score ≥1000 in 231 (6%).
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Table 2. General patient characteristics according to CAC 
CAC 0
n=1315
CAC 
1-99
n=1668
CAC 
100-399
n=918
CAC 
400-999
n=539
CAC 
≥1000
n=457
p-value 
Age, years 54±11 60±11 65±9 68±9 70±9 <0.001
Male gender 386 (29) 668 (40) 453 (49) 290 (54) 301 (66) <0.001
Cardiac risk factors, amount 1.6±1.1 1.9±1.1 2.0±1.1 2.0±1.1 2.2±1.1 <0.001
   Diabetes mellitus 85 (7) 192 (12) 130 (14) 111(21) 131 (29) <0.001
   Hypertension   646 (50) 1012 (61) 636 (69) 377 (70) 320 (70) <0.001
   Current smoking 230 (18) 236 (14) 139 (15) 98 (18) 72 (16) 0.91
   Hyperlipidemia 434 (33) 718 (43) 455 (50) 251 (47) 250 (55) <0.001
   Family history of CAD 758 (58) 928 (56) 494 (54) 253 (47) 232 (51) <0.001
Abnormal SPECT 159 (12) 320 (19) 289 (32) 201 (37) 226 (50) <0.001
      Small perfusion defect 107 (67) 212 (66) 165 (57) 107 (53) 100 (44) <0.001
      Moderate perfusion defect 46 (29) 93 (29) 96 (33) 55 (27) 69 (31) 0.67
      Large perfusion defect 6 (4) 15 (5) 28 (10) 39 (19) 57 (25) <0.001
   Reversible defect 93 (7) 191 (11) 202 (22) 131 (24) 182 (40) <0.001
      Small reversible defect 64 (69) 134 (70) 125 (62) 62 (47) 101 (56) <0.001
      Moderate reversible defect 29 (31) 54 (28) 70 (35) 55 (42) 62 (34) 0.14
      Large reversible defect 0 (0) 3 (2) 7 (4) 14 (11) 19 (10) <0.001
Values are shown as number (percentage), mean ± SD. CAC, coronary artery calcium; CAD, coronary 
artery disease; SPECT, single-photon emission computed tomography
Table 3. Independent predictors of abnormal SPECT. 
OR 95% CI p-value
Age (+ 10 year) 1.06 0.99-1.13 0.12
Male gender 1.61 1.39-1.87 <0.001
Diabetes mellitus 1.10 0.91-1.34 0.34
Hypertension 0.87 0.75-1.01 0.07
BMI (+1 kg/m2) 1.07 1.05-1.09 <0.001
CAC score 
   1-99 1.44 1.17-1.79 0.001
   100-399 2.78 2.20-3.51 <0.001
   400-999 3.44 2.63-4.49 <0.001
   ≥1000 5.24 3.95-6.96 <0.001
CAC, coronary artery calcium, reference CAC 0; CI, confidence interval; OR, odds ratio; Adjusted for the 
effects of age, gender, BMI and traditional risk factors which were significant in univariate analysis (diabetes 
mellitus and hypertension).
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Predictors of abnormal SPECT 
General characteristics of patients with normal and abnormal SPECT were significantly 
different (Table 1). Patients with abnormal SPECT were more likely to be older, 
male, diabetic, hypertensive, had higher BMI and CAC scores. After adjustment for 
differences in patients characteristics, a higher CAC score was still associated with risk 
of abnormal SPECT (p=0.001, Table 3). The OR for an abnormal SPECT was 5.24 
(95% confidence interval (CI) 3.95-6.96, p<0.001) for patients with a CAC score of 
≥1000, compared to patients with a CAC score of zero. Other significant independent 
predictors for abnormal SPECT were male gender (odds ratio (OR) 1.61, 95% CI, 1.40-
1.86, p<0.001) and higher BMI (OR 1.07 per 1 kg/m2, 95% CI 1.05-1.09, p<0.001). 
Other risk factors such as age, diabetes mellitus and hypertension were not associated 
with abnormal SPECT in multivariate analysis. The C-index increased from 0.66 to 
0.71 when the CAC score was included in the model on top of clinical characteristics.  
Follow-up
During a median follow-up of 940 days [25th-75th percentile, 581-1377], a total of 278 
MACE were observed (140 deaths, 31 nonfatal MIs and 107 late revascularizations). 
A total of 315 patients underwent early revascularization. Table 4 demonstrates 
Figure 1. Prevalence of abnormal SPECT according to CAC score
CAC, coronary artery calcium; SPECT, single-photon emission computed tomography
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an overview of the incidence of MACE stratified by SPECT and CAC score. 
Overall incidence of MACE was 2.3% per year. Unadjusted annualized event rates for 
patients stratified by SPECT and CAC score are shown in Figure 2. A stepwise increase 
of MACE was present with increasing CAC scores, both in patients with normal 
SPECT and abnormal SPECT. After multivariate analysis, patients with a CAC score 
1-99 did not demonstrate a statistically significant greater risk of events during follow-
up, compared to patients with a CAC score of 0 (hazard ratio (HR) 1.35, 95% CI 
0.80-2.28, p=0.27). In patients with a CAC score of 100 or higher, a significant stepwise 
increase of risk for events with higher CAC score was demonstrated independent of 
SPECT (Table 5). Older age was also a significant independent predictor of events (+10 
years: HR 1.40, 95%CI 1.22-1.60, p<0.001). The C-index of the model increased from 
0.73 to 0.77 when the CAC score was included on top of clinical characteristics and 
SPECT findings. Adjusted survival curves based on CAC score severity in patients with 
both normal and abnormal SPECT are demonstrated in Figure 3. Interaction terms for 
CAC score, SPECT findings and MACE outcome were not significant. No significant 
effect modification by gender, BMI, age, and traditional risk factors was demonstrated.
Table 4. Incidence of MACE stratified by SPECT and CAC score.
CAC score 
category
Late 
revascularization
MI Death
Normal SPECT
(n=3702)
0 
(n=1156)
1 (0.1) 4 (0.3) 14 (1.2)
1-99
(n=1348)
3 (0.2) 6 (0.4) 22 (1.6)
100-399
(n=629)
13 (2.1) 2 (0.3) 27 (4.3)
400-1000
(n=338)
11 (3.3) 5 (1.5) 19 (5.9)
≥1000
(n=231)
17 (7.4) 2 (0.9) 15 (6.5)
Abnormal SPECT
(n=1195)
0
(n=159)
1 (0.6) 0 (0) 1 (0.6)
1-99
(n=320)
4 (1.3) 2 (0.6) 7 (2.2)
100-399
(n=289)
11 (3.8) 2 (0.7) 14 (4.8)
400-1000
(n=201)
15 (6.5) 2 (1.0) 13 (6.5)
≥1000
(n=226)
31 (13.7) 6 (2.7) 8 (3.5)
Values are shown as number (percentage); CAC, coronary artery calcium; MI, myocardial infarction; 
SPECT, single-photon emission computed tomography
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DISCUSSION
Our study shows that in symptomatic patients, CAC score is a strong independent 
predictor of events irrespective of SPECT results. Combining functional imaging with 
SPECT and anatomical imaging with CAC scoring provides incremental information 
with regard to the degree of CAD. We suggest to routinely perform CAC scoring in 
adjunct to SPECT in patients suspected for CAD to better define the risk of events 
during follow-up.
In this large cohort of patients, the frequency of an abnormal SPECT was significantly 
higher in patients with higher CAC scores. This finding seems logical as CAC is a direct 
marker of the extent of coronary sclerosis which translates into the subsequent risk 
of significant stenosis. The association between CAC and SPECT result proved to be 
independent even after adjustment for the higher risk baseline characteristics in patients 
with higher CAC score. Patients with a CAC score ≥1000 were roughly 5 times more 
Figure 2. Incidence of MACE stratified by CAC score and SPECT 
CAC, coronary artery calcium; MACE, major adverse cardiac events; SPECT, single-photon emission 
computed tomography
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Figure 3. Adjusted event rates based on CAC score in patients with abnormal and normal SPECT. 
CAC, coronary artery calcium; MACE, major adverse cardiac events; SPECT, single-photon emission 
computed tomography. Adjusted for age, gender and traditional risk factors
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likely to have abnormal SPECT compared to patients without CAC. Other significant 
predictors for abnormal SPECT were male gender and higher BMI. Current results 
are in concordance with previous findings4,14,15. Interestingly, after adjustment for CAC 
score, other known risk factors for CAD such as age, diabetes and hypertension, were 
no longer associated with abnormal SPECT. This indicates that CAC score is a stronger 
predictor for abnormal SPECT than more traditional risk factors for CAD. 
Although the association between increasing CAC and abnormal SPECT score was 
evident, they represent different conditions (coronary sclerosis versus myocardial 
perfusion). About half of the patients with extensive CAC demonstrated no SPECT 
abnormalities. This finding has been demonstrated before in asymptomatic patients, 
although the reported frequencies of normal SPECT vary considerably3,4,16. On the 
Table 5. Cox survival analysis for MACE during follow-up.
Univariate Multivariate
HR 95%CI p-value HR 95%CI p-value
Age (+ 10 years) 1.84 1.65-2.06 <0.001 1.40 1.22-1.60 <0.001
Male gender 1.64 1.29-2.07 <0.001 1.32 1.02-1.70 0.04
Risk factors
   Hypercholesterolemia 1.12 0.89-1.42 0.34 0.91 0.71-1.16 0.43
   Current smoking 1.14 0.84-1.55 0.41 1.24 0.90-1.71 0.19
   Diabetes mellitus 2.09 1.58-2.76 <0.001 1.31 0.98-1.75 0.07
   Hypertension 1.29 1.01-1.66 0.04 1.01 0.78-1.32 0.94
   Family history of CAD 0.89 0.70-1.13 0.34 1.20 0.94-1.53 0.14
CAC score 
   CAC 1-99 1.69 1.00-2.84 0.048 1.35 0.80-2.28 0.27
   CAC 100-399 5.54 3.40-9.02 <0.001 3.31 1.97-5.55 <0.001
   CAC 400-999 9.70 5.93-15.86 <0.001 4.87 2.83-8.36 <0.001
   CAC ≥1000 17.42 10.76-28.20 <0.001 7.57 4.38-13.07        <0.001
BMI (>upper quartile) 1.10 0.83-1.42 0.52 - - -
SPECT findings
      Small perfusion defect 2.27 1.69-3.03 <0.001 1.64 1.22-2.21 0.001
      Moderate perfusion defect 3.11 2.14-4.52 <0.001 2.21 1.51-3.23 <0.001
      Large perfusion defect 9.04 5.73-14.26 <0.001 3.74 2.33-5.99 <0.001
BMI, body mass index, upper quartile 30; CAC, coronary artery calcium, reference CAC 0; CI, confidence 
interval; HR, hazard ratio; SPECT, single-photon emission computed tomography, reference: normal 
SPECT. 
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other end of the spectrum, 12% of patients with CAC 0 showed abnormal perfusion. 
This incomplete agreement between CAC and SPECT could be explained by different 
mechanisms. Firstly, extensive CAC can be present without hemodynamically relevant 
stenosis and therefore normal SPECT17. Secondly, normal SPECT can occur in the 
presence of balanced ischemia due to significant stenoses in multiple coronary regions18,19. 
Thirdly, SPECT abnormalities caused by attenuation artefacts (caused by fat or breast 
tissue) could be present in the absence of CAD. And finally, although rare, significant 
coronary stenosis may be caused by non-calcified plaque in patients with CAC scores 
of 020. As the correlation with CAC score and luminal narrowing is poor, CAC scoring 
is not recommended to identify patients with significant CAD21. However, the current 
data clearly show that concomitant CAC scoring provides additional information on 
CAD not obtained by SPECT alone. 
A significant increase of MACE was demonstrated in patients with higher CAC scores. 
This increase in MACE was evident in patients with both abnormal and normal SPECT, 
although event rates were significantly lower in the latter group, except for patients 
with a CAC score of zero. As patients with a CAC score of zero demonstrated excellent 
prognosis independent of SPECT findings, the additional CAC score is likely to reduce 
the use of downstream invasive testing in this subset of patients22. After multivariate 
analysis, both CAC score and SPECT were independently associated with MACE. For 
patients with a CAC score ≥100, a stepwise increase of risk for events was present with 
higher CAC scores. CAC score ≥1000 appeared to be an even greater predictor for 
future events than a large perfusion defect (HR 4.87 for CAC 400-1000, HR 7.57 for 
CAC ≥1000 and HR 3.74 for large perfusion defect, respectively). Conflicting results 
about the additive prognostic value of CAC score in addition to SPECT have been 
published. In a study by Ramakrishna et al. it was first demonstrated that CAC score 
and SPECT provided complementary prognostic information4. This was confirmed in a 
study by Chang et al.3, which demonstrated that asymptomatic patients with CAC score 
>400 had a 3.55-fold higher risk of events (revascularization, MI or death)  compared 
to patients with CAC <10, irrespective of SPECT. Schenker et al. also demonstrated 
a stepwise increase in the risk of events with increasing CAC scores, irrespective of 
positron emission tomography myocardial perfusion imaging23. Other research did not 
show an increase of events with elevated CAC scores in patients with normal MPI16. 
This discrepancy is probably caused by the lower risk profile and relatively shorter 
follow-up period in the latter study. In a study by Naya et al, it was demonstrated that 
coronary flow reserve acquired with positron emission tomography provided significant 
incremental risk stratification rather than the CAC score24. Up to now, no reliable 
assessment of quantitive perfusion can be performed with SPECT.
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With our current results, we demonstrate that additional prognostic information is 
obtained by CAC scoring as an adjunct to SPECT in symptomatic patients. The CAC 
score is easily acquired on a non-contrast enhanced CT scan and is associated with a 
modest additional radiation exposure of 1 mSv, while it enables clinicians to identify 
patients in higher risk categories than is expected with SPECT findings alone. The 
presence of a high CAC score could influence therapy decisions. Based on our findings 
that the CAC score is an independent predictor of MACE irrespective of the extent of 
SPECT abnormality, an earlier invasive strategy could be considered in patients with 
equivocal or small perfusion defects but extensive CAC.  This is strengthened by previous 
findings in patients with normal SPECT in which the CAC score was able to unmask 
CAD9,18. In patients with extensive CAD, life style advise and medication could be 
initiated or intensified. It could be considered to treat patients with high CAC score with 
statins irrespective of SPECT results, given the mechanism of action of statins and their 
effectiveness as shown in prevention trials25,26. However, data about the favorable effect 
of statin treatment in patients with high CAC scores are limited. In two observational 
studies it was demonstrated that patients with CAD on coronary computed tomographic 
angiography who were on statin therapy demonstrated better prognosis than patients 
who were not on statin therapy27,28. In a randomized controlled trial a trend towards 
reduction of cardiovascular events was observed in patients with CAC scores >400 who 
were treated with statin in combination with antioxidant vitamins29.
Although our study reflects true daily practice and included consecutive patients, we 
have to acknowledge several limitations. The observational design remains a major 
limitation of the current study, as end-points were not pre-specified. Also, this is a 
single-center study in patients with suspected CAD and a low- to intermediate pre-test 
likelihood undergoing predominantly pharmacological stress. Therefore, extrapolation 
of the present results is difficult to populations with different pre-test likelihood or 
patients undergoing traditional exercise testing. In addition, SPECT observers were not 
blinded for the CAC score, therefore it cannot be excluded that the SPECT results 
were biased by the CAC score. Moreover, all imaging results were available to referring 
physicians and medical management and downstream utilization of invasive testing 
were left to discretion of the referring physician. We did not investigate the impact of 
the CAC scoring on downstream intensification of medication and thereby were not 
able to investigate the possible favorable influence of the knowledge of the CAC score 
on patient outcome. Finally, we evaluated the additional predictive value of the CAC 
score on the prediction model with an established measure for prediction increment 
(C-index), and did not use more recently developed statistics (e.g. Net Reclassification 
Index).
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CONCLUSIONS
CAC score and SPECT findings are independent predictors of events in symptomatic 
patients. Our findings strongly support performing a CAC score in addition to SPECT 
in symptomatic patients to better define the risk of events during follow-up.
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ABSTRACT
The coronary artery calcium (CAC) score provides independent prognostic value on 
top of single photon emission computed tomography (SPECT) myocardial perfusion 
imaging (MPI). We sought to determine whether the prognostic value of the CAC score 
in patients with normal SPECT MPI is gender-specific. We studied 3705 consecutive 
symptomatic patients without a history of coronary artery disease with normal SPECT 
MPI. All patients underwent concomitant CAC scoring, which was categorized as CAC 
score 0, 1-99, 100-399, 400-999 or ≥1000. Major adverse cardiac events (MACE) 
were defined as revascularization, non-fatal myocardial infarction or all-cause mortality. 
The median CAC score was 9 in females (interquartile range 0-113) and 47 in males 
(interquartile range 1-307, p <0.001). The annual event rate was lower in females than 
in males (1.6% and 2.7%, respectively, p<0.001). When stratified by CAC score, annual 
event rates were similar (for females and males, respectively: CAC score 0; 0.6% and 
0.5%, p=0.95; CAC score 1-99; 0.9% and 1.2%, p=0.45; CAC score 100-399; 2.7% 
and 3.8%, p=0.23; CAC score 400-999; 3.8% and 5.3%, p=0.34; CAC score ≥1000; 
8.4% and 8.7%, p=0.99). The CAC score was an independent predictor of MACE 
in both genders (CAC score ≥1000: hazard ratio for females, 8.5, 95% confidence 
interval 4.0-18.1; hazard ratio for males, 14.8, 95% confidence interval, 5.3-41.1). In 
conclusion, risk for events are similar for both genders when stratified by CAC score, 
wherein a high CAC score carries a high risk for events despite normal SPECT MPI. 
Our findings do not reveal a gender-specific prognostic value of the CAC score.
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INTRODUCTION
Normal myocardial perfusion imaging (MPI) with single photon emission computed 
tomography (SPECT) is considered to represent the absence of hemodynamically 
significant coronary artery disease (CAD) and is associated with a favorable prognosis1. 
However, even in patients with normal SPECT MPI a low but well-defined annual 
risk of cardiac events during follow-up is present2. These events may be explained by 
the inability to identify non-obstructive coronary atherosclerosis with a functional 
imaging technique such as SPECT. The coronary artery calcium (CAC) score, as a 
direct marker of atherosclerotic plaque burden, can be used to identify the extent of 
coronary atherosclerosis. The CAC score has proven to provide independent additional 
prognostic information over SPECT imaging alone3-5. The prognostic value of CAC 
scoring may be gender-specific, as demonstrated in a large asymptomatic cohort with 
a greater probability of death in females when stratified by CAC score6. However, data 
about gender-specific prognostic value of the CAC score on top of SPECT MPI are 
lacking. Therefore, the aim of the current study was to evaluate gender differences in the 
prognostic value of coronary calcium in patients with normal SPECT MPI. 
METHODS
We studied stable patients referred for SPECT imaging because of suspected CAD 
prospectively enrolled in a SPECT/computed tomography (CT) registry. It is approved 
by the Isala Medical Ethics committee and includes a waiver of consent. Consecutive 
patients, without a known history of CAD, referred for non-invasive CAD detection 
with SPECT/CT in the Isala Hospital between January 2009 until June 2013 were 
included in the registry (n=5026). All patients underwent 99mTc-tetrofosmin stress-
first SPECT imaging combined with simultaneous CAC scoring. In case of normal stress 
SPECT MPI, no additional rest examination was performed. Patients who demonstrated 
normal stress SPECT MPI or normal SPECT MPI findings after both stress and rest 
imaging were included in the current analysis. Patients in whom no CAC score could 
be acquired (mainly because of high or irregular heart rate, n=123), and patients with 
abnormal SPECT findings (n=1198, 24%) were excluded. No other exclusion criteria 
were applied. Information regarding the presence of risk factors was prospectively 
collected by written questionnaires. These data were verified and complemented with 
demographic and clinical information collected from medical records. Height and 
weight were measured, and body mass index (BMI) was calculated.
Stress testing was routinely performed with pharmacological stress using adenosine (140 
μg /min/kg for 6 min), unless there was a contra-indication for pharmacological stress. 
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Due to logistical reasons this is common practice in our high volume centre. Patients 
were instructed to refrain from caffeine containing beverages for at least 24 h before 
the test. In case of a contraindication for adenosine, patients underwent dobutamine 
(starting dose of 10 μg/kg per min, increased at 3-min intervals to a maximum of 50 μg/
kg per min), regadenoson (fixed-dose of 400 ug bolus injection over 15 sec) or bicycle 
testing. A weight-adjusted dose of 99mTc-tetrofosmin (standard 370 MBq, 500 MBq 
for patients >100 kg) was administered after 3 minutes (adenosine), after 35 seconds 
(regadenoson) or when the target heart rate of >85% of predicted maximal was reached 
(dobutamine, bicycle test). Patients scheduled for rest imaging received a dose of 99mTc-
Tetrofosmin (standard 740 MBq, but 1000 MBq for patients > 100 kg).
Both stress and rest SPECT images were acquired 45–60 min after tracer injection. Time 
delay between the stress and rest studies was >3 hours7. All patients were imaged in the 
supine position with arms placed above the head. From January 2009 until April 2010, 
patients (n=977) were scanned on a conventional dual-detector gamma camera (Ventri-
LightSpeed VCT XT, GE Healthcare), using a low-energy, high-resolution collimator, 
a 20% symmetrical window at 140 keV, a 64x64 matrix, and an elliptical orbit with 
step-and-shoot acquisition at 6 º intervals over a 180 º arc (45 º anterior oblique to 45 
º left posterior oblique) with 15 steps (15 views). Acquisition time was 12 min for the 
stress images and 15 min for the rest images as previously described8. From May 2010 
until June 2013, patients (n=4057) were scanned with a cadmium zinc telluride (CZT)-
based SPECT/CT camera (Discovery NM/CT 570c, GE Healthcare) with 19 stationary 
CZT detectors simultaneously imaging 19 cardiac views. Each detector comprised 
32×32 pixelated (2.46×2.46 mm) CZT elements. Acquisition time was 5 min for the 
stress images and 4 min for the rest images. This was derived from the recommendations 
of the manufacturer, published experience and our own qualitative assessment in heart 
phantom studies and our initial experience in patients9. All SPECT studies were followed 
by an unenhanced low-dose CT scan during a breath-hold to provide the attenuation 
map for attenuation correction as previously described10.
SPECT MPI was unblindedly and semiquantitatively interpreted using a 17-segment 
model11. Segments were scored by consensus of 2 experienced nuclear cardiology 
observers using a 5-points scoring system (0=normal, 1= equivocal, 2=moderate, 3= 
severe reduction of radioisotope uptake, 4= absence of detectable tracer uptake)12. 
The combination of attenuation corrected and non-attenuation corrected images were 
reviewed. A stress study was interpreted as normal if the summed stress scores was ≤312. 
Additional rest SPECT was acquired if the stress images did not fulfill these criteria. The 
perfusion images were reviewed again after both stress and rest SPECT. An ischemic 
defect was defined as a summed difference score ≥212. Reversible defects not fulfilling these 
criteria were assessed as equivocal for ischemia. Perfusion defects which demonstrated no 
reversibility were defined as fixed defects. If, after reviewing both stress and rest SPECT, 
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no reversible of fixed defects were observed, SPECT was considered normal.
A nonenhanced CT study was performed for the CAC score by using the 64-section CT 
scanner of the integrated SPECT/CT scanner (LightSpeed VCT XT; GE Healthcare). 
All patients with heart rates >70 beats per minute received oral beta-blocker therapy, 
with 50 or 100 mg of metoprolol tartrate (AstraZeneca, Zoetermeer, the Netherlands) 
before the CAC scan. Images were obtained with electrocardiographic gating at 75% 
of the R-R interval and with the following scanning parameters: 40 or 48 sections and 
2.5-mm section thickness; gantry rotation time, 330 msec; tube voltage, 120 kV; and a 
tube current ranging from 125 to 250 mA, depending on patient size. Post-processing 
was conducted at a dedicated workstation using Smartscore software (GE Healthcare). 
The CAC score was calculated using the standard Agatston criteria13 and was categorized 
as CAC score 0, 1-99, 100-399, 400-999 or ≥1000.
Follow-up data were based on clinical visits or standardized telephone interviews. 
Major adverse cardiac events (MACE) were defined as revascularization (angioplasty 
or coronary artery bypass surgery), nonfatal myocardial infarction (MI) or all-cause 
mortality. Non-fatal MI was defined based on the criteria of typical chest pain, elevated 
cardiac enzyme levels, and typical changes on the ECG as defined by Thygesen et al14.
Continuous variables are expressed as mean ± SD or median (interquartile range) and 
categorical variables are expressed as frequency (percentage). Differences between groups 
were assessed by unpaired Student’s t-test, Mann-Whitney U test and by Chi-square test, 
where appropriate. Patient clinical characteristics were compared across different CAC 
score categories using the Chi-square test for trend. We calculated annualized event rates 
on the basis of events per patient per year and compared differences in annualized events 
between males and females in the different CAC score categories by Poisson regression 
for rate data. We used Cox proportional hazard regression to analyse the association 
between CAC scores, patient characteristics and clinical outcomes. The Cox model was 
adjusted for age, gender and traditional risk factors. Interaction terms were evaluated 
between CAC score, gender and the outcome measure with logistic regression. Two 
sided p-values <0.05 were considered statistically significant in all tests. All statistical 
analysis was performed with a commercially available software package (SPSS, version 
20.0 for Windows); the Poisson regression for rate data was performed with Medcalc 
(version 16.2 for Windows).
RESULTS
During a period of 4.5 years a total of 3705 patients were included. The main indications 
for referral were chest pain and dyspnea. The study population consisted of 2267 
females (61%) and 1438 males, clinical characteristics are demonstrated in Table 1. 
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Among patients with normal SPECT MPI, stress-only imaging was performed in 76% 
of females and in 58% of males (p <0.001). 
A total of 4 patients were lost to follow-up, the remainder of the 3701 patients (99.9%) 
were included for the follow-up analysis. Median follow-up duration was 2.8 years 
for females (interquartile range: 1.8 -3.8) and 2.8 years for males (interquartile range: 
1.9-3.9, p=0.61). Overall annual event rate was 2.01%. MACE during follow-up was 
demonstrated in 105 females and 113 males (Table 2). The annual event rates for 
females and males were 1.6% and 2.7%, respectively (p<0.001). Unadjusted event rates 
of MACE stratified by CAC score categories were similar for both genders (Figure 1). 
The CAC score was an independent predictor of MACE in both genders (Table 3). 
Adjusted survival curves stratified by CAC score for females and males are demonstrated 
in Figure 2. No significant interaction was present between the CAC score, gender 
and MACE (overall Wald for interaction p=0.65). Multivariate survival analysis in the 
different CAC categories demonstrated that gender was not an independent predictor 
of MACE in the different CAC categories (Figure 3).
Table 1. General characteristics of women and men  
Variable Women (n=2267) Men (n=1438) p-value
Mean age (years) 61 ± 11 59 ± 11 <0.001
Body mass index (kg/m2) 27 ± 5 27 ± 4 0.61
Diabetes Mellitus 254 (11%) 173 (12%) 0.44
Hypertension 1457 (64%) 778 (54%) <0.001
Family history of CAD 1334 (59%) 696 (49%) <0.001
Current smoking 308 (14%) 260 (18%) <0.001
Hypercholesterolemia 1001 (44%) 578 (40%) 0.02
CAC score (AU) 9 [0-113] 47 [1-307] <0.001
CAC score (categories)
   0 822 (36%) 337 (23%)
   1-99 845 (37%) 503 (35%)
   100-399 331 (15%) 297 (21%)
   400-999 175 (8%) 164 (11%)
   ≥1000 94 (4%) 137 (10%)
Values are shown as number (percentage), mean ± SD, median [interquartile range]. CAC, coronary artery 
calcium; CAD, coronary artery disease 
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Table 2. Major adverse cardiac events during follow-up for women and men 
Variable Women (n=2264) Men (n=1437) p-value 
Revascularization 42 (1.9%) 55 (3.8%) <0.001
Myocardial infarction 9 (0.4%) 10 (0.7%) 0.20
All-cause death 54 (2.4%) 48 (3.3%) 0.07
Values are shown as number (percentage)
Figure 1. MACE stratified by gender and coronary artery calcium score category 
CAC, coronary artery calcium; MACE, major adverse cardiac events
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DISCUSSION 
We demonstrated that the CAC score was a strong independent predictor of events 
for both female and male patients suspected for CAD. The risk for events was similar 
for both genders when stratified by CAC score, wherein a high CAC score carried a 
high risk for events despite normal SPECT MPI. Our findings did not reveal a gender-
specific prognostic value of the CAC score.
SPECT MPI is well recognized for the prognostic evaluation of patients with suspected 
CAD1. The CAC score has proven to provide additive prognostic information in these 
patients, independent of SPECT MPI3-5. The prognostic value of the CAC score could 
be gender-specific, as comparable CAC burden could have more impact in females 
because of smaller coronary arteries15, 16. However, up to now, data about the gender-
specific prognostic value of the CAC score on top of MPI were lacking.
In the current study, we demonstrated the independent prognostic value of the CAC 
score in both female and male patients with normal SPECT MPI. Overall, female 
patients had lower CAC scores than males, as previously demonstrated17, 18 and lower 
annual event rates. However, when stratified by CAC score category, females and 
males demonstrated similar unadjusted annual event rates. After adjusting for age and 
traditional risk factors, the risk for events was not significantly different for female 
and male patients when stratified by CAC score. Thereby, our findings did not reveal 
gender-specific prognostic value of the CAC score on top of normal SPECT MPI. This 
seems in contrast with previous findings, which demonstrated that females had a greater 
probability of death than males when stratified by CAC scores6. Possibly, this could be 
explained by a different outcome measure (all-cause mortality), the longer follow-up 
duration or differences in study population in the latter study, as only asymptomatic 
patients were included in that study. 
Table 3. Independent predictive value of the coronary artery calcium score in both genders
Women Men
HR 95% CI p-value HR 95% CI p-value
CAC score*
   1-99 1.2 0.6-2.4 0.56 2.4 0.9-6.4 0.92
   100-399 3.2 1.6-6.4 0.001 6.8 2.6-18.1 <0.001
   400-999 4.0 1.9-8.6 <0.001 9.0 3.2-25.1 <0.001
   ≥1000 8.5 4.0-18.1 <0.001 14.8 5.3-41.1 <0.001
Adjusted for age and traditional risk factors; CAC, coronary artery calcium; HR, hazard ratio; CI, confidence 
interval *reference category = 0 
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Figure 2.  Adjusted event rates for women (A) and men (B), stratified by coronary artery calcium score
Adjusted for age and traditional risk factors; CAC, coronary artery calcium; MACE, major adverse cardiac events
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The strength of the CAC score on top of normal SPECT MPI is the identification of 
patients with higher risk than expected based on MPI findings alone. With the current 
study we were able to demonstrate that the risk for events is similar for both genders 
when stratified by CAC score category. Thereby, a high CAC score is able to identify 
both female and male patients at increased risk, despite normal SPECT MPI. However, 
it is important to realize that the subset of female patients with severe CAC (CAC score 
≥400) is smaller than in males (12% versus 21%, respectively). Although a high CAC 
score is able to designate both female and male patients as high risk despite normal MPI 
findings, the subset of patients who are at high risk based on the CAC score is larger 
in males. Our study does not reveal an interaction between gender, CAC and outcome 
and thereby does not support gender-specific therapeutic regimens if the CAC score is 
known. In both female and male patients with a CAC score ≥400, life style advise and 
preventive cardiac medication could be initiated or intensified, despite normal MPI 
findings10, 19. Up to now, no irrefutable evidence was published which demonstrates a 
favorable impact on the prognosis of this more intensive management of patients with 
severe CAC. 
Although our study reflects true daily practice and included consecutive stable patients, 
we have to acknowledge several limitations. The observational design remains a major 
limitation of the current study, as end-points were not pre-specified. Also, this is a 
single-center study in patients with suspected CAD and a low- to intermediate pre-test 
likelihood. Therefore, extrapolation of the present results is difficult to populations with 
Figure 3. Risk for events for women and men stratified by coronary artery calcium score category
CAC, coronary artery calcium
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different pre-test likelihood or patient characteristics. In addition, SPECT observers 
were not blinded for the CAC score, therefore it cannot be excluded that the SPECT 
results were biased by the CAC score. Moreover, all imaging results were available to 
referring physicians and medical management and downstream utilization of invasive 
testing were left to discretion of the referring physician. Finally, we did not investigate 
the impact of the CAC scoring on downstream intensification of medication and thereby 
were not able to investigate the possible favorable influence of physicians’ knowledge of 
the CAC score on patient outcome.  
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ABSTRACT 
Background
The impact of coronary artery calcium (CAC) scoring on subsequent changes in 
cardiovascular medication use in symptomatic patients with normal myocardial 
perfusion imaging (MPI) findings is not well established. 
Aim
The aim of the current study was to evaluate changes in aspirin and statin use in patients 
suspected for coronary artery disease (CAD) after coronary artery calcium scoring and 
normal SPECT MPI.
Methods
In the current study, 1033 stable symptomatic patients without a known history of CAD 
with normal SPECT MPI who underwent concomitant CAC scoring were included. All 
patients had a clinical indication for imaging, mainly atypical chest pain and dyspnea, 
and were referred from the outpatient clinic of our hospital. Data regarding post-test 
medication change (either starting or discontinuation of aspirin and statin therapy at 
the subsequent outpatient visit) were retrospectively collected. Patients were categorized 
into 4 groups based on their CAC score. 
Results
Mean age of the patients was 61 ± 11 years and 39% were male. At baseline, 35% of 
the patients used aspirin and 39% used statin. In patients with CAC scores 0, 1-99, 
100-399 and ≥400, aspirin was started in 1%, 4%, 9% and 9% respectively, and statin 
was started in 0%, 7%, 18% and 24% of the patients, respectively (p<0.001). Aspirin 
was discontinued in 19%, 11%, 7% and 1% and statin was discontinued in 8%, 6%, 
2% and 0% (p<0.001) of the patients in these respective CAC score categories. After 
correction for differences in risk factors and baseline medication use, increased CAC was 
independently associated with post-test aspirin (odds ratio 4.6, 11.2 and 27.1 for CAC 
score 1-99, 100-399 and ≥400, respectively, p<0.001) and statin use (odds ratio 4.4, 
19.4 and 60.9 for CAC score 1-99, 100-399 and ≥400, respectively, p<0.001).
Conclusions
Higher CAC scores are associated with the initiation of aspirin and statin therapy in 
patients with normal SPECT MPI. In patients with lower CAC scores, discontinuation 
of cardioprotective medication is more likely. CAC score is independently associated 
with post-test statin and aspirin use. 
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INTRODUCTION
In general, patients with normal single photon emission computed tomography 
(SPECT) myocardial perfusion imaging (MPI) have a good prognosis1. However, the 
coronary artery calcium (CAC) score provides independent prognostic information on 
top of SPECT2-4. Patients with normal SPECT findings and high CAC scoring have an 
increased risk of events during follow-up. The presence of CAC is associated with aspirin 
and statin use in a healthy asymptomatic population5 and increasing CAC scores led to 
superior coronary risk factor control6. Especially in symptomatic patients the higher risk 
of events which is identified by a high CAC score may be used to strongly advise lifestyle 
changes and to intensify preventive medication use. In symptomatic patients with 
abnormal SPECT imaging it is expected that cardiovascular medication is expended 
based on the abnormal SPECT result, independent of the CAC score7,8. After normal 
SPECT MPI, the CAC score may be important to guide patient management. However, 
the impact of CAC scoring on subsequent changes in cardiovascular medication use 
in symptomatic patients with normal SPECT MPI findings is not well established. 
Therefore, we aimed to evaluate changes in aspirin and statin medication use in patients 
suspected for coronary artery disease (CAD) after CAC scoring and normal SPECT 
MPI.
METHODS
Study population
We studied stable symptomatic patients with suspected CAD prospectively enrolled 
in a SPECT/CT registry. It was approved by the Isala Medical Ethics committee and 
included a waiver of consent. Consecutive patients without a known history of CAD 
referred for clinically indicated non-invasive CAD detection with SPECT/CT in the 
Isala Hospital were included. Patients were referred from the cardiology outpatient 
clinic of our hospital, which is a large cardiovascular centre with a local, regional and 
supraregional catchment area. The pre-test likelihood of CAD was assigned according 
to the criteria of Diamond and Forrester9, with a risk threshold of <13.4% for low-
risk, between 13.4 and 87.2 % for intermediate-risk, and >87.2 % for high-risk. All 
patients routinely underwent initial 99mTc-tetrofosmin stress SPECT combined with 
simultaneous coronary artery calcium (CAC) scoring. After acquisition of stress SPECT 
and CAC scan, a cardiologist and nuclear physician in consensus assessed the need for 
additional rest SPECT imaging. In case of an abnormal stress perfusion, additional 
rest SPECT was performed, irrespective of CAC score. For the current study, we 
retrospectively identified subsequent patients scanned between January 2012 and June 
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2013 (n=1961). We excluded all patients with abnormal SPECT MPI (n=499), patients 
in whom no CAC score was acquired (mainly because of high or irregular heart rate, 
n=36) and patients referred from external hospitals who did not visit the outpatient 
clinic of the Isala Hospital (n=393). Information regarding the presence of risk factors 
and baseline medication use was prospectively collected from written questionnaires. 
These data were verified and complemented with demographic and clinical information 
collected from medical records. Height and weight were measured, and body mass index 
(BMI) was calculated. An unblinded reviewer retrospectively collected data about post-
test medication changes (either starting or discontinuation of statin and aspirin therapy 
at the first subsequent outpatient visit). First out-patients visits were generally within 
8 weeks of the non-invasive imaging. The pretest likely-hood of CAD was assigned 
according to the criteria of Diamond and Forrester9, with a risk threshold of <13.4 % 
for low risk, between 13.4 and 87.2 % for intermediate risk, and >87.2 % for high risk. 
No extramural funding was used to support this work. The authors are solely responsible 
for the design and conduct of this study, all study analyses, the drafting and editing of 
the paper and its final contents.
Stress procedures and tracer injection
Stress testing was routinely performed with pharmacological stress using adenosine (140 μg 
/min/kg for 6 min) in all patients, unless there was a contra-indication for pharmacological 
stress. Due to logistical reasons this is common practice in our high volume centre. Patients 
were instructed to refrain from caffeine containing beverages for at least 24 h before the 
test. In case of a contraindication for adenosine, patients underwent dobutamine (starting 
dose of 10 μg/kg per min, increased at 3-min intervals to a maximum of 50 μg/kg per 
min), regadenoson (fixed-dose of 400 ug bolus injection over 15 sec) or bicycle testing. A 
weight-adjusted dose of 99mTc-tetrofosmin (standard 370 MBq, 500 MBq for patients 
>100 kg) was administered after 3 minutes (adenosine), after 35 seconds (regadenoson) 
or when the target heart rate of >85% of predicted maximal was reached (dobutamine, 
bicycle test). Patients scheduled for rest imaging received a dose of 99mTc-Tetrofosmin 
(standard 740 MBq, 1000 MBq for patients >100 kg).
Myocardial perfusion image acquisition 
Both stress and rest SPECT images were acquired 45–60 min after tracer injection. 
Time delay between the stress and rest studies was >3 hours10. All patients were 
scanned with a cadmium zinc telluride (CZT)-based SPECT/CT camera (Discovery 
NM/CT 570c, GE Healthcare) with 19 stationary CZT detectors simultaneously 
imaging 19 cardiac views. Each detector comprised 32×32 pixelated (2.46×2.46 mm) 
CZT elements. Acquisition time was 5 min for the stress images and 4 min for the rest 
images. This was derived from the recommendations of the manufacturer, published 
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experience and our own qualitative assessment in heart phantom studies and our initial 
experience in patients11. All SPECT studies were followed by an unenhanced low-
dose CT scan during a breath-hold to provide the attenuation map for attenuation 
correction as previously described12.
Myocardial perfusion image interpretation
SPECT MPI was unblindedly and semiquantitatively interpreted using a 17-segment 
model13. Segments were scored by consensus of two unblinded experienced nuclear 
cardiology observers (not the study investigators) using a 5-points scoring system 
(0=normal, 1= equivocal, 2=moderate, 3= severe reduction of radioisotope uptake, 
4= absence of detectable tracer uptake)14. The combination of  attenuation corrected 
and non-attenuation corrected images were reviewed. A stress study was interpreted as 
normal if the summed stress scores was ≤314. Additional rest SPECT was acquired if 
the stress images did not fulfill these criteria. The perfusion images were reviewed again 
after both stress and rest SPECT. An ischemic defect was defined as a summed difference 
score ≥214. Reversible defects not fulfilling these criteria were assessed as equivocal for 
ischemia. Perfusion defects which demonstrated no reversibility were defined as fixed 
defects. An abnormal SPECT was defined as either ischemia, equivocal for ischemia or 
fixed defects. If, after reviewing both stress and rest SPECT, no reversible of fixed defects 
were observed, SPECT was considered normal.
CAC scoring acquisition and analysis 
A nonenhanced CT study was performed for the CAC score by using the 64-section CT 
scanner of the integrated SPECT/CT scanner (LightSpeed VCT XT; GE Healthcare). 
All patients with heart rates greater
than 70 beats per minute received oral beta-blocker therapy, with 50 or 100 mg of 
metoprolol tartrate (AstraZeneca, Zoetermeer, the Netherlands) before the CAC scan. 
Images were obtained with electrocardiographic gating at 75% of the R-R interval 
and with the following scanning parameters: 40 or 48 sections and 2.5-mm section 
thickness; gantry rotation time, 330 msec; tube voltage, 120 kV; and a tube current 
ranging from 125 to 250 mA, depending on patient size. Post-processing was conducted 
at a dedicated workstation using Smartscore software (GE Healthcare). The CAC score 
was calculated using the standard Agatston criteria15 and was categorized as none (CAC 
score 0), mild (CAC score 1-99), moderate (CAC score 100-399) or severe CAC (CAC 
score ≥400).  
Statistical analysis
Continuous variables are expressed as mean ± SD or median (25th-75th percentile) 
and categorical variables are expressed as frequency (percentage). Differences between 
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groups were assessed by unpaired Student’s t-test, Mann-Whitney U test and by Chi-
square test, where appropriate. The patient’s pre-test likelihood for CAD was determined 
with the standard Diamond criteria with the assumption that chest pain was atypical9. 
Patient clinical characteristics were compared across different CAC score categories 
using the Chi-square test for trend. Multivariate logistic regression was performed to 
investigate whether CAC score was an independent predictor for post-test aspirin and 
statin use after adjusting for baseline medication use and other significant variables in 
univariate analysis. For the model for prediction of post-test aspirin use the variables 
age, gender, diabetes mellitus, hypercholesterolemia, hypertension, current smoking, 
CAC score and baseline medication use were included. For the model for prediction of 
post-test statin use the variables age, gender, diabetes mellitus, hypercholesterolemia, 
baseline medication use and CAC score were included in the model. A value of 
p<0.05 in univariate analysis was required for entry into the multivariate analysis. Two 
sided p-values of less than 0.05 were considered statistically significant in all tests. 
All statistical analysis was performed with a commercially available software package 
(SPSS, version 20.0 for Windows). 
Table 1. General patient characteristics based on severity of coronary artery calcification 
All patients
n=1033
CAC score 
0
n=333
CAC score 
1-99
n=333
CAC score 
100-399
n=206
CAC score 
≥ 400
n= 161
p-value
Age, years 61 ± 11 55 ± 10 60 ±11 66 ±9 69 ± 9 <0.001
Male gender 400 (39) 87 (26) 128 (38) 98 (48) 87 (54) <0.001
BMI 27 ± 5 27 ± 5 28 ± 5 27 ± 4 28 ± 4 0.06
Risk factors
   Diabetes Mellitus 115 (11) 22 (7) 34 (10) 21 (10) 38 (24) <0.001
   Hypercholesterolemia 444 (43) 117 (35) 139 (42) 103 (50) 85 (53) <0.001
   Hypertension 601 (58) 166 (50) 182 (55) 140 (68) 113 (70) <0.001
   Current smoking 153 (15) 52 (16) 48 (14) 26 (13) 27 (17) 0.96
   Family history of  
   CAD
586 (57) 213 (64) 177 (53) 117 (57) 79 (49) 0.004
Medical history
   PAD 54 (5) 14 (4) 11 (3) 15 (7) 14 (9) 0.09
   TIA/Stroke 71 (7) 13 (4) 22 (7) 18 (9) 18 (11) 0.02
Baseline medication
   Aspirin 356 (35) 96 (29) 114 (34) 78 (38) 68 (42) 0.002
   Lipid lowering drugs 407 (39) 95 (29) 134 (40) 91 (44) 87 (54) <0.001
Values are shown as number (percentage), mean ± standard deviation, median [25th-75th percentile] 
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RESULTS
During a period of 1.5 years a total of 1033 patients were included. The main indications 
for referral were atypical chest pain and dyspnea. Pre-test likelihood was considered to 
be low in 11% of the patients and intermediate in 89% of the patients. Stress testing 
was performed with adenosine in 976 (94.5%), with dobutamine in 23 (2.2%), with 
regadenoson in 12 (1.2%) and with exercise testing in 22 (2.1%) of the patients. Clinical 
patient characteristics are shown in Table 1. The mean age was 61 ± 11 years and 39% 
of the patients were male. At baseline, 35% of the patients used aspirin and 39% used 
statin. Significant differences in general characteristics were present in patients with 
increasing CAC scores. Increasing CAC was associated with higher age, male gender 
and more cardiovascular risk factors. Baseline use of aspirin and statin was strongly 
associated with CAC score category (Table 1).  The median CAC score was 27 (25th-75th 
percentile, 0-213), with a range from 0 to 18041. CAC scores of 0, 1-99, 100-399 and 
≥400 were demonstrated in 333 (32%), 333 (32%), 206 (20%) and 161 (16%) of the 
patients, respectively.
Modification of medication
Of the total patient population, 242 patients (23%) had a post-test change in aspirin 
and/or statin therapy. In 119 (12%) of the patients statin and/or aspirin was started, 
in 125 (12%) statin and/or aspirin was discontinued. Medication treatment at baseline 
and modification post-test are demonstrated in Table 2. 
Table 2. Medication treatment at baseline and post-test, for total study population and stratified by CAC 
score category 
Total 
population
n=1033 
CAC score 
0
n=333
CAC score 
1-99
n=333
CAC score 
100-399
n=206
CAC score 
≥ 400
n= 161
p-value
Aspirin use (baseline) 356 (35) 96 (29) 114 (34) 78 (38) 68 (42) 0.002
   Start aspirin* 49 (7) 2 (1) 14 (6) 18 (1) 15 (16) <0.001
   Stop aspirin† 115 (32) 62 (65) 38 (33) 14 (18) 1 (1) <0.001
Aspirin use (post-test) 290(28) 36 (11) 90 (27) 82 (40) 82 (51) <0.001
Statin use (baseline) 407 (39) 95 (29) 134 (40) 91 (44) 87 (54) <0.001
   Start statin* 101 (16) 1 (0.4) 24 (12) 37 (33) 39 (53) <0.001
   Stop statin† 53 (13) 27 (28) 21 (16) 5 (5) 0 (0) <0.001
Statin use (post-test) 455 (44) 69 (21) 137 (41) 123 (59) 126 (78) <0.001
CAC, coronary artery calcium. Values are shown as number (percentage) * values are shown as number 
(percentage of patients without use at baseline) † values are shown as number (percentage of patients with 
use at baseline)
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In patients with CAC scores 0, 1-99, 100-399 and ≥400, statin was started in 0%, 
7%, 18% and 24% respectively, and aspirin was started in 1%, 4%, 9% and 9% of 
the patients, respectively (p<0.001). In these respective CAC categories, statin was 
discontinued in 8%, 6%, 2% and 0% and aspirin was discontinued in 19%, 11%, 
Table 3. Univariate analysis of general characteristics of patients with and without cardiovascular medication 
post-test. 
Statin  
post-test
n=452
No statin 
post-test
n=581
p-value ASA  
post-test
n=289
No ASA 
post-test
n=744
p-value 
Age 63 ± 10 60 ± 12 <0.001 63 ± 10 60 ± 11 <0.001
Male gender 199 (44) 201 (35) 0.002 126 (44) 274 (37) 0.045
Risk factors
   Diabetes Mellitus 95 (21) 20 (3) <0.001 49 (17) 66 (9) <0.001
   Hypercholesterolemia 306 (68) 138 (24) <0.001 149 (52) 295 (40) 0.001
   Hypertension 307 (68) 294 (51) <0.001 183 (63) 418 (56) 0.04
   Current smoking 69 (15) 84 (15) 0.71 58 (20) 95 (13) 0.003
   Family history of CAD 258 (57) 328 (57) 0.77 161 (56) 425 (57) 0.67
Baseline medication use
   Aspirin 219 (49) 137 (24) <0.001 240 (83) 116 (16) <0.001
   Lipid lowering drugs 352 (78) 55 (10) <0.001 168 (58) 239 (32) <0.001
CAC score 142 [18-451] 2 [0-68] <0.001 164 [13-487] 9 [0-113] <0.001
CAC, coronary artery calcium; CAD, coronary artery disease
Table 4. Multivariate analysis of post-test statin use
OR 95% CI P-value
Age 0.97 0.96-0.995 0.14
Gender 1.07 0.71-1.62 0.75
Hypertension 1.41 0.93-2.13 0.10
Diabetes mellitus 2.13 1.08-4.19 0.03
Hypercholesterolemia 3.06 2.02-4.64 <0.001
Aspirin at scan date 0.87 0.55-1.38 0.55
Statin at scan date 47.97 27.71-83.03 <0.001
OR, odds ratio; CI, confidence interval. Adjusted for baseline medication use and other significant variables 
in univariate analysis.
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7% and 1% (p<0.001). In none of the patients with a CAC score of ≥400, statin was 
discontinued. Patients who were treated with statin and/or aspirin post-test were older, 
more often male and diabetic, more often had hypertension and hypercholesterolemia 
and demonstrated higher CAC scores (Table 3). After correction for differences in 
risk factors and baseline medication use, severity of CAC scoring was independently 
associated with post-test aspirin and statin use (Figure 1, p<0.001). The other variables 
included in the multivariate analysis are demonstrated in Table 4 and Table 5. 
Figure 1. Multivariate analysis of effect of CAC score on post-test cardiovascular medication use
CAC, coronary artery calcium; OR, odds ratio; CI, confidence interval. *Reference category CAC score 0, 
adjusted for baseline medication use and other significant variables in univariate analysis.
Table 5. Multivariate analysis of post-test aspirin use
OR 95% CI P-value
Age 1.01 0.99-1.03 0.35
Gender 1.14 0.74-1.75 0.57
Hypertension 0.88 0.57-1.35 0.57
Current smoking 1.56 0.91-2.67 0.10
Diabetes mellitus 2.59 1.37-4.88 0.003
Hypercholesterolemia 1.47 0.94-2.28 0.09
Aspirin at scan date 40.40 24.23-67.38 <0.001
Statin at scan date 0.53 0.33-0.87 0.01
OR, odds ratio; CI, confidence interval. Adjusted for baseline medication use and other significant variables 
in univariate analysis.
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DISCUSSION
Our study showed that knowledge of CAC significantly influences subsequent 
cardiovascular medication use in patients with normal SPECT MPI findings. Patients 
with higher CAC scores were more likely to start with aspirin or statin therapy. Lower 
CAC scores were associated with cessation of this medication. The influence of CAC on 
aspirin and statin use proved to be independent of patient characteristics. 
Patients with normal SPECT MPI are generally considered to have a benign prognosis1, 
although it is associated with a low but well-defined risk for events16. This may be 
explained by underlying CAD, which remains undetected with a merely functional 
imaging technique such as SPECT. With the advent of hybrid SPECT/CT imaging, 
this underlying atherosclerosis can be easily detected with low-dose CAC scoring17. 
Indeed, in our population the majority of patients (68%) with normal SPECT MPI 
had subclinical CAD, which was severe (CAC score ≥400) in 16%. It has been well 
established that patients with higher CAC scores are at increased risk for cardiovascular 
events, even in the setting of normal SPECT2-4. Thereby, combining SPECT MPI 
with CAC scoring results in improved patient risk assessment. However, whether this 
improved risk assessment also leads to differences in medication management in patients 
with normal SPECT MPI was unclear.  
In our study, the referring physician initiates or discontinues treatment on the basis 
of simultaneous CAC scoring in nearly a quarter of patients. A step-wise increase 
of initiation of aspirin and statin and a decrease in cessation of this medication was 
present with increasing CAC score categories. We showed that patients with severe CAC 
(≥400) are treated with statin therapy post testing in 78% of the patients, even in the 
presence of normal SPECT MPI findings. Statin therapy was started in almost a quarter 
of these patients. Conversely, in patients with a CAC score of zero, aspirin and statin 
was discontinued in a substantial percentage of patients. This could lower costs and 
prevent side-effects in patients who are unlikely to benefit from this medication. After 
correcting for differences in baseline variables and medication use, CAC score remained 
independently associated with post-test statin and aspirin use.
It was previously demonstrated that the presence of coronary artery calcification 
(CAC score >0) was associated with an independent 3-fold greater likelihood of statin 
and aspirin usage in a male screening population5. This was confirmed by the large 
prospective Multi-Ethnic Study of Atherosclerosis, which demonstrated a higher 
likelihood of initiation and continuation of lipid-lowering drugs and aspirin in patients 
with CAC scores >40018. Although these two studies were performed in screening 
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populations and the CAC scoring was not combined with a functional imaging modality 
to assess myocardial perfusion, the results are similar to our findings. In two studies in 
patients with normal positron emission tomography MPI it was found that the presence 
of CAC was associated with initiation or intensification of treatment with statin or 
aspirin19,20, which is consistent with our study. However, in the latter two studies, the 
discontinuation of treatment was not evaluated. A remarkable difference in our study 
was that the frequency of patients with no CAC in who aspirin or statin therapy was 
started was negligible in our study, while this was still 14% and 11% in the study by 
Bybee et al, respectively. Possibly this is caused by the higher risk population included 
in that study, as patients were older and more frequently diabetic. However, due to the 
low risk of events demonstrated in these patients the indication of aspirin treatment in 
patients without CAC is questionable21. Importantly, recent findings demonstrated that 
patients with a CAC score of zero have unfavorable risk/benefit profiles with aspirin, 
independent of traditional risk factors22. 
The impact of more intensive cardiovascular medication management on patient 
outcome in patients with severe CAC is not yet established. One randomized trial was 
able to demonstrate a non-significant trend towards reduction of cardiovascular events 
in patients with CAC scores >400 who were treated with statin in combination with 
antioxidant vitamins23. In an observational study, patients with a CAC score ≥100 
demonstrated to have an estimated treatment benefit on aspirin22. Furthermore, in 
two observational studies in patients with CAD on coronary computed tomography, 
a better prognosis was observed if patients were taking statins24,25. At this moment, no 
irrefutable evidence of an improved patient outcome caused by intensified medication 
management in patients with severe CAC is available and no clear recommendations 
are given in current guidelines. In the 2013 ACC/AHA Guideline on the Treatment of 
Blood Cholesterol  to Reduce Atherosclerotic Cardiovascular Risk in Adults it is stated 
that it is reasonable to consider statin treatment in patients with a CAC score >30026. 
The 2012 European Guidelines on cardiovascular disease prevention in clinical practice 
does not make a statement about preventive medication in patients with severe coronary 
calcifications27 . Therefore, referring physicians are left with uncertainties how to optimally 
treat patients with coronary sclerosis, especially if there is a discrepancy between cardiac 
risk assessed with CAC scoring and standard risk scores. Our study demonstrated that the 
improved risk assessment with CAC scoring in patients with normal SPECT translates in 
downstream modification of cardiovascular medication and underlines the importance of 
further research of the effect of medication change on patient outcome.
Although our study included consecutive patients referred for normal SPECT MPI who 
underwent simultaneous CAC scoring, we have to acknowledge several limitations. This 
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is a single-center registry in patients with suspected CAD and a low- to intermediate 
pre-test likelihood undergoing predominantly pharmacological stress. Extrapolation of 
the current results is difficult to patients with different pre-test likelihood or or patients 
undergoing traditional exercise testing. Although the questionnaire is routinely used in 
patients undergoing SPECT-CT imaging in our centre and therefore the response rate 
is high, we did not collect a survey response rate. The pre-test likelihood is determined 
with Diamond and Forrester criteria. Although used often for research and clinical 
purposes, one must bare in mind that pre-test likelihood is probably overestimated using 
this method as was shown by Cheng et al.28 Also, data about medication change at the 
first outpatient visit were retrospectively collected. In addition, as follow-up data was 
not available, we were not able to compare outcomes in patient with or without post-test 
aspirin and/or statin therapy. Although we only included patients with normal SPECT 
MPI and monitored medication change at the first outpatient visit post-test, it cannot 
be excluded that other factors than CAC scoring influenced medication change. We did 
not perform follow-up of the medication use after the first outpatient visit. Therefore, 
our results only can be applied to very early adherence following testing. Finally, no 
systematic follow-up was performed of patients whom did not have an outpatients visit.
CONCLUSION 
Higher CAC scores are associated with the initiation of aspirin and statin therapy in 
patients with normal SPECT MPI. In patients with lower CAC scores, it is more likely 
that this medication is discontinued. CAC score is independently associated with post-
test statin and aspirin use. 
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ABSTRACT
Background
Performing both single photon emission computerized tomography (SPECT) and 
coronary computed tomography angiography (CCTA) in patients suspected for coronary 
artery disease (CAD) leads to increased radiation exposure. We evaluated the need for 
additional imaging and following implications for radiation exposure of a sequential 
SPECT/computed tomography (CT) algorithm.
Methods and Results
5018 consecutive patients without history of CAD were referred for stress-first SPECT 
and coronary artery calcium (CAC) scoring. If stress SPECT was abnormal, additional 
rest SPECT and, if feasible, CCTA were acquired. Stress SPECT was normal in 2617 
patients (52%). CCTA was not performed in 1289 of the 2401 patients referred for 
additional imaging (54%), mainly because of severe CAC (47%) or fast/irregular heart 
rate (22%). 642 patients with abnormal SPECT underwent CCTA, which excluded 
significant CAD in 378 patients (59%). Mean radiation dose was 4.5±0.3mSv for stress-
only imaging and 13.2±3.3mSv for additional imaging (p<0.001).
Conclusions
Half of the patients do not require additional imaging in our sequential SPECT/
CT algorithm, which is accompanied with low radiation exposure. CCTA cannot be 
performed in half of the patients who undergo additional imaging because of (relative) 
contra-indications. CCTA is able to correct for false positive SPECT findings in our 
algorithm. 
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BACKGROUND
Although coronary computed tomography angiography (CCTA) may be an excellent 
tool for ruling out relevant coronary artery disease (CAD)1, it is not able to assess the 
hemodynamic relevance of luminal stenosis2,3, and has limited diagnostic accuracy with 
higher coronary artery calcium (CAC) scores4. Furthermore, CCTA requires specific 
patient characteristics such as normal renal function and low regular heart rhythm5. 
Since the diagnostic and prognostic value of myocardial perfusion imaging with single 
photon emission computerized tomography (SPECT) has been well established, and 
is feasible in almost all patients, the combination of CCTA and SPECT has been 
suggested to result in a more definite diagnosis6-8. However, performing both SPECT 
and CCTA in all patients suspected for CAD would lead to increased radiation exposure 
and costs and therefore various suggestions for a sequential SPECT/CT protocol have 
been made9-12. We incorporated a sequential diagnostic algorithm starting with stress 
SPECT and CAC scoring, if necessary followed by additional imaging with rest SPECT 
and CCTA. With the current study, we evaluated the need for additional imaging 
and following implications for total radiation exposure of this sequential SPECT/CT 
imaging algorithm in patients with a low to intermediate pre-test likelihood of CAD.
METHODS
Study population
We performed a prospective observational single-centre cohort study, in which 
consecutive patients with suspected CAD referred for non-invasive CAD detection 
with SPECT/computed tomography (CT) between January 2009 until June 2013 
were included. Patients were referred from the cardiology outpatient clinics of our 
hospital, which is a large cardiovascular center with a local, regional and supraregional 
catchment area. The pretest likelihood of CAD was assigned according to the criteria of 
Diamond and Forrester13, with a risk threshold of <13.4% for low risk, between 13.4 
and 87.2% for intermediate risk, and >87.2% for high risk. Patients with known history 
of CAD  were excluded, no other exclusion criteria were applied. Information regarding 
the presence of risk factors were collected by written questionnaires. All patients 
underwent a sequential 1-day 99mTc-tetrofosmin SPECT/CT protocol according to 
an individualized algorithm. All patients underwent initial stress SPECT combined 
with CAC scoring. Immediately after acquisition of stress SPECT and CAC scan, a 
cardiologist and nuclear physician together assessed the need for additional rest SPECT 
imaging and CCTA. In case of an abnormal stress perfusion, additional rest SPECT 
was performed, independent of CAC scoring result. The rest SPECT was combined 
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   77 17-08-18   07:38
Chapter 5
78
with an additional CCTA if the heart rate allowed optimal diagnostic CT acquisition, 
CAC score was not too high (generally <400 and the absence of large calcified segments) 
and contraindications were absent (renal insufficiency, known hypersensitivity to iodine 
contrast media). The final diagnosis was considered normal (i.e. no or no significant 
CAD) if either SPECT perfusion was normal or if CCTA excluded obstructive CAD. 
All procedures were performed in accordance with the Declaration of Helsinki. The 
study was approved by the Committee on Research Ethics of our hospital, and written 
informed consent was obtained from all patients.
Myocardial perfusion imaging
Stress testing was routinely performed with pharmacological stress using adenosine 
(140 μg /min/kg for 6 min) in all patients, unless there was a contra-indication for 
pharmacological stress. Due to logistical reasons this is common practice in our high 
volume centre. Patients were instructed to refrain from caffeine containing beverages 
for at least 24 h before the test. In case of a contraindication for adenosine, patients 
underwent dobutamine (starting dose of 10 μg/kg per min, increased at 3-min intervals 
to a maximum of 50 μg/kg per min), regadenoson (fixed-dose of 400 ug bolus injection 
over 15 sec) or bicycle testing. A weight-adjusted dose of 99mTc-tetrofosmin (standard 
370 MBq, 500 MBq for patients >100 kg) was administered after 3 minutes (adenosine), 
after 35 seconds (regadenoson) or when the target heart rate of >85% of predicted 
maximal was reached (dobutamine, bicycle test)14. Patients scheduled for rest imaging 
received a dose of 99mTc-Tetrofosmin (standard 740 MBq, but 1000 MBq for patients 
> 100 kg). Both stress and rest SPECT images were acquired 45–60 min after tracer 
injection. Time delay between the stress and rest studies was >3 hours15. All patients 
were imaged in the supine position with arms placed above the head.
From January 2009 until April 2010, patients (n=977) were scanned on a conventional 
dual-detector gamma camera (Ventri-LightSpeed VCT XT, GE Healthcare), using a 
low-energy, high-resolution collimator, a 20% symmetrical window at 140 keV, a 64x64 
matrix, and an elliptical orbit with step-and-shoot acquisition at 6 º intervals over a 180 
º arc (45 º right anterior oblique to 45 º left posterior oblique) with 30 steps (30 views). 
Acquisition time was 12 min for the stress images and 15 min for the rest images as 
previously described16. 
From May 2010 until June 2013, patients (n=4057) were scanned with a cadmium zinc 
telluride (CZT)-based SPECT/CT camera (Discovery NM/CT 570c, GE Healthcare) 
with 19 stationary CZT detectors simultaneously imaging 19 cardiac views. Each 
detector comprised 32×32 pixelated (2.46×2.46 mm) CZT elements. Acquisition time 
was 5 min for the stress images and 4 min for the rest images. This was derived from the 
recommendations of the manufacturer, published experience and our own qualitative 
assessment in heart phantom studies and our initial experience in patients17. All SPECT 
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studies were followed by an unenhanced low-dose CT scan during a breath-hold to 
provide the attenuation map for attenuation correction as previously described18.
Perfusion images were unblindedly and semiquantitatively interpreted using a 17-segment 
model19. Segments were scored by consensus of two experienced nuclear cardiology 
observers using a 5-points scoring system (0=normal, 1= equivocal, 2=moderate, 3= 
severe reduction of radioisotope uptake, 4= absence of detectable tracer uptake)20. The 
combination of  attenuation corrected and non-attenuation corrected images were 
reviewed and rest SPECT was acquired if there was uncertainty about normalcy of 
perfusion using both image sets. A stress study was interpreted as normal if the summed 
stress scores was ≤320. Additional rest SPECT was acquired if the stress images did not 
fulfill these criteria. Gated SPECT analysis was used as an aid to differentiate between 
artefacts and perfusion defects.
The perfusion images were reviewed again by a cardiologist and a nuclear physician after 
both stress and rest SPECT. An ischemic defect was defined as a summed difference 
score ≥220. Reversible defects not fulfilling these criteria were assessed as equivocal for 
ischemia. Perfusion defects which demonstrated no reversibility were defined as fixed 
defects. An abnormal SPECT was defined as either ischemia, equivocal for ischemia or 
fixed defects. If, after reviewing both stress and rest SPECT, no reversible of fixed defects 
were observed, the SPECT was considered normal. 
CAC scoring and CCTA
All cardiac CT studies were performed by using the 64-section CT scanner of the 
integrated SPECT/CT scanner (LightSpeed VCT XT; GE Healthcare). All patients 
with heart rates greater
than 70 beats per minute received oral beta-blocker therapy, with 50 or 100 mg 
of metoprolol tartrate (AstraZeneca, Zoetermeer, the Netherlands) before the CAC 
scan. A nonenhanced CT scan to calculate the total CAC score was acquired with 
ECG triggering at 75% of the R-R interval and the following scanning parameters: 
40 or 48 sections and 2.5-mm section thickness; gantry rotation time, 330 msec; 
tube voltage, 120 kV; and a tube current ranging from 125 to 250 mA, depending 
on patient size. Post-processing was conducted at a dedicated workstation using 
Smartscore software (GE Healthcare). The CAC score was calculated using the 
standard Agatston criteria21.
Before acquiring CCTA images, patients with a heart rate exceeding the threshold of 
65/min were administered beta-blocking medication (50-100 mg metoprolol, oral, 
or 5 to 10 mg metoprolol, intravenous). A scout view of the chest was first obtained, 
followed by prospectively (83%) or retrospectively (on indication) ECG-triggered 
CCTA according to the guidelines provided by the Society of Cardiovascular Computed 
Angiography22. Coronary arteries were subdivided according to a 15-segment model 
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as proposed by the American Heart Association23. Each segment was evaluated on 
at least two planes according to Society of Cardiovascular Computed Tomography 
guidelines24, and the degree of diameter stenosis was visually graded by consensus of 
the two readers as obstructive CAD when narrowing of the coronary lumen was 50% 
or greater.
Effective radiation dose 
Radiation dose for SPECT was calculated as 99mTc-tetrofosmin activity times 7.9mSv/
GBq as suggested by the International Commission on Radiological Protection25. 
Effective radiation dose for CCTA was estimated as dose-length product times a 
conversion coefficient for the chest k (0.017 mSv/mGy/cm)26.
Follow-up
Follow-up data were based on clinical visits, standardized telephone interviews and by 
consulting the municipal population register. Events that were noted during follow-up 
were all-cause mortality and nonfatal myocardial infarction (MI). Non-fatal myocardial 
infarction was defined based on the criteria of typical chest pain, elevated cardiac enzyme 
levels, and typical changes on the ECG as defined by Thygesen et al27.
Statistical analysis
Continuous variables are expressed as mean ± SD or median [25th-75th percentile] 
and categorical variables are expressed as frequency (percentage). Differences between 
groups were assessed by unpaired Student t test, Mann-Whitney U test and by Chi-
square test, where appropriate. We evaluated the differences in general characteristics 
of patients with normal or abnormal stress SPECT, of patients who underwent rest 
SPECT with or without additional CCTA and of patients with normal or abnormal final 
diagnosis. The patient’s pre-test likelihood for CAD was determined with the standard 
Diamond criteria with the assumption that chest pain was atypical13. Multivariate 
logistic regression was performed to investigate which general characteristics were 
independent predictors for an abnormal stress SPECT and abnormal final diagnosis 
after adjusting for other significant variables in univariate analysis. A value of p< 0.05 
in univariate analysis was required for entry into the multivariate analysis. Significant 
variables analyzed are reported with their respective odds ratio and 95% confidence 
intervals. In the selected group of patients who underwent both SPECT and CCTA, 
sensitivity, specificity, negative predictive value and positive predictive value of SPECT 
was calculated with CCTA as gold standard. The normalcy rate, the rate of normal 
perfusion scans in patients with <5% likelihood of CAD, was reported as a surrogate 
for specificity to account for referral bias28. Differences in event-free survival over time 
were analyzed by the Kaplan-Meier method. Time 0 was defined as the date of SPECT 
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imaging. Annualized event rate was calculated on the basis of events per patients-year. 
Two sided p-values of less than 0.05 were considered statistically significant in all tests. 
All statistical analysis was performed with a commercially available software package 
(SPSS, version 20.0 for Windows).
RESULTS 
Study population
During a period of 4.5 years a total of 5026 patients were included. Follow-up 
information was complete for 99.8% of the patients, only 8 patients were lost to follow-
up. The remainder of 5018 patients are the subject of this report. The main indications 
for referral were atypical chest pain and dyspnoea. Pre-test likelihood was considered to 
be low in 9% of the patients and intermediate in 91% of the patients. The mean age 
was 61 ± 11 years, 57% of the patients were female, 14% were diabetic and the mean 
BMI was 27.6 ± 4.8. Stress testing was performed with adenosine in 4816 (96.0%), with 
dobutamine in 114 (2.3%), with regadenoson in 34 (0.7%) and with exercise testing in 
54 (1.1%) of the patients.
Sequential SPECT/CT algorithm
Figure 1 displays the individualized sequential SPECT/CT algorithm. All 5018 
patients underwent stress SPECT. CAC score was obtained in 4897 patients (97.6%). 
A fast or irregular heart rate was the main reason for not acquiring CAC score. In 
2617 patients (52% of the total population) the stress SPECT was normal and these 
patients were discharged without additional rest SPECT or CCTA. Differences in the 
general characteristics between patients with normal and abnormal stress SPECT are 
demonstrated in Table 1. Independent predictors for abnormal stress SPECT were older 
age, male gender, diabetes mellitus, current smoking, left bundle branch block (LBBB), 
higher body mass index and higher CAC score (Figure 2). In 2401 patients (48% 
of the total population) the stress SPECT was regarded abnormal and these patients 
underwent additional rest SPECT and CCTA (if feasible). CCTA was not performed 
in 1289 patients (54%) because of high CAC scoring  (n=591, 46.7%), fast/irregular 
heart rate (n=281, 21.8%), renal insufficiency (n=89, 6.9%), small atypical perfusion 
defects suspected for artefact (n=251, 19.5%), contrast allergy (n=9, 0.7%), expected 
scatter from pacemaker lead (n=6, 0.5%), anxiety/unable to hold breath (n=11, 0.9%), 
or unclear reasons (n=51, 3.9%). Table 2 demonstrates the differences in general 
characteristics between patients who underwent additional rest SPECT with or without 
CCTA.
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Table 1. General characteristics of patients with normal stress SPECT, compared to patients with abnor-
mal stress SPECT 
Normal stress 
SPECT
n=2617
Abnormal stress 
SPECT 
n=2401
p- value 
Age, years 60 ± 12 63 ± 11 <0.001
Males 851 (32.5) 1305 (54.4) <0.001
Cardiac risk factors
   Diabetes mellitus 257 (9.8) 420 (17.5) <0.001
   Hypertension   1539 (58.8) 1521 (63.4) 0.001
   Current smoking 386 (14.8) 406 (17.0) 0.034
   Hyperlipidemia 1100 (42.0) 1058 (44.1) 0.139
   Family history of CAD 1462 (56.0) 1255 (52.5) 0.015
LBBB 40 (1.5) 178 (7.5) <0.001
Atrial fibrillation 56 (2.1) 81 (3.4) 0.007
BMI 27 ± 4 28 ± 5   
<0.001
Systolic blood pressure 138 ± 21 142 ± 21 <0.001
Diastolic blood pressure 84 ± 13 85 ± 13 0.218
Heart rate 72 ± 12 71 ± 12 0.374
Creatinine 76 ± 41 80 ± 37 <0.001
CAC score 8 [0-108] 130 [8-549] <0.001
CAD, coronary artery disease; LBBB, left bundle branch block; BMI, body mass index; CAC, coronary 
artery calcium; values are shown as number (percentage), mean ± SD, median [25th-75th percentile]
Figure 1. Flowchart of the individualized sequential SPECT/CT algorithm
CAC, coronary artery calcium; CCTA, coronary computed tomography angiography; normal final 
diagnosis, SPECT perfusion normal or CCTA without significant coronary artery disease
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Effective radiation dose
The mean radiation dose after completing the diagnostic algorithm was 8.6 ± 4.9 mSv for 
the entire cohort. The mean radiation dose was 4.5 ± 0.3mSv in patients who underwent 
stress-only imaging and 13.2 ± 3.3 mSv in patients who underwent additional imaging 
(p<0.001).
Imaging results
All 2617 patients who were discharged after stress SPECT and CAC scoring had normal 
myocardial perfusion. Among 2401 patients who underwent additional rest SPECT, 
myocardial perfusion was considered normal in 1175 patients (49%) after reviewing 
both stress and rest images. Finally, SPECT was considered normal in 3790 (76%) of 
the total population. In the remaining 1228 patients SPECT was considered abnormal, 
of which 299 patients (24%) had equivocally reversible defects, 513 (42%) had findings 
clearly suggestive for ischemia and 416 (34%) showed fixed perfusion defects. 
The median CAC scoring for the total population was 39 [25th-75th percentile, 0 – 282]. 
1315 of the patients (27%) demonstrated a CAC score of zero, and 995 of the patients 
(20%) demonstrated a CAC score >400. A total of 1112 patients underwent CCTA, of 
which 751 (68%) showed no obstructive CAD,  349 (31%) showed significant CAD 
and 12 (1.0%) were assessed as non-evaluable due to limited image quality. 
Of the 2617 patients with normal stress SPECT, the CAC score was 0 in 37%, 1-100 in 
38%, 101-400 in 15% and >400 in 11%. Of the 2401 patients who required additional 
imaging, the CAC score was 0 in 16%, 1-100 in 30%, 101-400 in 23% and >400 in 
Figure 2. Significant independent predictors of initial stress SPECT result
Age (upper quartile 69); BMI, body mass index (upper quartile: 30); LBBB, left bundle branch block; 
CAC, coronary artery calcium (upper quartile: 282); CI confidence interval
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31%. In the 1228 patients who had an abnormal SPECT, 13%, 27%, 24% and 36% 
had CAC scores of 0, 1-100, 101-400 and >400, respectively.
Of the total of 1112 patients who underwent CCTA, in 470 (42%) SPECT perfusion 
was considered normal after viewing both stress and rest SPECT. CCTA excluded 
obstructive CAD in 373 (80%) of these 470 patients. In the remainder of the patients 
who underwent CCTA (n=642, 58%)  the perfusion was considered abnormal. Of these 
642 patients, in 378 patients (60%) obstructive CAD was excluded with CCTA. 
In the subpopulation of patients who underwent both CCTA and SPECT, the sensitivity 
of SPECT was 73% and the specificity was 50% (negative predictive value 79%, positive 
predictive value 41%). The normalcy rate of SPECT was 87%. 
With the combination of SPECT and CCTA imaging, 4168 (83%) of the patients were 
concluded to have normal final diagnosis after completing the diagnostic algorithm. 
Differences in general characteristics between patients with normal and abnormal 
Table 2. General characteristics of 2401 patients undergoing additional rest SPECT with or without CCTA 
Additional rest SPECT 
without CCTA
n=1289
Additional rest SPECT 
with CCTA
n=1112
p-value
Age, years 65 ± 11 60 ± 11 <0.001
Males 678 (52.6) 627 (56.4) 0.063
Cardiac risk factors
   Diabetes mellitus 294 (22.8) 126 (11.3) <0.001
   Hypertension   864 (67.1) 657 (59.1) <0.001
   Current smoking 185 (14.4) 221 (19.9) 0.001
   Hyperlipidemia 582 (45.2) 476 (42.8) 0.235
   Family history of CAD 643 (50.2) 612 (55.2) 0.016
LBBB 88 (6.9) 90 (8.2) 0.230
Atrial fibrillation 80 (6.2) 0 <0.001
BMI 29 ± 5 28 ± 5 0.004
Systolic blood pressure 143 ± 22 140 ± 20 0.001
Diastolic blood pressure 85 ± 13 84 ± 12 0.322
Heart rate 73 ± 13 70 ± 11 <0.001
Creatinine 84 ± 49 77 ± 16 <0.001
CAC score 260 [14-1119] 76 [5-258] <0.001
CAD, coronary artery disease; LBBB, left bundle branch block; BMI, body mass index; CAC, coronary 
artery calcium; CCTA, coronary computed tomography angiography; values are shown as number 
(percentage), mean ± SD, median [25th-75th percentile]
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final diagnosis are demonstrated in Table 3. Independent predictors of final abnormal 
diagnoses were older age, male gender, diabetes mellitus, LBBB, higher body mass index 
(BMI) and higher CAC scoring (Figure 3). 
Follow-up
Over a median follow-up duration of 965 days [25th-75th percentile, 600-1397], there 
were 205 events (166 all-cause deaths, 39 nonfatal MI). Annual event rate of patients 
with normal myocardial perfusion after stress-only SPECT was slightly lower compared 
to those with normal myocardial perfusion after additional rest imaging (1.07% vs 
1.60%, p=0.04). For patients with an abnormal SPECT but no obstructive CAD on 
CCTA the annual event rate was 0.85% (9 deaths, 1 MI), for patients with normal 
SPECT but obstructive CAD this was 1.64% (4 deaths, 1 MI) and for patients with 
both abnormal SPECT and obstructive CAD on CCTA this was 2.15% (11 deaths, 
Table 3. General characteristics of patients with normal final diagnosis, compared to patients with abnormal 
final diagnosis 
Normal final 
diagnosis 
N=4168
Abnormal final 
diagnosis 
N=850
p- value 
Age, years 60 ± 11 66 ± 10 <0.001
Males 1658 (39.8) 498 (58.6) <0.001
Cardiac risk factors
   Diabetes mellitus 492 (11.8) 185 (21.8) <0.001
   Hypertension   2477 (59.4) 583 (68.6) <0.001
   Current smoking 643 (15.5) 149 (17.6) 0.129
   Hyperlipidemia 1757 (42.2) 401 (47.2) 0.007
   Family history of CAD 2270 (54.6) 447 (52.8) 0.322
LBBB 140 (3.4) 78 (9.3) <0.001
Atrial fibrillation 98 (2.4) 39 (4.6) <0.001
BMI 27 ± 5 29 ± 5 <0.001
Systolic blood pressure 138 ± 21 145 ± 22 <0.001
Diastolic blood pressure 84 ± 13 85 ± 13 0.204
Heart rate 71 ± 12 72 ± 13 0.035
Creatinine 77 ± 39 83 ± 39 <0.001
CAC score 20 [0-174] 406 [107-1117] <0.001
CAD, coronary artery disease; LBBB, left bundle branch block; BMI, body mass index; CAC, coronary 
artery calcium; normal final diagnosis, SPECT perfusion normal or CCTA without significant CAD;
values are shown as number (percentage), mean ± SD, median [25th-75th percentile]
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Figure 3. Significant independent predictors of final diagnosis
Age (upper quartile 69); BMI, body mass index (upper quartile: 30); LBBB, left bundle branch block; BMI, 
body mass index; CAC, coronary artery calcium (upper quartile: 282); normal final diagnosis, SPECT 
perfusion normal or CCTA without significant CAD
Figure 4. Event rates categorized by CCTA and SPECT results
CAD, coronary artery disease; CCTA, coronary computed tomography angiography; SPECT, single 
photon emission computerized tomography
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6 MIs). Survival curves of these groups are demonstrated in Figure 4. The annual event 
rate was significantly higher in patients with abnormal final diagnosis compared to those 
with normal final diagnosis (2.55% vs. 1.19%, p<0.001). 
DISCUSSION
This study evaluated the need for additional imaging and following implications for 
total radiation exposure of an individualized sequential SPECT/CT algorithm in a large, 
low- to intermediate-risk population suspected for CAD. After initial stress SPECT 
and CAC scoring, additional rest SPECT imaging could be omitted in half of the 
patients, which is accompanied with a low radiation exposure. In patients who required 
additional imaging, CCTA could not be performed in nearly half of the patients because 
of (relative) contra-indications. CCTA was able to correct for false positive SPECT 
findings in our algorithm. 
Non-invasive imaging using both functional (SPECT) and anatomical data (CT) 
has been suggested to be the optimal approach in the evaluation of patients with 
suspected CAD6-8. Increasing concerns about both costs and radiation exposure, gave 
rise to sequential use of these modalities. Protocols with either initial SPECT or initial 
CCTA have been proposed9,10. CCTA might be appropriate as initial test in lower risk 
populations, due to its high negative predictive value. However, after initial CCTA 
half of the patients still require SPECT imaging10 and diagnostic quality of CCTA 
is reduced in a substantial number of patients due to extensive calcification, motion 
artefacts or low image quality6,8,29. SPECT is well-established for the diagnostic and 
prognostic evaluation of patient suspected for CAD30. When SPECT is combined 
with CAC scoring, information about myocardial perfusion and the extent of CAD 
and is acquired in a single setting. Therefore, we incorporated a sequential SPECT/
CT algorithm starting with stress SPECT and CAC scoring, if necessary followed by 
additional imaging with rest SPECT and CCTA.
In general, there may be several advantages of simultaneous CAC scoring in combination 
with stress-only SPECT. First, knowledge of CAC score results in more interpretative 
certainty for SPECT imaging with better selection of patients who require additional 
rest SPECT31,32. In the absence of any CAC the prevalence of significant CAD is low, 
thereby subtle stress SPECT abnormalities are likely to be disregarded whereas these 
may warrant further imaging in patients with extensive coronary calcifications18,33,34. 
The knowledge of CAC is likely to have contributed to our results that no additional 
rest SPECT was necessary in about half of the patients after stress SPECT. The patients 
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with stress-only SPECT demonstrated an excellent prognosis during follow-up, which 
is in line with previous studies35-39. Second, the CAC score assisted us to select patients 
suited to undergo additional CCTA, as we did not obtain additional CCTA in patients 
with very high CAC scores. By this means, the radiation dose from a CCTA with low 
expected diagnostic yield was prevented4. Finally, information about the extent of 
subclinical CAD was available in patients with normal myocardial perfusion. It has been 
demonstrated that CAC scoring adds independent prognostic information in addition 
to SPECT 40,41. Therefore, a high CAC score in these patients could potentially influence 
treatment decisions with improved patient care through life style advise, intensification 
of medication use and in case of persisting complaints an earlier invasive strategy18. 
One of the most important findings in the current study was that CCTA was not 
performed in about half of the patients referred for additional imaging. In a small 
portion of the patients this could be explained by inconsistent application of the clinical 
protocol leading to underuse of the CCTA in eligible patients (13% of the patients who 
underwent additional rest SPECT did not undergo CCTA because of atypical perfusion 
defect or unclear reasons). However, in the remaining 41% of the patients, CCTA 
indeed could not be performed. This percentage is higher than in previous observations, 
which demonstrated that up to 23% of the patients were unsuitable for CCTA because 
of calcifications or poor image quality6,8,29. This difference is likely to be explained by 
both strict selection for CCTA and the different patient population which is considered 
for CCTA. In our study, only patients with abnormal stress SPECT were considered to 
undergo CCTA and these patients probably have more (relative) contra-indications for 
CCTA. Of course, CCTA can be performed using less strict (relative) contra-indications, 
but this may be associated with more non-diagnostic scans4,5,42. The main advantage of 
CCTA in our algorithm is correcting for false positive SPECT, as previously suggested 
in the literature43. This can result in a reduction of unnecessary downstream invasive 
coronary angiography and thereby significant cost savings43.
In patients who underwent both CCTA and SPECT imaging, specificity of SPECT 
was lower than expected according to current literature44. This may be caused by 
patient selection. Patients who were eligible for CCTA had a lower risk of CAD, as 
contraindications for CCTA (high CAC score and renal insufficiency) are well known 
risk factors45,46. The normalcy rate (as a surrogate for specificity to account for referral 
bias) was 87%, which is comparable with previous findings28. Sensitivity of SPECT 
was also lower than expected44, possibly due to exclusion of  patients with normal stress 
SPECT, as these were not considered for CCTA in the current algorithm. Furthermore, 
CCTA is well known to overestimate the degree of coronary stenosis47.
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With our sequential SPECT/CT algorithm, 83% of the patients had normal final 
diagnosis (i.e. no or non-significant CAD). This high rate of normal findings in our 
study is explained by the fact that patients with known CAD were excluded and that 
our algorithm was not performed in patients with a high pre-test likelihood of CAD. 
Furthermore, CCTA increased the percentage of patients with a normal final diagnosis 
in case of an abnormal SPECT. The frequency of normal SPECT findings in our study 
are comparable to other studies47,48.
In our study, several predictors for normal initial stress SPECT were identified. Younger 
age, female gender, no current smoking and lower CAC score are indicators for low 
risk, with a subsequent lower prevalence of an abnormal stress SPECT, which is in line 
with previous studies37,38. As a lower CAC score is associated with a higher frequency of 
normal SPECT, it is not surprising that patients with lower CAC scores less frequently 
required additional imaging40,49,50. The absence of LBBB is an independent predictor 
for normal initial stress SPECT. This is likely due to anteroseptal and septal perfusion 
defects associated with LBBB51,52. Patients with lower BMI more often demonstrated 
normal stress SPECT perfusion, likely because of the lower risk of soft tissue attenuation 
artefacts. These predictors for normal initial stress SPECT could be taken into account 
when planning patients for the SPECT/CT algorithm, optimizing capacity utilization. 
The mean radiation dose for the total population after completing our diagnostic 
algorithm is lower compared to the radiation dose after the traditional stress-rest SPECT 
protocol53. Half of the patients did not require additional imaging after stress SPECT 
and CAC scoring and thereby had a low mean radiation dose of 4.5 mSv. Thus, the 
current algorithm easily complies with the recommendations of the American Society of 
Nuclear Cardiology to decrease patient radiation exposure to <9 mSv in 50% of patients 
by 201454.
Although our current algorithm proves feasible in daily practice, with very low event 
rates in patients with normal final diagnosis, alternative algorithms could be considered. 
A protocol starting with CAC scoring, without additional imaging in case of a CAC score 
of zero, could be very efficient55. However,  whether it is safe to omit further imaging in 
patients with a CAC score of zero remains a subject of debate, due to conflicting data 
with regard to the negative predictive value of CAC zero56,57. If the CAC score is low and 
CCTA is feasible, additional imaging should be performed with CCTA. Otherwise, an 
additional functional test should be performed. Another option could be modification 
of our protocol, by implementing a second evaluation after rest SPECT to assess if 
additional CCTA is necessary. Thereby, CCTA could be prevented in patients with a 
normal SPECT after stress and rest imaging. 
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Finally, a protocol starting with CCTA could be incorporated, although it is well known 
that half of the patients still require SPECT imaging after initial CCTA10. Irrespective 
of which specific algorithm used, when implementing SPECT/CT imaging in a clinic it 
is advised to opt for an individualized sequential algorithm to lower radiation dose and 
costs. Local expertise and logistics should be taken into consideration when choosing 
such an algorithm. 
Although our study reflects true daily practice and included consecutive patients, we 
have to acknowledge several limitations. The observational design remains a major 
limitation of the current study, as end-points were not pre-specified and no head-to-head 
comparison to other diagnostic algorithms were performed. Also, this is a single-center 
study in patients with suspected CAD and a low- to intermediate pre-test likelihood 
undergoing predominantly pharmacological stress. Therefore, extrapolation of the 
present results is difficult to populations with different pre-test likelihood or patients 
undergoing traditional exercise testing. Although CAC scoring was not included in the 
diagnostic algorithm to decide whether or not additional rest SPECT was performed, 
the SPECT observers were not blinded for the CAC score. Thus, it cannot be excluded 
that the need for additional rest SPECT is biased by the CAC score, as subtle stress 
SPECT abnormalities are possibly disregarded if the CAC score was 0. Furthermore, 
our current results are based on SPECT scanning predominantly performed on state 
of the art imaging equipment (CZT based SPECT/CT camera). The result can be 
different if other SPECT/CT cameras are used. CCTA was not performed in about half 
of the patients referred for additional imaging, which was partially caused by a strict 
selection for the eligibility for CCTA. Possibly, results of the current algorithm would be 
different if patients underwent CCTA with less strict selection. Although downstream 
invasive coronary angiography was performed for clinical reasons in selected patients 
during follow-up, this was not included in the current report, as this was not part of our 
research question. Finally, we did not include revascularizations as an outcome for the 
current study, as these outcomes can be driven by imaging results. 
CONCLUSIONS
Half of the patients do not require additional imaging in our sequential SPECT/
CT algorithm, which is accompanied with low radiation exposure. CCTA cannot be 
performed in half of the patients who undergo additional imaging because of (relative) 
contra-indications. CCTA is able to correct for false positive SPECT findings in our 
algorithm.
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NEW KNOWLEGDE GAINED
Sequential SPECT/CT imaging is feasible in clinical daily practice, without need for 
additional imaging after stress SPECT and CAC scoring in half of the patients. CCTA 
was less often performed than expected, because of (relative) contra-indications. 
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ABSTRACT 
Objectives
To investigate the impact of left bundle branch block (LBBB) on sequential single 
photon emission computed tomography (SPECT)/computed tomography (CT) 
imaging starting with stress-first SPECT. 
Methods
Consecutive symptomatic low- to intermediate-risk patients without a history of coronary 
artery disease (CAD) referred for SPECT/CT were included from an observational 
registry. If stress SPECT was abnormal, additional rest SPECT and, if feasible, coronary 
computed tomography angiography (CCTA) were acquired. 
Results
Of the 5018 included patients, 218 (4.3%) demonstrated LBBB. Patients with LBBB 
were slightly older than patients without LBBB (65±12 versus 61±11, p<0.001). Stress 
SPECT was more frequently abnormal in patients with LBBB (82% versus 46%, 
p<0.001). After reviewing stress and rest images, SPECT was normal in 43% of the 
patients with LBBB, compared to 77% of the patients without LBBB (p<0.001). 64 of 
the 124 patients with LBBB and abnormal stress-rest SPECT underwent CCTA (52%), 
which could exclude obstructive CAD in 46 of the patients (72%). 
Conclusions
Sequential SPECT/CT imaging starting with stress SPECT is not the optimal protocol 
in patients with LBBB, as the majority of these patients have potentially false positive 
stress SPECT. First-line testing using CCTA may be more appropriate in low- to 
intermediate-risk patients with LBBB.
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INTRODUCTION 
Left bundle branch block (LBBB) is associated with coronary artery disease (CAD) and 
in the presence of CAD, it is associated with increased mortality1,2. Conversely, patients 
with LBBB without the presence of CAD have an excellent prognosis3. Therefore, 
detection of CAD in this population is of high importance. However, non-invasive 
CAD detection in patients with LBBB is challenging. Current guidelines recommend 
to use imaging modalities in these patients, as the presence of baseline repolarization 
disorders hampers with the diagnostic value of exercise electrocardiogram (ECG)4,5. 
Myocardial perfusion imaging with single photon emission computed tomography 
(SPECT) is regarded appropriate in patients with LBBB, although it is well known that 
LBBB is associated with septal perfusion defects not necessarily caused by obstructive 
CAD6-8.
Recently, selective stress-first SPECT protocols have gained interest, wherein the 
additional rest study can be omitted when stress SPECT is normal. Stress-first protocols 
allow reduction of radiation dose and costs, while improving laboratory efficiency. 
Stress-first imaging is only attractive if a substantial percentage of the patients can be 
discharged without additional imaging. However, the impact of LBBB on stress-first 
protocols has not yet been studied. Therefore, we aimed to assess the impact of LBBB 
on sequential SPECT/computed tomography (CT) imaging starting with stress-first 
SPECT.
METHODS
Study population
We studied stable patients with suspected CAD prospectively enrolled in an observational 
SPECT/CT registry. It is approved by the Isala Medical Ethics committee and includes 
a waiver of consent. Consecutive patients referred for non-invasive CAD detection with 
SPECT/CT in the Isala Hospital between January 2009 until June 2013 were included. 
Patients were referred from the cardiology outpatient clinics of our hospital, which is 
a large cardiovascular center with a local, regional and supraregional catchment area. 
Patients with known history of CAD were excluded. No other exclusion criteria were 
applied. Information regarding the presence of risk factors was collected from written 
questionnaires. Height and weight were measured, and body mass index (BMI) was 
calculated. The pretest likely-hood of CAD was assigned according to the criteria of 
Diamond and Forrester9, with a risk threshold of <13.4 % for low risk, between 13.4 
and 87.2 % for intermediate risk, and >87.2 % for high risk. The presence of LBBB 
was assessed on an ECG obtained in the nuclear medicine department prior to stress 
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testing. LBBB was defined as QRS duration ≥0.12 s, with a broad-notched or slurred R 
wave in leads I, aVL, V5, and V6, absent Q waves in leads I, V5 and V6, and a R peak 
time >60 ms in leads V5 and V6 but normal in leads V1 to V3100. All patients routinely 
underwent our diagnostic SPECT/CT algorithm. The combination of functional 
(SPECT) and anatomical (CT) data has been suggested to result in a more definite 
diagnosis in patients suspected for CAD11-13. However, performing both SPECT and 
coronary computed tomography angiography (CCTA) would lead to high radiation 
exposure and costs, therefore we implemented an individualized sequential SPECT/
CT protocol. When SPECT is combined with coronary artery calcium (CAC) scoring, 
information about both myocardial perfusion and the degree of coronary artery sclerosis 
is obtained. Therefore, initial stress SPECT combined with coronary artery calcium 
(CAC) scoring was performed. Immediately after acquisition of stress SPECT and CAC 
scan, a cardiologist and nuclear physician together assessed the need for additional rest 
SPECT imaging and CCTA. In case of an abnormal stress perfusion, additional rest 
SPECT was performed. The rest SPECT was combined with an additional CCTA if 
the heart rate allowed optimal diagnostic CT acquisition, CAC score was not too high 
(generally <400 and the absence of large calcified segments) and contraindications were 
absent (renal insufficiency, known hypersensitivity to iodine contrast media). 
Myocardial perfusion imaging
Stress testing was routinely performed with pharmacological stress using adenosine 
(140 μg /min/kg for 6 min) in all patients, unless there was a contra-indication for 
pharmacological stress. Due to logistical reasons this is common practice in our high 
volume centre. Patients were instructed to refrain from caffeine containing beverages 
for at least 24 h before the test. In case of a contraindication for adenosine, patients 
underwent dobutamine (starting dose of 10 μg/kg per min, increased at 3-min intervals 
to a maximum of 50 μg/kg per min), regadenoson (fixed-dose of 400 ug bolus injection 
over 15 sec) or bicycle testing. A weight-adjusted dose of 99mTc-tetrofosmin (standard 
370 MBq, 500 MBq for patients >100 kg) was administered after 3 minutes (adenosine), 
after 35 seconds (regadenoson) or when the target heart rate of >85% of predicted 
maximal was reached (dobutamine, bicycle test)14. Patients scheduled for rest imaging 
received a dose of 99mTc-Tetrofosmin (standard 740 MBq, but 1000 MBq for patients 
>100 kg). Both stress and rest SPECT images were acquired 45–60 min after tracer 
injection. Time delay between the stress and rest studies was >3 hours15. All patients 
were imaged in the supine position with arms placed above the head.  
From January 2009 until April 2010, patients (n=977) were scanned on a conventional 
dual-detector gamma camera (Ventri-LightSpeed VCT XT, GE Healthcare), using a 
low-energy, high-resolution collimator, a 20% symmetrical window at 140 keV, a 64x64 
matrix, and an elliptical orbit with step-and-shoot acquisition at 6º intervals over a 180º 
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arc (45º right anterior oblique to 45º left posterior oblique) with 30 steps (30 views). 
Acquisition time was 12 min for the stress images and 15 min for the rest images as 
previously described16.
From May 2010 until June 2013, patients (n=4049) were scanned with a cadmium zinc 
telluride (CZT)-based SPECT/CT camera (Discovery NM/CT 570c, GE Healthcare) 
with 19 stationary CZT detectors simultaneously imaging 19 cardiac views. Each 
detector comprised 32×32 pixelated (2.46×2.46 mm) CZT elements. Acquisition time 
was 5 min for the stress images and 4 min for the rest images. This was derived from the 
recommendations of the manufacturer, published experience and our own qualitative 
assessment in heart phantom studies and our initial experience in patients17. All SPECT 
studies were followed by an unenhanced low-dose CT scan during a breath-hold to 
provide the attenuation map for attenuation correction as previously described18.
Perfusion images were unblindedly and semiquantitatively interpreted using a 17-segment 
model19. Segments were scored by consensus of two experienced nuclear cardiology 
observers using a 5-points scoring system (0=normal, 1= equivocal, 2=moderate, 3= 
severe reduction of radioisotope uptake, 4= absence of detectable tracer uptake)20. The 
combination of  attenuation corrected and non-attenuation corrected images were 
reviewed. A stress study was interpreted as normal if the summed stress scores was ≤320. 
Additional rest SPECT was acquired if the stress images did not fulfill these criteria. 
Final myocardial perfusion was assessed when viewing both stress-only and stress-rest 
images. An ischemic defect was defined as a summed difference score ≥220. Reversible 
defects not fulfilling these criteria were assessed as equivocal for ischemia. Defects 
equivocal for ischemia and ischemic perfusion defects were classified as reversible defects. 
Defects which demonstrated no reversibility were classified as fixed defects. Perfusion 
abnormalities in the septal, anteroseptal, and inferoseptal regions were considered to be 
possibly caused by LBBB6-8 and were defined as fixed or reversible septal defects. If, after 
reviewing both stress and rest SPECT, no reversible of fixed defects were observed, the 
SPECT was considered normal.
CT imaging
All cardiac CT studies were performed by using the 64-section CT scanner of the 
integrated SPECT/CT scanner (LightSpeed VCT XT; GE Healthcare). All patients with 
heart rates greater than 70 beats per minute received oral b-blocker therapy, with 50 or 
100 mg of metoprolol tartrate (AstraZeneca, Zoetermeer, the Netherlands) before the 
CAC scan. A nonenhanced CT scan to calculate the total CAC score was acquired with 
ECG triggering at 75% of the R-R interval and the following scanning parameters: 40 or 
48 sections and 2.5-mm section thickness; gantry rotation time, 330 msec; tube voltage, 
120 kV; and a tube current ranging from 125 to 250 mA, depending on patient size. 
Post-processing was conducted at a dedicated workstation using Smartscore software 
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(GE Healthcare). The CAC score was calculated using the standard Agatston criteria21.
Before acquiring CCTA images, patients with a heart rate exceeding the threshold of 
65/min were administered beta-blocking medication (50-100 mg metoprolol, oral, or 
5 to 10 mg metoprolol, intravenous). A scout view of the chest was first obtained, 
followed by prospectively (83%) or retrospectively (on indication) ECG-triggered 
CCTA according to the guidelines provided by the Society of Cardiovascular Computed 
Angiography22. Coronary arteries were subdivided according to a 15-segment model as 
proposed by the American Heart Association23. Each segment was evaluated on at least 
two planes according to Society of Cardiovascular Computed Tomography guidelines24, 
and the degree of diameter stenosis was visually graded by consensus of the two readers 
as obstructive CAD when narrowing of the coronary lumen was 50% or greater.
Effective radiation dose 
The radiation dose for SPECT was calculated by multiplying the dose of 99mTc-
tetrofosmin by 7.9mSv/GBq as suggested by the International Commission on 
Radiological Protection25. Effective radiation dose for CCTA was estimated as dose-
length product times a conversion coefficient for the chest (0.017 mSv/mGy/cm)26.
Follow-up
Follow-up data was obtained through clinical visits and standardized telephone 
interviews. Patients were monitored for referral for invasive coronary angiography 
(ICA). Obstructive CAD with ICA was defined as ≥70 % luminal narrowing in a major 
coronary vessel, ≥50% stenosis in the left main coronary artery or fractional flow reserve 
value ≤0.80. 
Statistical analysis
Continuous variables are expressed as mean ± SD or median [25th-75th percentile] and 
categorical variables are expressed as frequency (percentage). Differences between groups 
were assessed by unpaired Student’s t-test, Mann-Whitney U test and by Chi-square test, 
where appropriate. The patient’s pre-test likelihood for CAD was determined with the 
Diamond criteria with the assumption that chest pain was atypical9. Two sided p-values 
of less than 0.05 were considered statistically significant in all tests. All statistical analysis 
was performed with a commercially available software package (SPSS, version 20.0 for 
Windows).
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RESULTS
Patient characteristics
During a period of 4.5 years a total of 5026 consecutive patients were included. 
Follow-up information was complete for 99.8% of the patients, only 8 patients were 
lost to follow-up. The remainder of 5018 patients are the subject of this report. The 
main indications for referral were atypical chest pain and dyspnoea. The mean age was 
61 ± 11 years, 57% of the patients were female and 14% were diabetic. 218 of the 
patients (4.3%) demonstrated a complete LBBB on baseline ECG.  Stress testing was 
performed with adenosine in 4816 (96.0%), with dobutamine in 114 (2.3%), with 
regadenoson in 34 (0.7%) and with exercise testing in 54 (1.1%) of the patients. In 
patients with LBBB, stress testing was performed with adenosine in 209 (95.9%), with 
dobutamine in 7 (3.2%), with regadenoson in 1 (0.5%)    and with exercise testing 
in 1 (0.5%) of the patients. Pre-test likelihood was considered to be low in 5% of the 
patients with LBBB and in 9% of the patients without LBBB. 95% of the patients with 
LBBB and 91% of the patients without LBBB had an intermediate pre-test likelihood. 
Relevant general patient characteristics of the study population are demonstrated in 
Table 1. Patients with LBBB were slightly older and were more often known with 
hypertension. Conversely, these patients were less likely to have hypercholesterolemia 
and demonstrated lower BMI.
SPECT results
Scintigraphic findings in patients with and without LBBB are shown in Figure 1 and 
Table 2. The stress SPECT was normal in 40 of the 218 patients with LBBB (18%), 
compared to 2577 of the 4800 patients without LBBB (54%, p<0.001). The patients 
with abnormal stress SPECT underwent additional rest SPECT (Figure 2). SPECT was 
considered normal when viewing both stress and rest imaging in an additional 25% of 
the patients with LBBB and in an additional 23% of the patients without LBBB. In 
the total patient population, SPECT was normal in 43% of the patients with LBBB, 
compared to 77% of the patients without LBBB (p<0.001). A reversible defect was 
present in similar percentages in patients with LBBB compared to patients without 
LBBB (17% versus 16%, respectively, p=0.89). Of the reversible defects, 31% were 
located in the septal region in patients with LBBB compared to 7% in patients without 
LBBB (p<0.001). Patients with LBBB more often showed fixed defects compared to 
patients without LBBB (40% versus 7%, respectively, p<0.001). Of the fixed defects, 
38% were located in the septal region in patients with LBBB, compared to 5% in 
patients without LBBB (p<0.001). 
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CAC score 
In 208 of the 218 patients with LBBB (95%) and in 4689 of the 4800 patients 
without LBBB (98%), a CAC score was acquired. A high or irregular heart rate was the 
main reason for not measuring CAC score. The median CAC score was 39 [25th-75th 
percentile: 0-282], with a range from 0-18041. No difference in the median of CAC 
score was demonstrated in patients with and without LBBB (68 [0-386] and 38 [0-
279], respectively, p=0.26, Table 1). 
CCTA results
CCTA findings in patients with and without LBBB are shown in Table 2. CCTA was 
performed in 90 of the 178 patients (51%) with LBBB referred for additional rest 
SPECT (Figure 2). In the remaining 88 patients (49%), CCTA was not performed 
Table 1. General characteristic of patients without LBBB compared to patients with LBBB
No LBBB
n=4800
LBBB
n=218
p-value 
Age, years 61 ± 11 65 ± 12 <0.001
Female gender 2734 (57) 128 (59) 0.61
Cardiac risk factors
   Diabetes mellitus 651 (14) 26 (12) 0.49
   Hypertension   2910 (61) 150 (68) 0.02
   Current smoking 764 (16) 28 (13) 0.23
   Hyperlipidemia 2084 (43) 74 (34) 0.01
   Family history of CAD 2603 (54) 114 (52) 0.59
Medication use
   Aspirin 1901 (40) 87 (40) 0.93
   Beta blocker 2519 (53) 121 (56) 0.38
   Statin 1763 (37) 70 (32) 0.17
   ACE inhibitor 1648 (34) 90 (41) 0.04
Atrial fibrillation 129 (3) 8 (4) 0.38
BMI 27.6 ± 4.8 27.0 ± 4.6 0.03
Creatinine 78 ± 40 78 ± 19 0.54
CAC score 38 [0-279] 68 [0-386] 0.26
   CAC score 0 1255 (26) 60 (28) 0.65
CZT camera 3868 (81) 179 (82) 0.58
CAD, coronary artery disease; LBBB, left bundle branch block; BMI, body mass index; CAC, coronary 
artery calcium; CZT, cadmium zinc telluride; values are shown as number (percentage), mean ± SD, median 
[25th percentile – 75th percentile]
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Figure 1. SPECT findings in patients with (a) and without LBBB (b)
Table 2. Imaging findings in patients with and without LBBB
No LBBB
n=4800
LBBB
n=218
p- value 
Normal stress-only 2577 (54) 40 (18) <0.001
Normal SPECT (stress-rest) 3696 (77) 94 (43) <0.001
Abnormal SPECT (stress-rest) 1104 (23) 124 (57)
   Reversible defect 776 (16) 36 (17) 0.89
      Septal (% of total reversible defects) 55 (7) 11(31) <0.001
   Fixed defect 328 (7) 88 (40) <0.001
      Septal  (% of total fixed defects) 16 (5) 32(36) <0.001
CCTA performed 1022 (21) 90 (41)
   No significant CAD* 684 (67) 67 (74) 0.14
   1 vessel disease* 197 (19) 17 (19) 0.93
   2 vessel disease* 94 (9) 5 (6) 0.25
   3 vessel disease* 36 (4) 0 (0) 0.07
CAC score† 79 [6-268] 49 [0-167] 0.02
SPECT, single photon emission computed tomography; LBBB, left bundle branch block; CAC, coronary 
artery calcium; CCTA, coronary computed tomography angiography; CAD, coronary artery disease; 
*percentage of performed CCTAs; †of patients undergoing CCTA, values are shown as number (percentage), 
median [25th percentile – 75th percentile]
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   105 17-08-18   07:38
Chapter 6
106
because of high CAC scoring  (n=34, 39%), high/irregular heart rate (n=24, 27%), 
small atypical perfusion defects suspected for artefact (n=23, 26%), anxiety/unable to 
hold breath (n=1, 1%), or unclear reasons (n=6, 7%). 1 of the 90 CCTAs (1%) which 
were performed in patients with LBBB were assessed as non-evaluable due to limited 
image quality. Obstructive CAD could be excluded with CCTA in 67 of the 89 patients 
(75%). In the 2223 patients without LBBB who required additional rest SPECT, this was 
combined with CCTA in 1022 of the patients (46%). In the remaining 1201 patients 
Table 3. The combination of SPECT and CCTA findings for patients with and without LBBB. 
LBBB (n=89) No LBBB (n=1011)
CCTA with 
obstructive CAD
CCTA with no or 
non-obstructive 
CAD
CCTA with 
obstructive CAD
CCTA with no or 
non-obstructive 
CAD
SPECT abnormal 18 (20) 46 (52) 238 (24) 332 (33)
SPECT normal 4 (4) 21 (24) 89 (9) 352 (35)
CCTA, coronary computed tomography angiography; CAD, coronary artery disease; SPECT, single photon 
emission computed tomography; LBBB, left bundle branch block; values are shown as number (percentage)
Figure 2. Flowchart of the sequential SPECT/CT algorithm for patients with and without LBBB. 
SPECT, single photon emission computed tomography; LBBB, left bundle branch block; CAC, coronary 
artery calcium; CTCA, coronary computed tomography angiography
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without LBBB, CCTA was not performed because of high CAC scoring  (n=557, 
46%), high/irregular heart rate (n=257, 21%), renal insufficiency (n=89, 7%), small 
atypical perfusion defects suspected for artefact (n=228, 19%), contrast allergy (n=9, 
1%), expected scatter from pacemaker lead (n=6, 0.5%), anxiety/unable to hold breath 
(n=10, 1%), or unclear reasons (n=45, 4%). 11 of the 1022 CCTAs (1%) performed 
in patients without LBBB were assessed as non-evaluable due to limited image quality. 
Obstructive CAD could be excluded with CCTA in 684 of the 1011 patients (68%). 
Of the total of 218 patients with LBBB, 90 (41%) underwent CCTA, while 1022 of the 
4800 patients without LBBB underwent CCTA (21%).
Combination of SPECT and CCTA findings
SPECT and CCTA findings for both LBBB and non-LBBB patients are demonstrated 
in Table 3. A total of 39 of the patients with LBBB (44%) have concordant SPECT 
and CCTA findings, compared to 590 (58%) in the patients without LBBB (p<0.01). 
The frequency of abnormal SPECT findings but normal CCTA (false positive SPECT 
findings) is higher in patients with LBBB compared to patients without LBBB (52% 
vs 33%, respectively, p<0.001). An example of a false positive SPECT finding in a 
patient with LBBB is demonstrated in Figure 3. Of the 64 patients with LBBB and 
abnormal perfusion after stress-rest imaging, obstructive CAD could be excluded with 
CCTA in 46 (72%) of the patients. The perfusion defect was located in the septal 
region in 18 of these 46 patients (39%). The general characteristics of patients with 
concordant and discordant SPECT and CCTA findings in patients with and without 
LBBB are demonstrated in Table 4. In the patients with discordant findings, the 
patients without LBBB demonstrated slightly higher CAC and BMI than the patients 
with LBBB. 
Radiation dose 
The mean radiation dose after completing the diagnostic algorithm was 8.6 ± 4.9 mSv 
for the entire cohort. For patients with LBBB the mean radiation dose was 11.6 ± 4.7 
mSv, compared to 8.5 ± 4.9 mSv for patients without LBBB (p<0.001). 
Follow-up
Over a median follow-up of 937 days [25th percentile-75th percentile, 600-1397], a total 
of 950 ICAs were performed. 19% of the patients without LBBB (n=904) underwent 
ICA which is comparable to the patients with LBBB (21%, n=46). The percentage of 
ICAs which demonstrated obstructive CAD was also comparable in patient with and 
without LBBB (48% versus 53%, respectively). 
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DISCUSSION
This study evaluated the impact of LBBB on sequential SPECT/CT imaging starting 
with stress SPECT in a low- to intermediate-risk population suspected for stable CAD. 
As the majority of the patients with LBBB demonstrated abnormal stress SPECT 
despite absence of obstructive CAD, this SPECT first approach for sequential imaging 
is not the optimal protocol in these patients. First-line testing using CCTA may be more 
appropriate in patients with LBBB.
The current results show that 82% of the patients with LBBB demonstrated abnormal 
stress SPECT. Thereby, most of the patients with LBBB required additional imaging 
in this sequential SPECT/CT imaging protocol starting with stress-first SPECT. The 
impact of LBBB on the abnormal stress SPECT findings, and thereby the requirement 
for additional rest SPECT was not demonstrated previously. The finding is not 
surprising however, since it is well known that septal perfusion defects are associated 
with this conduction disorder6-8. After the combination of stress-only and stress-rest 
SPECT, still  57% of the patients with LBBB demonstrated abnormal SPECT in our 
Figure 3. Discordant SPECT and CCTA images in patient with LBBB
Stress and rest SPECT findings on the left demonstrate a partly reversible apicoseptal perfusion defect. The 
CCTA demonstrates no significant CAD (LAD shown). 
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study. This frequency of abnormal SPECT perfusion is in concordance with previous 
research, which described 53- 82% of the SPECT perfusion to be abnormal in patients 
with LBBB7,27-30. 
Patients with LBBB demonstrated a higher frequency of fixed defects rather than 
reversible defects in our study. Both reversible and fixed defects were more often located 
in the septal region in patients with LBBB. It remains a subject of debate if LBBB itself 
is associated with reversible or fixed septal perfusion defects.  It was demonstrated by 
Alexanderson et al. that reversible perfusion defects correlated better with underlying 
CAD than fixed defects in patients with LBBB30. This was strengthened by a study 
in patients with LBBB but without CAD, which mainly demonstrated fixed septal 
Table 4. General characteristic of patients with concordant and discordant SPECT and CCTA findings, 
stratified by the presence of LBBB
Concordant
findings
n= 629
Discordant
findings 
n= 471
LBBB
n= 39
No LBBB
n= 590
p-value LBBB
n= 50
No LBBB
n= 421
p-value 
Age, years 63 ± 10 60 ± 10 0.04 60 ± 11 59 ± 10 0.98
Female gender 19 (49) 228 (38) 0.19 26 (52) 205 (49) 0.66
Cardiac risk factors
   Diabetes mellitus 2 (5) 64 (11) 0.26 4 (8) 56 (13) 0.29
   Hypertension   31 (80) 359 (61) 0.02 30 (60) 229 (54) 0.45
   Current smoking 6 (15) 135 (23) 0.27 6 (12) 72 (17) 0.36
   Hyperlipidemia 17 (44) 268 (45) 0.82 14 (28) 171 (41) 0.08
   Family history of CAD 21 (54) 328 (56) 0.81 27 (54) 231 (55) 0.89
Medication use
   Aspirin 16 (41) 297 (50) 0.26 19 (38) 174 (41) 0.65
   Beta blocker 20 (51) 308 (52) 0.91 27 (54) 211 (50) 0.60
   Statin 11 (28) 231 (39) 0.17 20 (40) 132 (31) 0.22
   ACE inhibitor 16 (41) 200 (34) 0.36 16 (32) 121 (29) 0.63
BMI 27 ± 4 28 ± 5 0.08 27 ± 4 29 ± 5 0.01
Creatinine 76 ± 13 77 ± 15 0.76 80 ± 18 75 ± 16 0.04
CAC score 114 [29-204] 111 [16-325] 0.58 10 [0-119] 44 [2-190] 0.05
CCTA, coronary computed tomography angiography; CAD, coronary artery disease; LBBB, left bundle 
branch block; BMI, body mass index; CAC, coronary artery calcium; values are shown as number 
(percentage), mean ± SD, median [25th percentile – 75th percentile]\
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perfusion defects6. However, Mahrholdt et al. showed that fixed perfusion defects do 
not exclude CAD in patients with LBBB31. In the latter study, 139 patients with LBBB 
and fixed perfusion defects were included to undergo ICA, 120 (86%) of these patients 
demonstrated obstructive CAD. These conflicting results underline the challenge for the 
clinician to correctly interpret SPECT findings in patients with LBBB and to choose 
whether a conservative patient management is justified. 
In about half of the patients who were referred for additional rest SPECT, CCTA 
was not performed. This was higher than expected on the basis of current literature, 
which demonstrated that 76% of the patients are expected to be eligible for CCTA32. 
This difference is mainly explained by strict selection criteria for patients undergoing 
CCTA in our study and because of the higher risk population in which CCTA 
is considered (only patients with abnormal stress SPECT). A small part however, is 
explained by inconsistent application of the protocol leading to underuse of the CCTA 
in eligible patients. Nevertheless, patients with LBBB were equally frequent considered 
eligible for additional CCTA as patients without LBBB. 
We demonstrated that patients with LBBB more often had discordant SPECT and 
CCTA findings than patients without LBBB. False positive SPECT findings were 
demonstrated significantly more often in patients with LBBB. This difference in 
diagnostic performance of the SPECT could not explained by differences in baseline 
characteristics. High BMI can cause soft tissue attenuation artefacts, however, in our 
patient population with discordant findings, the BMI was lower in patients with LBBB 
than without LBBB. 
In our study, patients with and without LBBB demonstrate similar frequencies of ICA 
during follow-up. Given the higher frequency of abnormal SPECT in patients with 
LBBB, the use of CCTA in these patients is likely to have prevented further downstream 
invasive coronary imaging. The ability of CCTA to correct for false positive SPECT 
findings, underlines the importance of the use of CCTA in this specific patient group.  
There are several findings in our study advocating first-line testing using CCTA in 
patients with LBBB. Firstly, we demonstrated that patients with LBBB were equally 
suitable to undergo CCTA and that CCTA is able to exclude obstructive CAD in a high 
frequency of these patients. In the selected patients with LBBB who underwent CCTA 
in our study, obstructive CAD could be excluded in nearly three-quarter of the patients. 
Secondly, although patients with LBBB more often demonstrated abnormal SPECT 
imaging, this did not result in a higher frequency of ICA with obstructive CAD during 
follow-up. This suggests that SPECT is not the most optimal technique to identify 
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patients with LBBB and obstructive CAD. Finally, we demonstrated that our sequential 
SPECT/CT imaging protocol resulted in a higher mean radiation dose in patients with 
LBBB. Therefore, we suggest a diagnostic protocol starting with CCTA in patients 
with LBBB. A study in a limited number of patients demonstrated that CCTA has an 
excellent diagnostic accuracy in patients with LBBB33. Further research should evaluate 
how many patients with LBBB are eligible for CCTA and in which number of patients 
obstructive CAD can be excluded. 
Although our study reflects true daily practice and included consecutive patients, we 
have to acknowledge several limitations. The observational design remains a major 
limitation of the current study, as end-points were not pre-specified and no head-to-
head comparison to other diagnostic algorithms were performed. Some patients with 
LBBB did not receive vasodilator stress imaging although this is not in concordance 
with current guidelines. However, as this is only a small percentage of patients (4%), 
this is not likely to influence current results. Not all patients underwent ICA, as ICA 
was only performed on clinical indication. Thereby, we cannot evaluate the diagnostic 
accuracy of SPECT and CCTA in patients without LBBB compared to patients with 
LBBB. Also, this is a single-center study in patients with suspected CAD and a low 
to intermediate pre-test likelihood. Therefore, extrapolation of the present results is 
difficult to populations with a different pre-test likelihood. 
CONCLUSIONS
Sequential SPECT/CT imaging starting with stress SPECT is not the optimal 
imaging protocol in patients with LBBB, as the majority of these patients demonstrate 
abnormal stress SPECT. First-line testing using CCTA may be more appropriate in low-
intermediate risk patients with LBBB.
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Introduction 
Despite many efforts and successes in primary prevention, prevalence and incidence 
of coronary artery disease (CAD) is still high, especially in developed  and developing 
countries1. In general, stable patients with CAD have an excellent prognosis, also because 
there are a number of therapeutic options, including life style interventions, cholesterol 
and blood pressure lowering medication and coronary revascularization. Therefore, in 
symptomatic patients, an accurate diagnosis is of importance 1) to rule out a cardiac 
cause to enable search for non-cardiac causes; 2) to start treatment in those with CAD 
to relief symptoms and prevent myocardial infarction and/or death; and 3) to provide 
prognostic information. In general, tests are divided in screening  and diagnostic tests. 
The primary purpose of screening tests is to detect early disease or risk factors for disease 
in large numbers of apparently healthy individuals. The purpose of a diagnostic test 
is to establish the presence (or absence) of disease as a basis for treatment decisions in 
symptomatic or screen positive individuals (confirmatory test).  
A non – invasive method to detect CAD is the coronary artery calcium (CAC) score. 
The CAC score is based on the quantification of calcium deposits in the coronary 
arteries. The formation of these calcium deposits occurs during more advanced stages 
of atherosclerotic disease process and thereby provides an excellent measure of the 
atherosclerotic plaque burden2.  The value of the CAC score has been demonstrated in 
several population based studies in asymptomatic people (screening test)3-5. The question 
is whether it can also be used as a diagnostic test, and potentially serve as a gatekeeper in 
symptomatic patients with suspected CAD.
Diagnostics tests for suspected CAD in symptomatic patients
In symptomatic patients, diagnostic tests should provide information about the absence 
or presence of CAD, and preferable the extend of CAD. Since a substantial part of the 
patients will have another cause for their complaints, for example pulmonary, gastric or 
myogenic, non-invasive imaging is important to exclude CAD. 
As in all diagnostic tests, we have to face sensitivity, specificity and the negative and 
positive predictive value against a “gold standard”. Although in the past the gold 
standard was the invasive coronary angiography, nowadays this is probably replaced 
by measurement of fractional flow reserve. Furthermore, it should be kept in mind 
that sensitivity and specificity are independent of prevalence of disease, i.e. test specific 
(they describe how well the screening test performs against the gold standard), but that 
positive and negative predictive value are disease prevalence dependent. The old “simple” 
exercise test to demonstrate or exclude myocardial ischemia has many advantages, it is 
low - cost, it is reasonably easy to perform and interpretation is fairly straightforward. 
However, it has also major limitations, particularly its low accuracy, especially in several 
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sub-groups, as in females6. Because its high sensitivity and specificity, single photon 
emission computed tomography (SPECT) myocardial perfusion imaging (MPI)  has 
been a cornerstone of non-invasive CAD detection for decades7. However, several other 
modalities have entered the non-invasive CAD imaging arena such as the CAC score 
and coronary computed tomography angiography (CCTA). These anatomical imaging 
modalities have gained interest and are increasingly combined with functional imaging 
techniques. Both anatomical and functional imaging provide clinically important 
information about the coronary status of the patient suspected for CAD. However, 
performing both anatomical and functional imaging in all patients suspected for CAD 
results in higher costs, radiation dose and decreased imaging laboratory efficacy. Therefore, 
a step-wise hybrid imaging protocol seems more appropriate.  The CAC score, which 
can be considered as a direct measure of coronary sclerosis, is highly suitable to act as a 
gatekeeper in such a step – wise imaging protocol because of several test characteristics. 
The non – contrast enhanced CT scan used for the CAC score can be acquired in 
all patients, irrespective of  kidney function or the presence of contrast allergy. The 
CT scan is easily obtained during breath hold (<15 seconds) requiring minimal patient 
preparation and is associated with low radiation dose. Finally, the post processing of the 
CT scan is very fast, enabling incorporation into a one day step-wise hybrid imaging 
protocol. Until now, however, clinical use of the CAC score as a diagnostic imaging 
modality in symptomatic patients is not common practice. In our opinion, increasing 
evidence has paved the way for a much more prominent place of this modality. 
The CAC score to rule-out significant CAD in stable symptomatic patients
The CAC score is traditionally used in screening populations and in these asymptomatic 
people the amount of CAC has proven to be a strong predictor for future risk of 
myocardial infarction and sudden cardiac death, independent of conventional 
coronary risk factors3-5. Despite a strong correlation between the CAC score and the 
severity of CAD, the CAC score in itself cannot differentiate between obstructive and 
non – obstructive CAD.  Therefore, its use in symptomatic patients is still regarded 
controversial, mainly as it is dependent of the population which is studied8.  However, 
the CAC score is of great clinical value when applied in selected patient populations.   
Compelling evidence demonstrates that the absence of any detectable calcium in the 
coronary arteries, virtually rules out obstructive CAD in symptomatic patients with an 
estimated low-intermediate risk. Literature about these low-intermediate risk patients, 
whom constitute a large part of patients referred for non-invasive testing, is superfluous. 
A large meta-analysis including 1,941 patients with a CAC score of 0 demonstrated a 
pooled sensitivity of 98% for a CAC score of zero to exclude obstructive CAD (invasive 
coronary angiogram as reference standard)9. More recent studies, mostly using CCTA as 
a reference standard (with a cutoff value of > 50% or >70% luminal narrowing)  have a 
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pooled incidence of obstructive CAD  of 3.1% in patients without CAC (374 of a total 
of 12,072 patients with a CAC score of zero, negative predictive value of 97%)8,10-21. 
In a study by Mouden et al, 868 of 3501 low-intermediate patients referred for SPECT 
and CAC had a CAC score of zero. In all 868 patients obstructive CAD could be 
excluded (defined as normal SPECT, non-obstructive CAD with CCTA or invasive 
coronary angiogram)22. These persuasive data in almost 15,000 patients with a CAC 
score of zero, demonstrate that the CAC score is excellent in ruling out obstructive CAD 
in low-intermediate risk patients. 
In patients with high risk, which in clinical practice constitutes a small subset of 
patients referred for non – invasive imaging, the CAC score is less useful for excluding 
obstructive CAD. Studies investigating the value of a CAC score of zero in patients with 
a clinical indication for invasive coronary angiogram demonstrated that still 19-32% had 
anatomical significant CAD23,24. Moreover, in patients with suspected acute coronary 
syndrome, obstructive CAD was present up to 39% of the patients despite zero CAC25. 
Various papers describe cases of clinically relevant stenoses without any CAC26,27, which 
are often used to underline limitations of the CAC score as a gatekeeper for further 
tests. However, none of the currently available non-invasive tests (Table 1) have a 100% 
sensitivity to exclude obstructive CAD and inherent false negative results will occur. 
With regard to reduction in post-test probability of a diagnostic test, a CAC score of zero 
clearly outperforms commonly used tests which are recommended in current guidelines 
such as SPECT MPI, traditional exercise test, dobutamine echocardiography and MRI 
perfusion. Not only is a CAC score of zero associated with a very low risk of significant 
CAD in symptomatic patients, follow – up studies have shown that prognosis is excellent9.
The NICE guideline already recommends to abstain from further imaging in patients 
with a CAC score of zero and an estimated likelihood for CAD of 10-29%28. An expert 
consensus document of the American College of Cardiology and American Heart 
Association (AHA) states that exclusion of measurable coronary calcium may be an 
effective filter before undertaking invasive diagnostic procedures or hospital admission29.
Additional value of SPECT in patients with CAC score 0 and CAC score >1000
When performing SPECT MPI in patients with zero CAC, one must be aware that 
abnormal MPI results are more likely to result from false positive findings than from 
true perfusion abnormalities. This is also reflected by comparable and excellent prognosis 
in patients with CAC zero, both in patients with normal and abnormal SPECT results 
(annual event rate of late revascularization, myocardial infarction or all-cause mortality 
of 0.6% and 0.4% respectively, p=0.61)30. The addition of SPECT MPI in patients with 
a CAC score of zero could even result in unjust invasive imaging, with additional costs 
and risk of complications. Therefore, SPECT MPI is not useful in patients with CAC 
score of zero.
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On the other end of the spectrum are patients with extensive CAD with high CAC scores. 
These patients have a substantial risk for false negative SPECT findings. Ghadri et al. 
investigated 50 patients with suspected CAD with normal SPECT MPI and extensive 
CAC (CAC score >1000)31. All patients underwent invasive coronary angiogram, and 
obstructive CAD (defined as ≥50% luminal narrowing) was identified in 74% of the 
patients with normal SPECT. Yuoness et al. investigated 26 patients with a CAC score 
>1000, of which 58% had obstructive CAD (defined as ≥70% stenosis)32. Mouden et 
al. investigated 204  patients with a CAC score ≥1000 and normal SPECT33. Of the 
65 patients referred for invasive coronary angiogram, 43 (66%) had obstructive CAD 
(defined as≥70 % luminal narrowing,≥50 % stenosis in the left main coronary artery or 
fractional flow reserve value ≤0.80). Although MPI is still useful to identify ischemia in 
patients with extensive CAC, one must keep in mind a substantial  risk on false negative 
findings. In case of persistent complaints, an invasive strategy seems warranted in 
patients with extensive CAC,  also with normal SPECT. Moreover, life style counseling 
and possibly even use of preventive medication (such as statin or aspirin) could be 
considered in patients with extensive CAC.  
The CAC score provides incremental diagnostic and prognostic value on top of 
SPECT MPI 
In patients with suspected CAD, around a quarter demonstrated a CAC score of zero9,30. 
So, using the CAC score as a gatekeeper,  further imaging can be omitted in a substantial 
number of patients. However, also in patients in whom further imaging is performed 
(CAC >0), knowledge of the CAC score has diagnostic and therapeutic consequences.  
Table 1. Characteristic of test commonly used to diagnose the presence of CAD (invasive angiography 
without FFR as the gold standard)
Diagnosis of CAD
Sensitivity (%) Specificity (%)
CCTA 95-99 64-83
CAC score 0 9 85-100 21-83
Vasodilator stress PET 81-97 74-91
Dobutamine stress 
echocardiography
79-83 82-86
Exercise stress SPECT 73-92 63-87
Vasodilator stress MRI 67-94 61-85
Exercise ECG 45-50 85-90
Table adapted from ESC guidelines on the management of stable coronary artery disease40. CAD, coronary 
artery disease; SPECT, single-photon emission computed tomography; CCTA, coronary computed 
tomography angiography; PET, positron emission tomography; CAC, coronary artery calcium
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First of all, knowledge of the CAC score has shown to improve interpretative certainty 
for SPECT MPI34,35. A cutoff of CAC ≥709 improved the sensitivity of SPECT alone 
(from 76% to 86%) for the detection of significant CAD36.  Secondly,  the CAC score 
holds independent prognostic information on top of SPECT imaging37.  Chang et al. 
demonstrated that asymptomatic patients with a normal SPECT and a CAC score >400 
had a 3.55 fold higher risk of events (revascularization ,myocardial infarction or death), 
compared to patients with CAC score <1038. Recently, Engbers et al. demonstrated that 
the CAC score is an independent predictor of events (late revascularization, myocardial 
infarction and death) in patients with normal and abnormal SPECT30. In patients with 
a CAC score ≥100 a stepwise increase of risk for events was demonstrated independent 
of SPECT (hazard ratios of 3.3, 4.9 and 7.6 for CAC scores 100-399, 400-999 and 
≥1000, respectively)30. 
Proposed sequential individualized imaging protocol in stable low-intermediate 
risk patients
In stable low-intermediate-risk patients suspected for CAD, the CAC  score could be 
used as a gatekeeper. Further imaging after the CAC score depends on the extent of 
calcification (Figure 1). If the CAC score is zero, no additional imaging is necessary. If 
the CAC score is 1-599, CCTA should be considered due to its high negative predictive 
value in these patients39. If CCTA is not possible due to high/irregular heart rate, severe 
renal insufficiency or known hypersensitivity to iodine contrast media), additional MPI 
Figure 1. Proposed sequential individualized imaging protocol in stable low-intermediate risk patients 
suspected for coronary artery disease 
CAC, coronary artery calcium; CCTA, coronary computed tomography angiography; MPI, myocardial 
perfusion imaging; ICA, invasive coronary angiogram
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should be performed. If the CAC score is >600, additional MPI should be obtained. 
In case of extensive coronary calcification (CAC score >1000), invasive imaging should 
be considered in patients with persistent complaints even in the presence of normal 
SPECT MPI, as these patients have a high risk of false negative findings SPECT MPI. 
One may argue that  CCTA is also a excellent gatekeeper. However, in our opinion it is 
less suitable to act as a gatekeeper in a one-day hybrid imaging protocol as it cannot be 
acquired in all patients (high/irregular heart rate, renal failure and contrast allergy) and 
the post processing can be time consuming.
Conclusion
The test characteristics of the CAC score make it an ideal gatekeeper in symptomatic 
patients with low-intermediate risk of CAD. In the case of a CAC score of zero, the 
CAC score can be used as a single diagnostic test and  further testing is not necessary. If 
CAC is present (CAC score >0), additional imaging should be considered, dependent 
of the extent of coronary calcification and patient characteristics.  In patients with high 
risk of CAD and in patients with suspected acute coronary event, the CAC score is not 
an ideal gatekeeper.
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ABSTRACT
The prognostic value of myocardial perfusion imaging (MPI) with the cadmium zinc 
telluride (CZT) single photon emission computed tomography (SPECT) camera is not 
well established. Therefore, the aim of the current study was to evaluate the prognostic 
value of MPI performed with a CZT SPECT camera in a large cohort of patients 
suspected for coronary artery disease (CAD).
Methods
4057 consecutive symptomatic stable patients without a history of CAD underwent 
CZT SPECT MPI. During a median follow-up of 2.4 years (25th-75th percentile:1.7-3.4), 
patients were monitored for primary (nonfatal myocardial infarction and cardiac 
mortality) and secondary outcomes (late revascularization (>90 days after scanning) and 
primary outcome). 
Results
Patients with normal perfusion demonstrated low annual event rates (primary outcome: 
0.2%, secondary outcome: 0.6 %). Annual event rates increased with the extent of 
abnormality of myocardial perfusion. In patients with small ischemic perfusion defects, 
annual event rates were 0.7% and 2.8% for the primary and secondary outcome, 
respectively. In patients with moderate or large ischemic perfusion defects these event 
rates were 1.2% and 4.3%, respectively. After multivariate analysis, the risk for events 
were significantly associated with the extent of ischemia (hazard ratio for small ischemic 
defects: 2.2, 95%CI 0.9-5.9 and 4.6, 95%CI 2.8-7.6, hazard ratio for moderate or large 
ischemic defects: 4.0, 95%CI 1.5-10.5 and 12.1, 95%CI 7.2-20.2 for primary and 
secondary outcomes, respectively). 
Conclusion
Our findings show that MPI acquired with CZT SPECT camera provides excellent 
prognostic information, with low event rates in patients with normal myocardial 
perfusion. In patients with abnormal SPECT MPI, the extent of abnormality is 
independently associated with an increased risk of events.  
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INTRODUCTION 
SPECT MPI is an established and widely available technique for the diagnostic and 
prognostic evaluation of patients suspected for CAD1. Guidelines appropriate use 
criteria recommend SPECT MPI in patients with an intermediate pre-test likelihood 
of CAD2-4. Normal SPECT MPI is associated with an excellent prognosis, with annual 
cardiac event rates <1%5,6. In recent years, concerns about radiation exposure and 
time efficacy have led to development of a new generation of gamma camera systems 
based on a novel detector technology utilizing semiconductor detectors of CZT. This 
new technology, with solid-state CZT detectors and multipinhole collimators focused 
on the heart, allows reduced radiation exposure and acquisition time without loss of 
image quality7,8. Although research about the diagnostic accuracy of these dedicated 
CZT SPECT cameras has been performed9,10, data on the prognostic value  of SPECT 
imaging acquired on CZT imaging are scarce11,12. Therefore, the aim of the current 
study was to evaluate the prognostic value of MPI performed with CZT SPECT camera 
in a large cohort of patients suspected for CAD.
METHODS
Study population
Patients referred for clinically indicated SPECT MPI in our hospital were prospectively 
enrolled in our registry. It was approved by our local Medical Ethics committee and 
included a waiver of consent. For the current analysis, consecutive patients referred 
between May 2010 until June 2013 were included. Patients with a known history of 
CAD were excluded, no other exclusion criteria were applied. Information regarding the 
presence of risk factors was prospectively collected by written questionnaires. These data 
were verified and complemented with demographic and clinical information collected 
from medical records. All patients underwent initial low-dose 99mTc-tetrofosmin stress-
first SPECT imaging. In case of an abnormal stress perfusion, additional rest SPECT 
was performed. The pre-test likelihood of CAD was assigned according to the criteria 
of Diamond and Forrester13, with a risk threshold of <13.4 % for low-risk, between 
13.4 and 87.2 % for intermediate-risk, and >87.2 % for high-risk. The presence of 
left bundle branch block (LBBB) was assessed on an electrocardiogram obtained in the 
nuclear medicine department prior to stress testing. LBBB was defined as QRS duration 
≥0.12 s, with a broad-notched or slurred R wave in leads I, aVL, V5, and V6, absent Q 
waves in leads I, V5 and V6, and a R peak time >60 ms in leads V5 and V6 but normal 
in leads V1 to V314. 
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Stress procedures and tracer injection
Stress testing was routinely performed with pharmacological stress using adenosine (140 
μg /min/kg for 6 min), unless there was a contra-indication for pharmacological stress. 
Due to logistical reasons this is common practice in our high-volume centre. Patients 
were instructed to refrain from caffeine containing beverages for at least 24 h before 
the test. In case of a contraindication for adenosine, patients underwent dobutamine 
(starting dose of 10 μg/kg per min, increased at 3-min intervals to a maximum of 
50 μg/kg per min), regadenoson (fixed-dose of 400 ug bolus injection over 15 sec) 
or bicycle testing. A weight-adjusted dose of 99mTc-tetrofosmin (standard 370 MBq, 
500 MBq for patients >100 kg) was administered after 3 minutes (adenosine), after 35 
seconds (regadenoson) or when the target heart rate of >85% of predicted maximal was 
reached (dobutamine, bicycle test). Patients scheduled for rest imaging received a dose 
of 99mTc-Tetrofosmin (standard 740 MBq, but 1000 MBq for patients > 100 kg). 
Myocardial perfusion image acquisition 
Both stress and rest SPECT images were acquired 45–60 min after tracer injection. 
Time delay between the stress and rest studies was >3 hours15. All patients were imaged 
in the supine position with arms placed above the head. All patients were scanned with a 
cadmium zinc telluride (CZT)-based SPECT/CT camera (Discovery NM/CT 570c, GE 
Healthcare) with 19 stationary CZT detectors simultaneously imaging 19 cardiac views. 
Each detector comprised 32×32 pixelated (2.46×2.46 mm) CZT elements. Acquisition 
time was 5 min for the stress images and 4 min for the rest images. This was derived 
from the recommendations of the manufacturer, published experience and our own 
qualitative assessment in heart phantom studies and our initial experience in patients16. 
All SPECT studies were followed by an unenhanced low-dose CT scan during a breath-
hold to provide the attenuation map for attenuation correction as previously described17.
Myocardial perfusion image interpretation
SPECT MPI was performed in an unmasked manner and semiquantitatively interpreted 
using a 17-segment model18. Segments were scored by consensus of two experienced 
nuclear cardiology observers using a 5-points scoring system (0=normal, 1= equivocal, 
2=moderate, 3= severe reduction of radioisotope uptake, 4= absence of detectable tracer 
uptake)19. The combination of attenuation corrected and non-attenuation corrected 
images were reviewed. A stress study was interpreted as normal if the summed stress 
scores were ≤319. Additional rest SPECT was acquired if the stress images did not 
fulfill this criterion. The perfusion images were reviewed again after both stress and rest 
SPECT. An ischemic defect was defined as a summed difference score ≥219. Reversible 
defects not fulfilling these criteria were assessed as equivocal for ischemia. Perfusion 
defects which demonstrated no reversibility were defined as fixed defects. SPECT was 
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considered normal in absence of reversible or fixed defects. Reversible perfusion defects 
constituting <10% of the myocardium were defined as small ischemic perfusion defects. 
Moderate/large ischemic perfusion defects were defined as reversible perfusion defects 
constituting >10% of the myocardium. Fixed or reversible perfusion defects constituting 
<10% of the myocardium were defined as small total perfusion defects. Moderate/large 
total perfusion defects were defined as fixed or reversible perfusion defects constituting 
>10% of the myocardium. Summed stress (total perfusion defect), summed rest, and 
difference scores (ischemic perfusion defect) were converted to percent total myocardium 
(% myocardium: summed scores/68 [maximum potential score = 4 x 17] x 100). 
Effective radiation dose 
The radiation dose for SPECT was calculated by multiplying the dose of 99mTc-tetrofosmin 
by 7.9mSv/GBq as suggested by the International Commission on Radiological 
Protection20. 
Follow-up
Follow-up data was based on clinical visits or standardized telephone interviews. 
Patients were monitored for primary (nonfatal myocardial infarction and cardiac 
mortality) and secondary outcomes (late revascularization (>90 days after scanning) 
and primary outcome). Early elective revascularizations within 90 days after imaging 
were excluded from the survival analysis to eliminate events driven by imaging findings. 
Patients undergoing early revascularization were censored. Cardiac death was defined as 
death due to MI, significant cardiac arrhythmia, refractory heart failure, or cardiogenic 
shock. Sudden death occurring without another explanation was included as cardiac 
death. For the analysis of death from cardiac causes, we regarded death from other 
or unknown causes as censored observations. Non-fatal MI was defined based on the 
criteria of typical chest pain, elevated cardiac enzyme levels, and typical changes on the 
electrocardiogram as defined by Thygesen et al21.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation or median (25th-75th 
percentile) and categorical variables are expressed as frequency (percentage). Differences 
between groups were assessed by unpaired Student’s t-test, Mann-Whitney U test and 
by Chi-square test, where appropriate. The patient’s pre-test likelihood for CAD was 
determined with the standard Diamond criteria with the assumption that chest pain 
was atypical13. We calculated annualized event rates on the basis of events per patients-
year and compared differences in annualized events between patients with different 
SPECT outcomes by Poisson regression for rate data. We used Cox proportional hazard 
regression to analyze the association between imaging result, patient characteristics 
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and clinical outcomes. Continuous predictors with a linear relationship were included 
in the model as a continuous variable, otherwise it was included as a dichotomous 
variable (>upper quartile). A value of p<0.05 in univariate analysis was required for 
entry into the multivariate analysis. The proportional hazard assumption was evaluated 
graphically using “log-log” plots. Variables which did not demonstrate an effect on the 
outcome measure were not included in the Cox model. The multivariate analysis for the 
primary outcome included age, LBBB, BMI, diabetes mellitus and SPECT results. For 
the secondary outcome age, gender, LBBB, diabetes mellitus and SPECT results were 
included. Two-sided p-values of less than 0.05 were considered statistically significant 
in all tests. All statistical analysis was performed with a commercially available software 
package (SPSS, version 20.0 for Windows), the Poisson regression for rate data was 
performed with Medcalc (version 16.2 for Windows).
RESULTS
Study population
During a period of 3 years and 1 month a total of 4057 patients were included. The 
main indications for referral were atypical chest pain and dyspnea. Pre-test likelihood 
was low in 9% of the patients and intermediate in 91% of the patients. The baseline 
characteristics are shown in Table 1. The mean age was  61 ± 11 years, 42% of the 
patients were male and 13% were diabetic. Stress testing was performed with adenosine 
in 3864 (95%), with dobutamine in 103 (3%), with regadenoson in 37 (1%) and with 
exercise testing in 53 (1%) of the patients.
SPECT results
Of the total patient population, 3137 (77%) demonstrated normal SPECT MPI 
findings. Differences in baseline characteristics of patients with normal and abnormal 
SPECT MPI are demonstrated in Table 1. Patients with abnormal SPECT MPI were 
older, more often male and diabetic, had higher BMI and more often had hypertension 
and a LBBB. Of the 920 patients with abnormal perfusion results, 558 (61%) had small 
total perfusion defects and 362 (39%) had moderate/large total perfusion defects. Of the 
575 patients with ischemic defects, 353 (61%) had small and 222 (39%) had moderate/
large ischemic perfusion defects. The baseline characteristics in patients with small and 
moderate/large ischemic and total perfusion defects were similar, with the exception 
of a lower frequency in family history of CAD in patients with a moderate/large total 
perfusion defect and a higher frequency of LBBB in patients with a small ischemic 
defect (Table 1). The mean radiation dose was 6.5 ± 3.5 mSv, the mean administered 
dose of 99mTc-tetrofosmin was 736 ± 410 MBq for the entire cohort. 
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Follow-up
A total of 8 patients were lost to follow-up, the remainder of 4049 patients (99.8%) were 
included for the follow-up analysis. During a median follow-up of 2.4 years (25th-75th 
percentile:1.7-3.4), a total of 37 primary events (14 cardiac deaths and 23 nonfatal MIs) and 
116 secondary events (79 late revascularizations plus primary events) occurred. Unadjusted 
annual event rates for both outcome measures stratified by SPECT MPI findings are 
demonstrated in Figure 1. After multivariate analysis, LBBB, diabetes mellitus and SPECT 
findings were significant independent predictors for cardiac death/MI (Figure 2). Significant 
independent predictors for late revascularization/cardiac death/MI were age, male gender, 
diabetes mellitus and SPECT MPI (Figure 3). Adjusted survival curves based on ischemic 
and total perfusion defect for the primary and secondary outcomes are demonstrated in 
Figure 4. The risk of cardiac death/MI showed a significant higher risk for both ischemic 
and total moderate/large perfusion defects. With respect to late revascularization/cardiac 
death/MI, a significant step-wise increase was present for patients with small ischemic or 
total perfusion defect and moderate/large ischemic or total perfusion defects.
DISCUSSION
Our study demonstrated that MPI acquired with the CZT SPECT camera has excellent 
prognostic value in patients suspected for CAD. A normal MPI is associated with 
low event rates and in abnormal MPI, the extent of abnormality is associated with an 
increased risk of events.  
SPECT MPI is well established for the diagnostic and prognostic evaluation of patients 
with suspected CAD. Novel cardiac gamma cameras utilizing multipinhole collimation 
and solid-state detectors offer several advantages compared to the conventional SPECT 
cameras. Imaging time and radiation dose can be reduced, while diagnostic accuracy 
appears to be unchanged9,10,22. However, large clinical studies evaluating the prognostic 
value of SPECT imaging with CZT are scarce11,12.
The present study, in the largest cohort of patients to date, shows a very low event rate of 
both cardiac death/MI as well as late revascularization/cardiac death/MI in patients with 
normal myocardial perfusion (0.21% and 0.62% annual risk, respectively). Patients with 
abnormal SPECT MPI findings had a significantly higher risk of events during follow-
up and with the extent of abnormality this risk increased. These findings demonstrate 
that MPI obtained with CZT SPECT is appropriate for the prognostic evaluation of 
patients suspected for CAD. In a previous study performed in 1613 patients on a CZT 
camera, annual event rates for all-cause death were 1.3% for normal SPECT and 5.6% 
for moderate/severely abnormal SPECT12. Another study performed on a CZT camera 
in 1109 patients, described event rates for cardiac death/MI of 0.4% for patients with 
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Figure 2. Multivariate cox survival analysis for cardiac death/MI 
*Reference category, normal SPECT; BMI, body mass index, upper quartile 30; LBBB, left bundle branch 
block; CI, confidence interval. The variables gender, hypercholesterolemia, family history of coronary artery 
disease, current smoking and hypertension were not included in the multivariate analysis due to no effect 
on the outcome measure or a p-value >0.05 in univariate analysis.
Figure 1. Unadjusted annual event rates stratified by SPECT MPI findings. 
SPECT, single photon emission computed tomography; MI, myocardial infarction 
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no significant perfusion abnormalities and 6.8% for patients with abnormal perfusion 
during a median follow-up of 1.7 years11. In both studies, a perfusion defect of >10% of 
the myocardium was shown to be an independent predictors of hard events11,12,23. These 
results are similar to our findings, although lower annual event rates in our study were 
demonstrated in patients with abnormal SPECT. This annual event rate could be could 
be explained by the relatively low risk population included in our study, as patients with 
a history of CAD were excluded. However, also in this low-risk population SPECT 
findings were independently associated with events. These findings are comparable with 
conventional SPECT cameras 23. More recently, Oldan et al. compared the prognostic 
value of conventional and CZT camera in 2088 patients and found that the extent of 
ischemia was associated with death and MI, without difference between camera type24. 
It was also demonstrated that the prognostic value of normal SPECT imaging acquired 
with CZT camera is excellent in obese patients25.
With the excellent prognostic value of the CZT camera as demonstrated by our results 
and the above described findings, future perspectives lie in lowering radiation dose and 
imaging time. This can be achieved by implementing a stress-first imaging protocol, 
in which rest imaging is omitted when the stress images are normal. These stress-only 
protocols are recommended for appropriately selected patients to lower radiation dose 
and imaging time26. With the use of CZT cameras these stress-first imaging protocols 
could be more effectively implemented, as imaging results of the CZT camera are more 
often interpreted as normal22. The prognostic value of the CZT camera has also been 
Figure 3. Multivariate cox survival analysis for late revascularization/cardiac death/MI 
*Reference category, normal SPECT; CI, confidence interval; LBBB, left bundle branch block. The variables 
BMI, hypercholesterolemia, family history of coronary artery disease, current smoking and hypertension 
were not included in the multivariate analysis due to no effect on the outcome measure or a p-value >0.05 
in univariate analysis.
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   138 17-08-18   07:38
Prognostic value of myocardial perfusion imaging with CZT SPECT 
139
C
ha
pt
er
 8
studied in stress first-imaging protocols. Einstein et al studied 100 patients undergoing a 
low-dose CZT scan in the emergency department and demonstrated that the prognosis 
with a normal MPI was excellent. Yokota et al. demonstrated that the prognostic 
Figure 4. Adjusted survival curves of the primary and secondary outcome measure for ischemic and total 
perfusion defects 
Cardiac death/MI curves adjusted for age, BMI, left bundle branch block and diabetes mellitus. Late 
revascularization/cardiac death/MI curves adjusted for age, gender, LBBB and diabetes mellitus.   
*Reference category, normal SPECT
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value of normal stress-only SPECT imaging was excellent in patients with CZT and 
conventional camera (cardiac events 1.5%/year and 2%/year, respectively, p = 0.08)27. 
In addition, the injected radiation dose could be lowered in patients undergoing CZT 
SPECT, as the heart-centric method of collimation of the CZT camera enhances count 
sensitivity28 The effective radiation dose could be less than 1 mSv, without significant 
sacrifice of accuracy29,30. 
Although our study represents true daily practice and included consecutive patients, 
we have to acknowledge several limitations. The observational design remains a major 
limitation, as endpoints were not pre-specified. Also, this is a single-center study in 
patients with suspected CAD and a low- to intermediate pre-test likelihood undergoing 
mainly pharmacological stress. Therefore, results cannot be generalized to patient 
populations with different pre-test likelihood or patients undergoing traditional exercise 
testing. Although we corrected for well-known factors which could induce non-ischemic 
SPECT defects (obesitas, LBBB), it cannot be excluded that other variables could cause 
non-ischemic defects. Also, we did not perform follow-up for procedures which are 
generally not the result of myocardial perfusion imaging, as non-bypass grafting cardiac 
surgery or ICD implantation. Moreover, we did not include the gated LV function in 
the survival analysis. No comparison with conventional SPECT MPI was performed. 
Furthermore, CZT cameras differ significantly in design, and it cannot be excluded 
that different CZT cameras have different prognostic ability. Recent studies show that 
lowering dose is feasible without negative impact on image quality29,30. However, this 
lower dose was not yet implemented in this study period. 
CONCLUSIONS
Our findings show that MPI acquired with CZT SPECT camera provides excellent 
prognostic information, with low event rates in patients with normal myocardial 
perfusion. In patients with abnormal SPECT MPI, the extent of abnormality is 
independently associated with an increased risk of events.  
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ABSTRACT
Background
The coronary calcium score (CCS) provides independent diagnostic and prognostic 
information on top of myocardial perfusion imaging (MPI) in patients suspected for 
coronary artery disease, but requires an additional computed tomography (CT) scan. 
Objective
We investigated the accuracy and inter-reader reproducibility of visual estimation of the 
CCS on the CT used for attenuation correction. 
Methods
250 patients undergoing single photon emission computed tomography MPI and 
Agatston CCS were included. The CCS was also visually estimated on the CT for 
attenuation correction by two separate readers blinded to the Agatston CCS, and was 
categorized into a six-point scale (0, 1-10, 11-100, 101-400, 401-1000 and >1000). 
Results
The median Agatston CCS was 82 [25th-75th percentile: 0-562], with a range from 0 
to 7287. Of the visually estimated CCS, 60% (reader 1) and 65% (reader 2) were 
classified correctly into the 6 categories. 93% (reader 1) and 88% (reader 2) of the 
visually estimated CCS did not vary by more than one category from the Agatston CCS. 
The intraclass correlation coefficient for agreement between the Agatston CCS and the 
visually estimated CCS was 0.95 for reader 1 and 0.94 for reader 2. The intraclass 
correlation coefficient for inter-reader reproducibility of the visually estimated CCS was 
0.96.
Conclusion
The CCS can be accurately estimated on the CT for attenuation correction, as high 
agreement is demonstrated with the Agatston CCS and inter-reader reproducibility is 
excellent. If no traditional Agatston CCS is performed, the degree of atherosclerosis 
should be assessed by means of estimating CCS on the CT for attenuation correction.
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   146 17-08-18   07:38
Visual estimation of CAC
147
C
ha
pt
er
 9
INTRODUCTION
The coronary calcium score (CCS) provides diagnostic and prognostic information 
as an adjunct to single photon emission computed tomography (SPECT) myocardial 
perfusion imaging (MPI) in asymptomatic as well as in symptomatic patients.1-3 The 
CCS is traditionally obtained on a dedicated ECG gated computed tomography (CT) 
scan, with a modest additional radiation dose of 1 mSv.4 In SPECT MPI, the perfusion 
images are often combined with a low dose CT for attenuation correction. We evaluated 
whether the CT images used for attenuation correction could be used to reliably estimate 
the CCS. 
TECHNICAL METHODS
Study population 
We studied 250 patients with suspected stable coronary artery disease (CAD), referred for 
clinically indicated non-invasive CAD detection with SPECT/CT in the Isala Hospital 
between January and August 2014. Patients with unstable chest pain syndromes and a 
known history of CAD were excluded. Patients underwent SPECT MPI with CT for 
attenuation correction, as well as the CCS using an additional CT acquisition. 
CT acquisition
All cardiac CT studies (both the CT for attenuation correction as well as the CCS 
scan) were acquired using the 64 slice-CT scanner of an integrated SPECT/CT device 
(LightSpeed VCT XT; GE Healthcare). The CT for attenuation correction was acquired 
after SPECT MPI. This low-dose CT was performed without ECG triggering, during 
breath-hold and covered the entire chest with the following axial scanning parameters: 
5.0-mm slice thickness using a reconstruction algorithm with a 512 x 512 matrix, and 
800 ms rotation times at 120 kV and 20 mA. Settings were identical for all patients, 
irrespective of weight and size. The typical dose length product was  17 mGy x cm, 
corresponding to an estimated effective dose of 0.48 mSv. The CT for attenuation 
correction was reconstructed in slices of 2.5 mm thickness for the visual analysis.
Immediately after acquisition of the CT for attenuation correction, a prospectively 
ECG-triggered scan for the CCS was performed at 75% of the RR-interval during 
breath-hold. The following axial scan parameters were used: 40 or 48 sections and 2.5-
mm section thickness, gantry rotation time 330 ms, tube voltage 120 kV and a tube 
current ranging from 125 to 250 mA, depending on patient size. The coronary calcium 
scoring computer software (SmartScore; GE Healthcare) automatically defined the 
presence of calcified lesions as those > 130 HU. The coronary calcium was manually 
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depicted and allocated to the corresponding coronary artery by an experienced reader 
using the Agatston method for quantification.5 The typical dose length product for the 
CCS scan was 30 mGy x cm, corresponding to an estimated effective dose of 0.85 mSv. 
Image analysis
The CT for attenuation correction was used for visual estimation of CCS by two single 
readers in separate sessions  (Reader 1 = J.R.T., Reader 2 = E.M.E.). The readers were 
blinded for all patient characteristics as well as the Agatston CCS. These readers were 
both highly experienced with CT of the coronary arteries and the CSS in general. 
Readers estimated the CCS in each of the coronary arteries, the total CCS score was 
then assigned to one out of 6 categories: CCS 0, 1-10, 11-100, 101-400, 401-1000 and 
>1000. 
Statistical analysis
Quantitative variables were expressed as mean ± SD, median [25th-75th percentile] and 
categorical variables as frequencies or percentages. Agreement between visually estimated 
CCS and Agatston score as well as inter-reader reproducibility of visually estimated CCS 
were calculated using intraclass correlation coefficient. Two-sided p-values of <0.05 were 
considered statistically significant in all tests. 
TECHNICAL RESULTS
The mean age of the study population was 62±16 years, 45% of the patients were male, 
the body mass index was 28±5 kg/m2 and the heart rate was 65±10 beats/min. The 
median Agatston CCS was 82 [25th-75th percentile: 0-562], with a range from 0 to 
7287. 30% of the patients had a CCS of 0, and 6%, 16%, 19%, 15% and 14% had 
CCS of 1-10, 101-400, 401-1000 and >1000, respectively. Using the CT for attenuation 
correction, 60% (reader 1) and 65% (reader 2) of the visually estimated CCS were 
classified correctly. 93% (reader 1) and 88% (reader 2) of the visually estimated CCS 
scores did not vary by more than one category from the Agatston CCS (Table 1 and 2). 
Intraclass correlation coefficient for agreement between Agatston CCS and estimated 
CCS was 0.95 (95%CI 0.94-0.96, p<0.001) for reader 1 and 0.94 (95%CI 0.91-0.96, 
p<0.001) for reader 2. Intraclass correlation coefficient for inter-reader reproducibility 
of visually estimated CCS was 0.96 (95%CI 0.95-0.97, p<0.001). The two observers 
classified 71 % of the CCS in the exact same category, and 94% within 1 category of 
each other (Table 3).
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The frequency of correct classification per CCS category is displayed in Figure 1. Correct 
classification was most often present in patients with CCS 0 (87% for reader 1, 92% for 
reader 2) and those with CCS>1000 (81% for reader 1 and 61% for reader 2). Reader 1 
classified 87 patients as having a CCS of 0 by visual estimation, which was correct in 66 
patients (76%). Incorrectly classified as CCS 0 were 10 patients with CCS 1-10 (11%), 
10 patients with CCS 10-100 (11%) and 1 patient with CCS score 100-400 (1%). 
153 of the 176 (87%) of the patients with any coronary calcifications were correctly 
classified. Reader 2 classified 101 patients as having a CCS of 0 by visual estimation, 
this was correct in 70 patients (69%). Incorrectly classified as CCS 0 were 11 patients 
with CCS 1-10 (11%), 19 patients with CCS 10-100 (19%) and 1 patient with CCS 
100-400 (1%). 143 of the 176 (81%) of the patients with any coronary calcifications 
were correctly classified.
Table 1. Agreement between visually estimated CCS and Agatston CCS for reader 1.
Agatston CCS
Estimated CCS 0 1-10 11-100 101-400 401-1000 >1000
0 66 10 10 1 0 0 87
1-10 5 1 7 0 0 0 13
11-100 5 4 17 17 1 0 44
101-400 0 0 5 23 10 1 39
401-1000 0 0 0 6 15 6 27
>1000 0 0 0 0 11 29 40
76 15 39 47 37 36
CCS; coronary calcium score, values are shown as number
Table 2. Agreement between estimated CCS and Agatston CCS for reader 2.
Agatston CCS
Estimated CCS 0 1-10 11-100 101-400 401-1000 >1000
0 70 11 19 1 0 0 101
1-10 0 1 0 0 0 0 1
11-100 5 3 15 9 2 0 34
101-400 1 0 5 33 13 2 54
401-1000 0 0 0 4 21 12 37
>1000 0 0 0 0 1 22 23
76 15 39 47 37 36
CCS; coronary calcium score, values are shown as number
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DISCUSSION
The CCS could be accurately estimated on the CT acquired for attenuation correction, 
as high agreement was demonstrated with the Agatston CCS and inter-reader 
reproducibility was excellent. If no traditional Agatston coronary calcium scoring is 
performed, the degree of atherosclerosis should be assessed by means of estimating CCS 
on the CT for attenuation correction images. 
Although the 35-40% the incorrect classifications were mostly by no more than one 
CCS category, this may still be of clinical relevance. In about 25-30% of all patients who 
were visually estimated as having no coronary calcium, the Agatston score was actually 
Table 3. Agreement between estimated CAC scores for both readers.
Estimated CCS Reader 2
Estimated CCS Reader 1 0 1-10 11-100 101-400 401-1000 >1000
0 83 1 2 1 0 0 87
1-10 10 0 3 0 0 0 13
11-100 7 0 25 12 0 0 44
101-400 1 0 2 32 4 0 39
401-1000 0 0 2 8 16 1 27
>1000 0 0 0 1 17 22 40
101 1 34 54 37 23
CCS; coronary calcium score, values are shown as number
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Figure 1. Frequency of correct classification per CCS category for both readers. 
CCS; coronary calcium score
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higher than 0. This is particularly important as a CCS of 0 is likely to have clinical 
implications for patient management, due to its strong association with the absence of 
CAD.6 Therefore, in our opinion the higher accuracy of the CCS on an ECG gated CT 
scan outweighs the modest additional radiation dose (0.85 mSv in the current report). 
However, if the Agatston CCS is not available, we advise to visually estimate the degree 
of atherosclerosis on the CT acquired for attenuation correction.
A previous study estimating CCS on the CT acquired for attenuation correction was 
performed by Einstein et al., which demonstrated similar results. Using the same six-
point scale as in our study, it was demonstrated that 63% of the patients were classified 
correctly and 93% of the were classified correctly when one category margin was 
allowed.7 Various other studies have investigated visual coronary calcium scoring on 
non-gated CT scans, primarily in the setting of lung cancer screening. However, due to 
differences in scanning parameters and patient population comparison with our results 
is cumbersome.8-10
CONCLUSION
The coronary calcium score can be accurately estimated on a computed tomography 
scan for attenuation correction, as high agreement is demonstrated with the Agatston 
coronary calcium score and inter-reader reproducibility is excellent. If no traditional 
Agatston coronary calcium scoring is performed, the degree of atherosclerosis should be 
assessed by means of estimating coronary calcium score on computed tomography scan 
acquired for attenuation correction.
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Non-invasive imaging is the cornerstone in the diagnostic and prognostic work-up of 
patients with suspected coronary artery disease (CAD). There are various imaging 
techniques, that can be divided into anatomical imaging and functional imaging techniques. 
With the advent of hybrid devices, such as SPECT/CT, combining anatomical with 
functional imaging has become available in clinical practice. The combined use of these 
different imaging techniques may improve diagnostic and prognostic patient evaluation. 
The downside could be increased total imaging time, higher radiation dose for patients 
and inefficient use of laboratory facilities. This thesis investigated novel features in non-
invasive imaging and the added prognostic and diagnostic value of combining different 
imaging techniques, particularly coronary artery calcium (CAC) scoring, coronary 
computed tomography angiography (CCTA) and SPECT myocardial perfusion imaging 
(MPI) in patients without known CAD. The implications, clinical recommendations and 
suggestions for future research regarding our findings will be discussed in this chapter.
Main findings of this thesis
I. The added value of CAC score to SPECT MPI
 •  CAC score is an independent predictor of major adverse cardiac events in addition 
to SPECT MPI in patients suspected of CAD (chapter 2). 
 •  Severe CAC is a stronger predictor for major adverse cardiac events than a large 
perfusion defect on SPECT MPI (chapter 2). 
 •  Patients with abnormal SPECT MPI without any CAC have an excellent prognosis 
(chapter 2).
 •  Gender has no prognostic value in patients evaluated for CAD after stratification 
by CAC score (chapter 3).
 •  Knowledge of the CAC score influences the subsequent cardiovascular medication 
prescription in patients with normal SPECT MPI (chapter 4). 
II. The benefits of sequential cardiac imaging in clinical practice
 •  Combining CAC scoring with initial stress SPECT MPI obviates the need for 
additional imaging in half of the patients evaluated for suspected CAD (chapter 5). 
 •  Sequential CCTA after SPECT corrects for false positive SPECT findings 
(chapter 5).
 •  In patients with left bundle branch block, initial CCTA rather than SPECT is 
preferred, as the majority of these patients have abnormal stress SPECT (chapter 6). 
 •  The CAC score is an excellent gatekeeper in selected patients, as stable patients 
without CAC are unlikely to benefit from further imaging. When additional 
imaging is necessary, it can help determine the most appropriate imaging 
technique (chapter 7). 
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III. Evaluation of novel features in non-invasive imaging
 •  The CAC score can be estimated from the already available CT acquired for 
attenuation correction of SPECT MPI with reasonable accuracy (chapter 8).
 •  Stress-first SPECT imaging with the novel cadmium zinc telluride (CZT) SPECT 
camera provides excellent prognostic value (chapter 9). 
Part I. The added value of CAC score to SPECT
In chapter 2 we evaluated symptomatic patients suspected for CAD who underwent 
both SPECT and CAC scoring. We were able to demonstrate an impressive additional 
prognostic value of the CAC score over SPECT alone, wherein severe CAC was an 
even stronger predictor for major adverse cardiac events than a large SPECT perfusion 
defect (hazard ratio (HR) 4.87 for CAC 400-1000, HR 7.57 for CAC ≥1000 and 
HR 3.74 for large perfusion defect). These findings can be explained by the ability of 
CAC score to directly visualize and quantify the burden of coronary sclerosis, whereas 
SPECT can only assess myocardial perfusion. Particularly in patients with normal 
SPECT and high CAC scores, the high CAC score may impact patient management 
through intensification of life style advice and cardioprotective medication. Patients 
with abnormal SPECT without any CAC demonstrated to have an excellent prognosis 
(annual event rate 0.4%) and additional invasive imaging may not be necessary. Because 
of the additional prognostic value which is obtained by the CAC score in addition to 
SPECT, we conclude that the CAC score should be an integral part of SPECT imaging 
when evaluating patients with suspected CAD. 
In chapter 3 we evaluated the gender-specific prognostic value of the CAC score in 
addition to SPECT MPI. After adjusting for age and traditional risk factors, the risk for 
cardiac events did not differ in female and male patients when stratified by CAC score 
score (HR 1.1, 95% confidence interval (CI) 0.6-1.9 for gender in patients with CAC 
score >1000, unadjusted event rates of 8.4% for female and 8.7% for male patients). 
Thereby, our findings do not support a gender-specific prognostic value of the CAC 
score. 
In chapter 4 we demonstrated that knowledge of CAC score in patients with normal 
SPECT influences the prescription of cardioprotective medication by the referring 
cardiologist, as cardioprotective medication was discontinued in patients with low CAC 
scores whereas it was initiated in the presence of high CAC scores. Of the patients without 
CAC, statin therapy was discontinued in 28% and aspirin therapy was discontinued in 
65%. Of the patients with a CAC score ≥400, statin therapy was initiated in 53% and 
aspirin therapy was initiated in 16%. 
However, currently there is only limited clinical evidence for the logical assumption that 
cardioprotective medication in patients with a high calcium score is beneficial1,2. 
201835 ElsemiekEngbers_binnenwerk_grid 5.indd   157 17-08-18   07:38
Chapter 10
158
Part II. The benefits of sequential cardiac imaging in clinical practice
Combining both functional (SPECT MPI) and anatomical (CAC scoring and CCTA) 
imaging methods results in improved diagnostic and prognostic value. However, 
acquiring these imaging modalities in all patients would result in higher costs, higher 
radiation dose and decreased laboratory efficacy. As it is unlikely that all patients 
benefit equally from these techniques, a more tailored approach may be preferable. 
We evaluated an individualized sequential SPECT/CT protocol as incorporated in 
our clinical practice, that starts with stress SPECT and CAC score in all patients with 
suspected CAD. In case of an abnormal SPECT we additionally acquire rest SPECT 
and, if feasible, CCTA. In chapter 5 we demonstrated that half of the patients in this 
approach did not require additional imaging after the initial stress SPECT and CAC 
scoring. The knowledge of the CAC score in these patients likely contributed to the low 
necessity of additional imaging, as subtle stress SPECT abnormalities can correctly be 
ignored in the absence of any CAC. In addition, CCTA was successful in identifying 
false-positive SPECT findings. In over half of the subgroup of patients with abnormal 
SPECT who underwent CCTA, CCTA excluded obstructive CAD. 
Although sequential imaging starting with stress SPECT and CAC scoring can be 
applied in all patients suspected of CAD, in some patients it may be better to perform 
CCTA as initial test.  Currently, CCTA as initial test is recommended especially in 
low-intermediate risk patients3,4. Possibly, a CCTA-first protocol would be appropriate 
in other selected patients as well. In chapter 6 we demonstrated that the majority 
of patients with left bundle branch block have abnormal stress SPECT (82%) and 
therefore required additional imaging after initial stress SPECT and CAC scoring, while 
the CCTA was able to exclude obstructive CAD in nearly three quarter of the subgroup 
of patients with abnormal SPECT who underwent CCTA. Therefore, patients with left 
bundle branch block are more likely to benefit from a CCTA-first protocol. 
A different sequential approach is described in chapter 7, where the CAC score is done 
as the initial test, without directly acquiring additional MPI. We reviewed the literature 
and concluded that stable patients with low or intermediate pretest likelihood and a CAC 
score of zero have an excellent prognosis and are unlikely to suffer from obstructive CAD. 
Therefore, these patients are unlikely to benefit from additional imaging. The downside of 
using CAC scoring as a gatekeeper is that only a limited number of patients have a CAC 
score of zero, and therefore the majority of patients still require additional imaging. However, 
even if patients require additional imaging (in case of a CAC score > 0), the CAC score 
still holds clinical value. It can be used to evaluate whether patients are eligible to undergo 
CCTA, as this is generally not diagnostic in case of extensive coronary calcifications3. If 
patients are not eligible for CCTA, additional imaging with SPECT should be performed. 
In those patients in whom additional SPECT is deemed necessary after initial CAC scoring, 
the CAC score holds independent prognostic value, as described in part I. 
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Part III. Evaluation of novel features in non-invasive imaging
In recent years, a new type of gamma camera system has been introduced5. These 
dedicated cardiac cameras use semiconductor CZT detector technology and allow 
reduction of radiation exposure and faster acquisition times without loss of image 
quality. Although the diagnostic accuracy of CZT SPECT imaging has been described 
thoroughly, data about the prognostic value of SPECT MPI acquired with this camera 
are scarce6,7. In chapter 8 we demonstrated, in the largest study population to date, that 
SPECT obtained with the novel CZT camera holds excellent prognostic value. Patients 
with normal perfusion demonstrated low event rates (annual event rate for nonfatal 
myocardial infarction or cardiac mortality of 0.2%), and the extent of abnormality 
was independently associated with an increased risk of events (HR for small ischemic 
defects: 2.2, 95% CI 0.9-5.9, HR for moderate or large ischemic defects: 4.0, 95% CI 
1.5-10.5). This finding paves the way for further implementation of this camera system. 
Another feature that is relatively new is to estimate the CAC score from the CT scan 
that is acquired for attenuation correction. In chapter 9 we demonstrated that the CAC 
score estimated on the CT for attenuation correction holds high agreement with the 
Agatston CAC score (around 90% of the visually estimated CAC scores did not vary by 
more than one category from the Agatston CAC score) and inter-reader reproducibility 
is excellent. Although the traditional Agatston CAC score remains superior to the 
estimated CAC score, we think that the estimation of the CAC score on attenuation 
CT is a suitable alternative if dedicated CAC score is not available. As it is currently not 
routine practice that a dedicated CT for the CAC score is acquired in combination with 
SPECT MPI, this estimation should be used when the Agatston CAC score cannot be 
obtained.  
Future directions
The strength of combined anatomical and functional imaging in symptomatic patients 
without known CAD is demonstrated in this thesis. Stepwise anatomical and functional 
imaging protocols performed in a single day should be the cornerstone in the non-
invasive evaluation of CAD, as it enables a fast and well-informed decision about the 
appropriate patient management.  
Sequential one-day hybrid imaging protocols 
We have shown the feasibility of a step-wise one-day individualized imaging protocol 
starting with stress SPECT and CAC scoring. However, other stepwise algorithms could 
also be considered. Future research should evaluate an imaging protocol with CAC 
score alone as a gatekeeper for further imaging. In patients without any CAC additional 
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imaging could possibly be safely omitted in patients with low or intermediate likelihood 
of CAD that present with stable angina complaints. In patients with low CAC scores, 
CCTA could be obtained if feasible, due to the high negative predictive value in such 
patients8. The CCTA has proven to improve the prediction of cardiac events over CAC 
scoring and conventional risk scores9. However, the added prognostic and diagnostic 
value of the CCTA in very low CAC scores remains to be examined. Patients with 
severe CAC should then undergo additional functional imaging with either SPECT or 
positron emission tomography (PET) MPI. 
Functional imaging 
Despite the foreseeable growth in the application of CT techniques, functional 
imaging tools such as SPECT will remain important as they are widely available and 
play an important role in revascularization decisions. SPECT MPI should always be 
performed with a stress-first protocol in order to limit radiation dose. Several technical 
advances have increased the confidence in interpreting a study as normal, such as ECG 
gating, attenuation correction and quantification of perfusion, which are now current 
practice10. More recently, the most significant development is the introduction of the 
CZT detectors which has resulted in an increase in image quality, higher scan speed and 
fewer equivocal results11,12 13. Future research should evaluate further dose reductions on 
the CZT SPECT camera while maintaining adequate image quality.
Although SPECT is likely to remain in use, the significantly better diagnostic 
performance (both sensitivity and specificity) of cardiac perfusion PET may slowly take 
over SPECT14. Currently, it is not widely available due to high costs and the necessity for 
an on-site cyclotron or Rubidium generator. However, more easily available tracers could 
facilitate widespread use of cardiac PET MPI15. How PET compares to CZT SPECT 
MPI (combined with CAC/CCTA) remains to be elucidated.  Another promising 
MPI technique is cardiovascular magnetic resonance imaging, which has demonstrated 
higher sensitivity than SPECT, albeit when compared without more recent SPECT 
technologies as attenuation correction and CZT-SPECT MPI16,17.
CT-imaging
In current clinical practice the CCTA faces several limitations. Diagnostic accuracy 
has proven to be lower in patients with high or irregular heart rates and lesions tend 
to be overestimated in the presence of calcifications3. Recently, several advances have 
been made to reduce these limitations. With the advent of 320-slice CT scanners and 
dual-source CT scanners, faster acquisitions are possible, even to the point where the 
whole heart can be imaged within one heartbeat, which reduces artefacts18. In addition, 
faster rotation allows scanning at slightly higher heart rates which reduces the need for 
aggressive heart rate lowering, which could be a major advantage compare to the current 
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standard 64-slice scanner generation19,20. Also, high-definition CT scanning reduces the 
overestimation of calcified lesions by partial volume effects13,21,22. These developments 
are expected to further extend the applicability of CCTA for identification of obstructive 
CAD. 
An intrinsic limitation of CCTA is that it does not provide a functional assessment of 
coronary stenosis. Recently, non-invasive prediction of coronary flow in coronary arteries 
has been made possible with the fractional flow reserve (FFR) CT. However, clinical use 
of the FFR CT is limited because it is not widely available, it is associated with high 
cost and the specificity remains low23. Also, CT perfusion has emerged as a method to 
functionally assess CAD. Up to now, limited evidence is available for this technique, 
demonstrating the ability to improve the diagnostic accuracy of CCTA alone24,25.
Impact of CAC in medication prescription
In this thesis we demonstrated that knowledge of the CAC score influences the referring 
cardiologist in prescribing cardioprotective medication. In patients with low CAC 
scores, aspirin and statin therapy are likely to be discontinued, while high CAC scores 
are associated with the initiation of cardioprotective medication. However, evidence to 
support the effect on prognosis of initiation of cardioprotective medication based on 
CAC scoring is limited. Only one randomized trial was performed, which demonstrated 
a non-significant trend towards reduction of cardiovascular events in patients with CAC 
scores >400 who were treated with statin in combination with antioxidant vitamins1. 
Future research should evaluate the effect on patient prognosis of medical intervention 
based on CAC scoring. 
In summary, non-invasive imaging remains the cornerstone of the diagnostic and 
prognostic evaluation of patients suspected of CAD. Important steps have been made in 
demonstrating the added diagnostic and prognostic value when combining the different 
imaging methods. The non-invasive work-up of patients with suspected stable CAD has 
improved considerably in recent years, with rapid developments in both functional and 
anatomical imaging modalities. We recommend a one-day sequential imaging algorithm 
combining both anatomical and functional imaging to accurately diagnose relevant 
CAD and assess patient prognosis. 
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Inleiding
Hart- en vaatziekten zijn verantwoordelijk voor 30% van alle sterfte en zijn daarmee 
de grootste doodsoorzaak wereldwijd. Een groot deel van deze sterfte (40%) is toe te 
schrijven aan vernauwing van de kransslagaderen (coronairlijden). De klachten van 
patiënten met coronairlijden zijn vaak divers en voor de arts kan het lastig zijn om 
onderscheid te maken met andere, soms ook onschuldige, ziektebeelden. Indien er na 
het uitvragen van de klachten en het verrichten van lichamelijk onderzoek, onvoldoende 
duidelijkheid is over de oorzaak van de klachten wordt soms beeldvormend onderzoek 
van het hart verricht. 
Bij patiënten bij wie de arts inschat dat de kans op ernstig coronairlijden groot is, 
wordt soms direct een hartkatheterisatie verricht worden. Hierbij worden invasief (via 
een punctie in de pols of lies) de kransslagaderen (coronairen) in beeld gebracht met 
een contrastmiddel, waarna bekeken kan worden of er vernauwingen aanwezig zijn. 
Een hartkatheterisatie is relatief duur, belastend voor de patiënt en kan gepaard gaan 
met ernstige complicaties, al is het risico hierop laag. Om het risico op complicaties te 
voorkomen wordt bij patiënten met een minder groot geschat risico op coronairlijden 
eerder voor niet-invasieve beeldvorming gekozen wordt. Hieronder worden kort 3 niet-
invasieve beeldvormingstechnieken beschreven.
 
1. SPECT-perfusie
 Door toediening van een licht radioactieve stof kan met een SPECT-scanner de door-
bloeding (perfusie) van het hart worden onderzocht. Voorheen werd meestal eerst een 
SPECT in rust (rest-SPECT) en pas hierna een SPECT tijdens inspanning (stress-
SPECT) gemaakt. Minder doorbloeding bij inspanning, maar normaal in rust kan 
duiden op vernauwing in de coronairen. Als de doorbloeding van het hart zowel bij 
inspanning als rust slecht is, kan dit duiden op een doorgemaakt hartinfarct (afster-
ving van een deel van de hartspier). Er wordt steeds vaker eerst voor stress-SPECT 
gekozen (stress-first SPECT). Als de doorbloeding van het hart normaal is tijdens 
inspanning, is het niet nodig om nog rust-SPECT uit te voeren.
2. CT-kalkscore
 Met een CT-scanner kunnen de coronairen direct in beeld gebracht worden. Bij een 
CT-kalkscore wordt een korte CT-scan verricht, zonder dat hierbij contrast wordt 
toegediend. Alleen de aanwezige kalk in de coronairen wordt hierbij in beeld geb-
racht, waarna uit de beelden de kalkscore berekend wordt. De kalkscore is een maat 
voor de totale hoeveelheid kransslagaderverkalking, wat kan variëren van geen kalk 
(kalkscore 0) tot ernstige verkalking (kalkscore boven de 1000).  
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3. CT-coronairen
 Hierbij wordt een CT-scan verricht met contrast, waardoor de coronairen zelf en 
eventueel aanwezige vernauwingen kunnen worden afgebeeld. 
Alle bovenstaande beeldvormingstechnieken hebben hun eigen voor- en nadelen. Nadelen 
van de ene techniek kunnen soms worden gecompenseerd door voordelen van de andere 
techniek. Daarnaast bekijken ze verschillende kanten van coronairlijden. Bij SPECT 
wordt de doorbloeding in beeld gebracht en bij de CT kalk en vernauwingen, waardoor 
het toegevoegde waarde kan hebben deze onderzoeken te combineren. Het nadeel van 
het combineren van de verschillende technieken is de stralingsbelasting en langere duur 
van het onderzoek. Niet alle patiënten hebben echter altijd al deze onderzoeken nodig, en 
er is behoefte aan een geïndividualiseerd, stapsgewijs beeldvormingsprotocol waarbij alle 
benodigde informatie wordt verkregen maar geen overbodig onderzoek wordt gedaan. 
Het doel van deze niet-invasieve testen is om de aanwezigheid van coronairlijden aan te 
tonen of uit te sluiten. Ook kunnen deze testen goed gebruikt worden om een inschatting 
te maken van het risico op een hartziekte of het overlijden daaraan in de toekomst. Mensen 
met een normale testuitslag hebben dan een uitstekende prognose en mensen met een 
afwijkende test een groter risico op een cardiale gebeurtenis in de toekomst.
De doelstellingen van dit proefschrift
In dit proefschrift wilden we: 1) de toegevoegde prognostische waarde van de kalkscore 
gecombineerd met SPECT onderzoeken; 2) verschillende stapsgewijze gecombineerde 
SPECT/CT-beeldvormingsprotocollen evalueren; 3) beoordelen of het mogelijk is om 
de kalkscore te schatten op een CT die sowieso gemaakt wordt ter correctie van SPECT-
beelden; 4) de prognostische waarde van de nieuwe SPECT CZT camera evalueren. 
Belangrijkste bevindingen 
I.   Toegevoegde waarde van de gecombineerde SPECT/ kalkscore scan in patiën-
ten verdacht voor coronairlijden
 •  Het risico op cardiale gebeurtenissen in de toekomst kan beter voorspeld worden 
als de kalkscore gecombineerd wordt met SPECT dan met SPECT alleen 
(hoofdstuk 2).
 •  Een hoge kalkscore is een betere voorspeller voor cardiale gebeurtenissen dan een 
afwijkende SPECT (hoofdstuk 2). 
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 •  Patiënten met een perfusiedefect op SPECT zonder kalk in de coronairen 
hebben een uitstekende prognose, met een laag risico op cardiale gebeurtenissen 
(hoofdstuk 2). 
 •  Als patiënten worden ingedeeld aan de hand van de hoeveelheid kalk, hebben 
mannen en vrouwen hetzelfde risico op cardiale gebeurtenissen in de toekomst 
(hoofdstuk 3).
 •  Bij een normale SPECT beïnvloedt de kalkscore welke medicatie wordt 
voorgeschreven (hoofdstuk 4).
II.  De voordelen van stapsgewijze cardiale beeldvorming in de klinische praktijk
 •  Als de kalkscore gecombineerd wordt met een stress-first SPECT, is in de helft van 
de patiënten geen aanvullend onderzoek nodig (hoofdstuk 5). 
 •  CT-coronairen kan een onterecht afwijkende SPECT-uitslag corrigeren 
(hoofdstuk 5). 
 •  Bij een patiënt met een linker bundeltakblok, een vorm van een geleidingsvertraging 
op het elektrocardiogram, kan beter direct voor een CT-coronairen worden 
gekozen, omdat deze patiënten vaak onterecht een abnormale stress-SPECT 
hebben (hoofdstuk 6).
 •  De kalkscore kan gebruikt worden als poortwachter voor verdere beeldvorming. 
Patiënten met een kalkscore van 0 hebben een goede prognose en aanvullende 
beeldvorming lijkt dan ook nauwelijks toegevoegde waarde te hebben. Als 
aanvullende beeldvorming wel nodig is bij kalkscore >0, kan de kalkscore helpen 
te bepalen welke beeldvormingstechniek het meest geschikt is (hoofdstuk 7). 
III.  Evaluatie van nieuwe ontwikkelingen in niet-invasieve beeldvorming
 •  Stress-first SPECT-beeldvorming met de nieuwe cadmium zinc telluride (CZT) 
gammacamera geven een uitstekende inschatting van de prognose van patiënten 
(hoofdstuk 8).
 •  De kalkscore kan redelijk nauwkeurig geschat worden op de al aanwezige CT 
vervaardigd voor correctie van verzwakkingsdefecten op de SPECT (hoofdstuk 9). 
Deel I. Toegevoegde waarde van de gecombineerde SPECT/ kalkscore scan in pati-
enten verdacht voor coronairlijden
In hoofdstuk 2 hebben we een grote patiëntenpopulatie (n=4897) onderzocht die 
zowel een kalkscore als SPECT-perfusie onderzoek heeft ondergaan. Hierbij hebben 
we kunnen aantonen dat de kalkscore een belangrijke voorspeller is voor cardiale 
gebeurtenissen (hartinfarct, overlijden, bypassoperatie of dotterbehandeling), naast het 
nu gangbare SPECT-perfusie onderzoek. Sterker nog, een erg hoge kalkscore is zelfs 
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een betere voorspeller voor cardiale gebeurtenissen dan een afwijkende SPECT (groot 
perfusiedefect geeft een 3,7 keer groter risico op cardiale gebeurtenis, en een kalkscore 
>1000 een 7,6 keer zo groot risico). Dit valt te verklaren uit het feit dat de kalkscore 
direct de hoeveelheid kransslagaderverkalking weergeeft, terwijl de SPECT alleen 
de doorbloeding van het hart beoordeelt. Ook hebben we aangetoond dat patiënten 
zonder kransslagaderverkalking (kalkscore 0) een uitstekende prognose hebben, ook al 
is de SPECT abnormaal (jaarlijks risico op een cardiale gebeurtenis van 0,4%). Als 
deze laatste groep patiënten de kalkscore niet gehad hadden zouden ze waarschijnlijk 
medicatie voorgeschreven hebben gekregen of zelfs een hartkatheterisatie hebben moeten 
ondergaan. Wij vinden dan ook dan de kalkscore standaard verricht zou moeten worden 
in combinatie met het SPECT-perfusie onderzoek. 
In hoofdstuk 3 laten we zien dat de prognose voor mannen en vrouwen gelijk is nadat 
patiënten zijn ingedeeld in verschillende categorieën van kalkscores (jaarlijks risico op 
cardiale gebeurtenis van 8,4% voor vrouwen en 8,7% voor mannen bij een kalkscore 
>1000). Het is dus niet zo dat vrouwen met dezelfde kalkscore een hoger risico hebben 
op cardiale gebeurtenissen dan mannen, of andersom. 
In hoofdstuk 4 tonen we aan dat de kalkscore beïnvloedt welke medicatie patiënten 
met een normale SPECT voorgeschreven krijgen. Bij patiënten met een lage kalkscore 
wordt de cholesterolverlager en bloedverdunner vaak gestaakt, terwijl dit gestart 
wordt bij patiënten met een hoge kalkscore. Van de patiënten met een kalkscore van 
0 werd bij 28% de cholesterolverlager en bij 65% de bloedverdunner gestaakt. Van de 
patiënten met een kalkscore ≥400 werd bij 53% een cholesterolverlager en bij 16% een 
bloedverdunner gestart. 
Deel II. De voordelen van stapsgewijze cardiale beeldvorming in de klinische praktijk
Omdat het niet nodig is dat alle patiënten alle onderzoeken ondergaan, lijkt een meer 
gepersonaliseerde aanpak de voorkeur te hebben. In hoofdstuk 5 hebben we onderzoek 
gedaan naar een stapsgewijs geïndividualiseerd beeldvormingsprotocol zoals we dat 
toepassen in de dagelijkse praktijk. Om te beginnen krijgen alle patiënten die verdacht 
worden van coronairlijden een stress-SPECT en een kalkscore. Als de stress-SPECT 
een abnormale perfusie toont, wordt aanvullend een rust-SPECT en, indien haalbaar, 
een CT-coronairen verricht. We hebben aangetoond dat de helft van de patiënten na 
de stress-SPECT en kalkscore geen aanvullend onderzoek meer nodig hebben. De 
kennis van de kalkscore heeft hier waarschijnlijk aan bijgedragen, omdat subtiele of 
twijfelachtige SPECT-perfusie defecten terecht genegeerd kunnen worden. 
Bij een abnormale SPECT kan de CT-coronairen deze SPECT-bevindingen corrigeren: 
in de helft van de patiënten met een abnormale SPECT die ook een CT-coronairen 
ondergingen, kon de CT belangrijk coronairlijden uitsluiten. Dit zijn patiënten die 
anders ten onrechte mogelijk verwezen waren voor een hartkatheterisatie. 
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Er kunnen echter andere beeldvormingsprotocollen worden overwogen. In patiënten 
met een geleidingsvertraging in het hart (linker bundeltakblok) zou bijvoorbeeld eerder 
als initieel onderzoek voor een CT-coronairen gekozen kunnen worden, omdat deze 
patiënten vaak onterecht een abnormale stress-SPECT hebben (van de patiënten met 
een linker bundelblok die een abnormale SPECT hadden en CT hebben ondergaan, 
kon bij 72% belangrijk coronairlijden worden uitgesloten door middel van de CT), zoals 
we hebben aangetoond in hoofdstuk 6. Een ander protocol zou bijvoorbeeld kunnen 
starten met een kalkscore, zoals we hebben beschreven in hoofdstuk 7. Patiënten met 
een kalkscore van 0 hebben een goede prognose en zouden dus wellicht geen aanvullend 
onderzoek meer nodig hebben. Patiënten met een kalkscore >0 zouden wel aanvullend 
onderzoek moeten krijgen door middel van een CT-coronairen mits de kalkscore niet te 
hoog is, of anders perfusieonderzoek. 
Deel III. Evaluatie van nieuwe ontwikkelingen in niet-invasieve beeldvorming
In de afgelopen jaren is een nieuwe SPECT-camera geïntroduceerd: de “cadmium zinc 
telluride” (CZT) camera. Omdat over de prognostische waarde van de SPECT-beelden 
verkregen op deze camera nog weinig bekend was, hebben wij hier in hoofdstuk 8 
onderzoek naar gedaan. Hierin hebben we kunnen aantonen dat de prognostische 
waarde uitstekend is, wat wil zeggen dat patiënten met een normale CZT SPECT een 
goede prognose hebben (jaarlijks risico op myocardinfarct of overlijden aan het hart van 
0,2%) en dat de omvang van perfusie defecten een inschatting geeft over het risico op 
cardiale gebeurtenissen (2,2 keer groter risico bij klein perfusiedefect, 4 keer groter risico 
bij matig of groot perfusiedefect).
Een andere nieuwe ontwikkeling is het schatten van de kalkscore op de CT die al 
vervaardigd is voor het corrigeren van de SPECT-beelden. We hebben in hoofdstuk 9 
aangetoond dat de geschatte kalkscore een hoge mate van overeenkomst toont met de 
traditionele kalkscore (rond de 90% van de geschatte kalkscores varieerde niet meer dan 
1 categorie ten opzichte van de traditionele kalkscore). Echter, de traditionele kalkscore 
blijft superieur, en daarom denken we dat het schatten van de kalkscore enkel een 
alternatief is als de traditionele kalkscore niet beschikbaar is. 
Toekomstperspectieven 
De kracht van het combineren van perfusie- en CT-beeldvorming van het hart is 
aangetoond in het huidige proefschrift. Het stapsgewijs, geïndividualiseerd toepassen 
van deze combinatie van technieken zou wat ons betreft de standaard moeten zijn in het 
analyseren van coronairlijden. Het geeft in één sessie informatie over de doorbloeding 
van het hart en over kransslagaderverkalkingen en vernauwingen. Zo is een snelle en 
goed geïnformeerde besluitvorming mogelijk over de meest geschikte behandeling van 
patiënten met mogelijk coronairlijden.
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Stapsgewijze beeldvormingsprotocollen 
Wij hebben de haalbaarheid aangetoond van een stapsgewijs geïndividualiseerd 
beeldvormingsprotocol dat start met stress-first SPECT en kalkscore. Verder onderzoek zal 
zich moeten richten op de klinische haalbaarheid van andere beeldvormingsprotocollen, 
zoals bijvoorbeeld starten met alleen de kalkscore. 
Perfusieonderzoek
Hoewel er steeds meer CT-onderzoek verricht wordt, zal perfusieonderzoek waarschijnlijk 
belangrijk blijven omdat het wereldwijd beschikbaar is en een belangrijke rol speelt in de 
beslissing over het wel of niet ondergaan van een dotterbehandeling of bypassoperatie. 
Verder onderzoek zal zich moeten richten op vermindering van straling bij CT en 
SPECT, hoewel de stralenbelasting anno 2018 al veel lager is dan vroeger. 
Verder wordt het in steeds meer ziekenhuizen mogelijk om perfusieonderzoek te 
verrichtten met een PET-scanner. Voordelen van PET-perfusieonderzoek zijn mogelijk de 
grotere nauwkeurigheid, de betere beeldkwaliteit en de mogelijkheid om nog specifieker 
de doorbloeding te meten. Er zijn echter nog geen vergelijkende studies verricht tussen 
perfusieonderzoek verkegen met de PET en de nieuwe CZT SPECT camera. 
CT-onderzoek
Door technische ontwikkelingen van de CT-scanner zullen steeds meer patiënten 
geschikt zijn voor het ondergaan van dit onderzoek, met lage straling en goede 
beeldkwaliteit. Een beperking van de CT-coronairen blijft dat de techniek niet in staat 
is om de doorbloeding van het hart weer te geven, hoewel er een start wordt gemaakt 
met deze toepassing. Toekomstig onderzoek zal zich moeten richten op methoden die 
dit mogelijk maken voor de klinische praktijk. 
Invloed van kalkscore op voorschrijven van medicatie
We hebben aangetoond dat bij patiënten met een hoge kalkscore vaak bloedverdunners 
en cholesterolverlagende medicatie gestart wordt, terwijl dit bij een lage kalkscore vaak 
gestaakt wordt. Verder onderzoek moet evalueren of dit een gunstige invloed heeft op de 
prognose van de patiënt, daar is op dit moment onvoldoende bewijs voor. 
Samenvattend, niet-invasieve beeldvorming blijft van groot belang bij de evaluatie van 
patiënten verdacht voor coronairlijden. Belangrijke stappen zijn gemaakt in het aantonen 
van het belang van combineren van verschillende niet-invasieve beeldvormingstechnieken. 
Wij willen dan ook een geïndividualiseerd stapsgewijs beeldvormingsprotocol aanbevelen 
met een combinatie van verschillende beeldvormingstechnieken. 
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aan onze vele telefoongesprekken. Weinig kinderen kunnen hun werk zo inhoudelijk 
bespreken met hun vader. Fijn om je zo enthousiast te zien als opa, niets is je te veel. 
Dieta, bedankt voor je interesse de afgelopen jaren en ik blijf het onvoorstelbaar vinden 
hoe jouw organisatietalent de vele (grote) familiebijeenkomsten tot een succes maken. 
Madelon en Barbara, bedankt voor de gezelligheid. Mijn lieve grote zussen, Hanna, ik 
ben blij met de warme band die we hebben, Ris, fijn dat we zo’n hecht contact hebben 
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en dat ik altijd bij je terecht kan voor adviezen. Mijn broer Gerrie, ik geniet ervan om 
samen foute grappen te maken, hoewel er ook voldoende ruimte is om serieuzere zaken 
te bespreken. Mijn broertje Jossie, we hebben zo’n sterke band, ik hecht veel waarde aan 
onze gesprekken die over de meest uiteenlopende zaken kunnen gaan.
Lief gezin, als wij samen zijn voel ik me compleet. 
Lieve Myrthe en Jacob, met jullie om ons heen kunnen we van de meest simpele dingen 
genieten. 
Lieve Lammert, wat ben ik blij dat ik dit alles samen met jou mag doen. Ontzettend 
gelukkig ben ik met je!
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